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Abstract 
 In this manuscript I seek to demonstrate the importance of gene-environment 
interactions in cardiovascular disease.  This manuscript contains five studies each of 
which contributes to our understanding of the joint impact of genetic variation and 
environmental exposures to cardiovascular disease: a candidate gene study for gene-
smoking interactions associated with early-onset coronary artery disease, an 
epidemiology study of the association between traffic-related air pollution and 
cardiovascular disease, a Genome-Wide Interaction Study for gene-by-traffic related air 
pollution interactions associated with peripheral arterial disease, a Genome-Wide 
Interaction Study for gene-by-traffic related air pollution interactions on coronary 
atherosclerosis burden, and a method for analyzing associations between high-
dimensional genomics datasets. 
 Smoking is a strong risk factors for coronary artery disease, and may play a 
causative role in the incidence of coronary artery disease.  Smoking had been implicated 
as a reason for heterogeneity observed in associations between genetic variants on 
chromosome three and coronary artery disease.  I used a family-based early-onset 
coronary artery disease cohort (GENECARD) to study gene-smoking interactions.  I also 
used data from the three independent cohorts to perform a meta-analysis of gene-
smoking interactions focusing on the KALRN gene and Rho-GTPase pathway.  I found 
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significant evidence for gene-smoking interactions associations involving variants in 
KALRN and other Rho-GTPase pathway genes on chromosome 3.   
Though the estimated increase in incident cardiovascular disease or 
cardiovascular events due to air pollution exposure is modest at 3-5%, the ubiquitous 
nature of air pollution exposures means it has a substantial population-level impact on 
cardiovascular disease.  Historically genome-wide interaction studies with air pollution 
have not yielded genome-wide significant interactions, however by implementing 
statistical tools novel to this field I have discovered significant interactions between 
genetic variants and traffic-related air pollution that are associated with cardiovascular 
diseases.   
I studied interactions associated with peripheral arterial disease and the number 
of diseased coronary vessels (an indicator for coronary artery disease burden) using 
race-stratified cohort study designs.  With peripheral arterial disease I observed that 
variants in both BMP8A and BMP2 showed evidence for interactions in both European-
American and African-American cohorts.  In BMP8A I uncovered the first genome-wide 
significant interaction with air pollution associated with cardiovascular disease.  BMP2 
gene expression is upregulated after exposure to black carbon, a major component of 
diesel exhaust, and coding variants within this gene showed evidence for interaction.  
With the number of diseased coronary vessels I observed that variants in PIGR showed 
significant evidence for involvement in gene-traffic related air pollution interactions.  I 
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observed that coding variation within PIGR was associated with coronary artery disease 
burden in a gene-by-traffic related air pollution interaction model.  As PIGR is involved 
in the immune response it represents a strong candidate gene discovered via an 
unbiased genome-wide scan. 
 The use of high dimensional data to study chronic disease is becoming 
commonplace.  In order to properly analyze high-dimensional data without suffering 
from high false-discovery rate penalties, the data is often summarized in a way that 
takes advantage of the correlation structure. Two common approaches for this are 
principal components analysis and canonical correlation analysis.  However neither of 
these approaches are appropriate when one preferentially desires to preserve structure 
within the data.  To address this shortcoming I developed constrained canonical 
correlation analysis (cCCA).  With cCCA one can evaluate the correlation between two 
high dimensional datasets while preferentially preserving structure in one of the 
datasets.  This has uses when studying multi-variate outcomes such as cardiovascular 
disease using multi-variate predictors such as air pollution.  Additionally cCCA can be 
used to create endophenotype factors that specifically explain the variation within a 
high-dimensional set of predictors (such as gene expression or metabolomics data) with 
respect to potential endophenotypes for cardiovascular disease, such as cholesterol 
measures. 
 vii 
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1. Introduction  
1.1 Cardiovascular Disease 
Cardiovascular disease (CVD) is a heterogeneous set of clinical outcomes that 
affect the heart or related vascular systems.  The term cardiovascular disease 
encompasses chronic clinical outcomes such as coronary artery disease, hypertension, 
and peripheral arterial disease as well as acute coronary syndromes like myocardial 
infarction (MI) and sudden cardiac death.  Over the past several decades significant 
resources have been expended to understand both the pathophysiology of 
cardiovascular disease as well as its common risk factors (Libby and Theroux 2005; 
Nabel and Braunwald 2012; Wilson et al. 1998). 
The common thread through the most if not all cardiovascular diseases is the 
atherosclerotic lesion.  Atherosclerotic lesions are lesions of the vascular intima and 
associated tissues that can block blood flow and in some cases rupture.  Upon rupture 
these lesions release prothrombic factors which can then occlude the vasculature leading 
to an acute cardiovascular event such as MI (Nabel and Braunwald 2012; Tabas 2011).  
Cardiologists have suspected occlusions of the coronary vessels and atherosclerotic 
lesions as the primary culprit for acute coronary syndromes since the end of the 19th 
century (McWilliam 1889; Porter 1893).  Initially these lesions were primarily thought of 
as a symptom of fibrin-initiated thickening of the arterial wall (von Rokitansky 1852) or 
improper lipid storage (Virchow 1856).  However the current and prevailing hypothesis 
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suggests that arterial wall thickening and improper lipid storage/clearance are only 
components of a much more complicated pathophysiology (Libby and Theroux 2005; 
Sugamura and Keaney Jr 2011).   
Current research suggests that atherosclerotic lesions are primarily an 
inflammatory condition and are the result of repeated insults to the vascular intima 
(Hulsmans and Holvoet 2010; Libby and Theroux 2005).  In this view the most 
dangerous lesions are not necessarily the largest but are those most at risk of rupturing 
and precipitating acute coronary syndromes, which are called high-risk or vulnerable 
lesions (Schaar et al. 2004).  Vulnerable lesions however may be either small or large and 
are at risk of sudden rupture.  Though there is no histologic test for a vulnerable lesion, 
retrospective studies have revealed several characteristics of these lesions, including the 
necurotic core, prothromic factors, and the thin fibrous cap (Schaar et al. 2004; Tabas 
2011).  The necrotic core is a nucleus of dead and dying foam cells which remain in the 
lesion due to defective efferocytosis.  Foam cells are macrophages that have ingested 
oxidized-LDL (ox-LDL) which is created by the oxidation of low-density lipoproteins 
(LDL).  Ingestion of ox-LDL by macrophages can induce apoptosis thereby releasing and 
recruiting a host of prothrombic factors.   
All of these aforementioned elements involve endothelial cells in the intima 
however smooth muscle cells also form an important component of coronary 
atherosclerosis.  Smooth muscle cells are often found in abundance in areas that are 
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prone to atherosclerotic regions indicating a potentially functional role for smooth 
muscle cells in the initiation of coronary atherosclerosis (Stary, 1995; Doran, 2008).  As 
the mediators of vascular tone and reactivity, vascular smooth muscle cells are integral 
to cardiovascular function.  Thus disruption of smooth muscle cells, with smooth muscle 
cell migration into the intima and death being hallmarks of atherosclerotic lesions 
(Rudijanto 2007; Tabas 2011; Willis et al. 2004), can contribute to a host of cardiovascular 
outcomes, e.g. hypertension.  Vascular smooth muscle cells are unique in that they 
occupy two states, a synthetic phenotype and a contractile phenotype, each associated 
with a specific morphology and function.  In response to injury, often the beginning of 
the atherosclerotic process, smooth muscle cells will switch from the contractile to the 
more motile synthetic phenotype.  In this state smooth muscle cells may migrate to the 
intima where they proliferate and eventually undergo apoptosis.  Defective efferocytosis 
can cause accumulation of dead vascular smooth muscle cells which contribute to the 
necrotic core (Tabas 2011) and the death of smooth muscle cells contributes to loss of 
vascular function.  Additionally synthetic smooth muscle cells express extracellular 
matrix proteins and cytokines in greater abundance than in their contractile state (Frid et 
al. 1997), all of which may contribute to the initiation, growth, and eventual 
destabilization of the atherosclerotic plaque (Doran et al. 2008; Stary et al. 1994; Tabas 
2011; Willis et al. 2004). 
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The final component of a vulnerable lesion is the thin fibrous cap.  This cap 
separates the lesion from the blood flow through the artery.  This cap is stressed and 
eroded by both the factors within the lesion as well as the stress of vascular remodeling 
and blood flow across the cap.  An acute coronary event occurs when the cap ruptures 
releasing prothrombic factors into the lumen.  These prothrombic factors cause the blood 
to coagulate which occludes its flow (Tabas 2011).   
1.2 Genetics of Cardiovascular Disease 
In addition to several traditional risk factors genetics is known to play a 
significant role in cardiovascular disease.  Family history has long been known to be a 
risk factor for cardiovascular disease in future generations (Myers et al. 1990; Shea et al. 
1984; Wilson et al. 1998).  This relationship between the cardiovascular profile of one’s 
ancestors and your own risk of cardiovascular disease implicates genetic variation as a 
contributor to the cardiovascular disease risk.  Beginning with small scale mapping 
studies to uncover the causes of monogenic cardiovascular disease (Nabel 2003) and 
progressing to large scale genome-wide interaction studies (Deloukas et al. 2013; Feero 
et al. 2011; Schunkert et al. 2011) researchers have uncovered a number of genetic loci 
associated with cardiovascular disease risk.  With the current number of accepted CVD 
risk variants approaching 50 (Deloukas et al. 2013) it is likely that we will soon see 
genetic research yield actionable insights into non-monogenic forms of CVD, in similar 
ways that genetic research has yielded insights into monogenic CVD. 
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For some of these loci researchers have been able to causally link them to a 
particular presentation of cardiovascular disease, e.g. Long-QT syndrome and idiopathic 
ventricular fibrillation (Nabel 2003).  However for most presentations of CVD and many 
of the loci associated with CVD a simple interpretation is elusive.  Perhaps the best 
known example of this is the 9p21 locus.  This locus has been repeatedly found to be 
strongly associated with cardiovascular disease (Helgadottir et al. 2007; Schunkert et al. 
2008).  However a functional interpretation of this intergenic locus has largely eluded 
researchers.   
Despite the complexity of functional interpretation the large scale cardiovascular 
disease genome-wide association studies have uncovered a number of novel candidate 
genes for cardiovascular disease.  Many of these loci uncovered in genome-wide 
association studies (GWAS) have clinical relevance given the known function of the 
genes and their previous associations with risk factors for cardiovascular disease 
(Deloukas et al. 2013; Feero et al. 2011).  These cases, where genetic associations from 
candidate gene studies or GWAS yield information on the underlying pathophysiology 
of CVD, are particularly rewarding.  An example of this is the apolipoprotein E (ApoE) 
locus.  This locus is strongly associated with plasma low-density lipoprotein cholesterol 
(LDL-C) concentration and through LDL-C explains a portion of the variance of CVD 
risk (Davignon et al. 1988).  LDL-C is a known to be a modifiable risk factor for CVD 
(Assmann et al. 1998), and observing the association between ApoE alleles and CVD 
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gives a more precise picture of the LDL-C metabolic pathways that may be disrupted in 
CVD pathogenesis.  Overall understanding the genetic basis behind a risk factor for 
cardiovascular disease allows for more effective therapies and treatments to be 
constructed while also informing researchers on the pathogenic processes underlying 
cardiovascular disease.   
Despite the success of genetic association studies for cardiovascular diseases 
much of the heritability of cardiovascular disease remains to be explained with known 
variants only explaining about 13% of the estimated genetic variance of CVD (Peden and 
Farrall 2011; So et al. 2011).  When combined into genetic risk models or genetic risk 
scores genetic variants gleaned from candidate gene or GWAS studies are often 
predictive of CVD (Yamada et al. 2002).  However, many of the genetic variants do not 
add much to risk prediction when added to traditional cardiovascular disease risk 
models (Humphries et al. 2004; Paynter et al. 2009).  This lack of prediction in the context 
of traditional clinical risk factors may be due to the fact that the genetic variants act 
through phenotypes already included in the model, or it may be because often we use 
marker loci rather than the true causal locus which can reduce power and impair risk 
prediction.  It is likely that the environment (Brook et al. 2010), and gene-environment 
interactions (Lanktree and Hegele 2009; Zuk et al. 2012) will explain much of this 
heterogeneity.   
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1.3 Air Pollution, Smoking and Cardiovascular Disease 
There are several risk factors for cardiovascular disease including body mass 
index (Romero-Corral et al. 2006), stress (Krantz et al. 2000; Strike and Steptoe 2004), 
hypertension/endothelial dysfunction (Al Suwaidi et al. 2000; Sowers et al. 2001), and 
elevated triglycerides among others (Miller et al. 2011; Wilson et al. 1998).  In this 
dissertation I focus on two environmental risk factors for cardiovascular disease: 
smoking and air pollution.   
1.3.1 Smoking Background 
Smoking, here specifically referencing primary cigarette smoke, is one of the 
strongest and most common risk factors for cardiovascular disease (Burns 2003; Jonas et 
al. 1992; van Werkhoven et al. 2011).  Primary (directly inhaled from a filtered or 
unfiltered cigarette) smoke is a multi-factorial exposure composed of particulate matter, 
carbon monoxide, as well as many volatile organic and inorganic compounds.  Each of 
these compounds may affect one or more pro-atherosclerotic pathways which can lead 
to cardiovascular disease and eventually an acute cardiovascular event (Ambrose and 
Barua 2004; Peters 2009).  The pathophysiological initiated by primary cigarette smoke 
exposure often begin with oxidative stress or direct biochemical effects of the 
components of cigarette smoke exposure which includes many oxidants (Pryor and 
Stone 1993).  These effects may induce vascular injuries that can initiate or exacerbate the 
effects of a vulnerable atherosclerotic lesion (Burke and FitzGerald 2003).   
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Smoking has been shown to regulate gene expression (Charlesworth et al. 2010), 
and is associated with the metabolome (Mueller et al. 2013; Vulimiri et al. 2009).  Given 
that one of the primary effects of primary cigarette smoke exposure is to induce 
oxidative stress (Ambrose and Barua 2004) it is possible that few organ systems fully 
escape its effects.  Through the use of interaction studies researchers have uncovered 
several genetic loci that modify the association between cigarette smoke exposure and 
cardiovascular disease and may in fact mediate some of the adverse cardiovascular 
effects of cigarette smoke exposure (Humphries et al. 2002; Wang et al. 2003; Wei et al. 
2007).  Some of these genetic loci include the chromosome 3q13 locus and associated 
Rho-GTPase pathway genes within this locus (Horne et al. 2009; Ward-Caviness et al. 
2013), and genetic loci related to detoxification, e.g. CYP1A1 (Wang et al. 2003). 
1.3.2 Air Pollution Background 
Unlike primary cigarette smoke air pollution exposure is not a behavioral 
exposure subject so modification or elimination in most scenarios.  Air pollution is a 
heterogeneous exposure composed of particulate matter with varying sizes and 
chemical compositions, metallic and inorganic compounds, and volatile organic 
compounds which can have a range of effects on human health (Bell et al. 2009; 
Brunekreef et al. 1995; Gilmour et al. 2007; Zanobetti A 2009).   
Air pollution particulate matter is primarily classified into varying size ranges 
based on the diameter of the particle.  PM10 refers to particulate matter with a diameter 
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less than 10 micrometers.  PM2.5 is particulate matter with a diameter less than 2.5 
micrometers.  Ultrafine particulate matter (UFP) is the smallest class of particulate 
matter with a size of 100 nanometers or less.  PM10 and PM2.5 are often reported by their 
total mass while UFP are often reported as the particle number count.  For all size 
ranges, as important as the mass or particle number count is the composition of the 
particles.  Air pollution particles can be produced by a variety of sources including 
industrial, agriculture, biological (e.g. methane from bovine flatulence and biomass 
decomposition), indoor, vehicular, and the natural accumulation of organic or inorganic 
crystals to form increasing particulate sizes.  Each of these sources of particulate matter 
contributes to a range of particle compositions.  Specific components of particulate 
matter have been associated with varying health outcomes (Bell et al. 2009; Zanobetti A 
2009), and recent research has shifted to encompass studies on particulate matter 
components as well as particulate matter mass and counts. 
Measuring or estimating the quantity of air pollution at a specific geospatial 
location can often be a complicated task.  Particulate matter often has a relatively 
homogenous concentration over a large area, and often within a single metropolitan area 
a single fixed monitor station will be used (Park et al. 2006; Ren et al. 2011).  For greater 
spatial variability land use regression is often used.  Land use regression involves using 
land characteristics, such as roadway types and industrial source locations, to calculate 
the air pollution at a particular spatial location at a particular time.  These models also 
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often include local meteorology such as temperature and humidity and are validated 
against fixed monitoring stations distributed across the study area.  Unlike fixed 
monitors which provide a single value for a large area, the variability of land use 
regression estimates for air pollution can be on the order of 100s of meters (Hoek et al. 
2008; Johnson et al. 2010). 
Similar to land use regression techniques air pollution can be estimated using 
meteorology, atmospheric chemistry, and point sources using a series of mass balance 
and differential equations to model ground level air pollution as a function of the inputs.  
One common example of this is the Community Multi-Scale Air Quality (CMAQ) Model 
(Byun and Schere 2006).  In this model data on meteorology, point sources of air 
pollution, e.g. industry and biomass, and atmospheric chemistry are collected.  Each of 
these components has a specific effect on the generation or dispersion of air pollution 
within a defined grid.  Modules within the overall model will specifically assess the 
effect of biomass, meteorology, atmospheric chemistry, industrial sources, and other 
input data on air pollution generation and dispersion.  Mass balance equations will 
govern the transport of air pollution from one grid cell to another.  The outputs of these 
modules are integrated to give an estimate of the air pollution within each grid cell.  The 
grid cell sizes can be as small as 12km2 and cover the entire United States or even be 
assessed worldwide.  An advantage of this air pollution estimation method is that it can 
be estimated as far back as data are available and does not suffer from missing data due 
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to monitor inactivity as is often the case with fixed monitors.  This method is not 
completely immune to missing data as it can suffer from missing data if one of the input 
data sources is not available for all desired measurement days.  Another advantage of 
this method is that primary sources of air pollution are used to generate the air pollution 
estimates, rather than calibration to fixed monitors.  The use of primary sources allows 
for the effect of various air pollution mitigation strategies can be tested via simulation, 
e.g. shutting down a particular industrial source or zoning to limit agricultural burning 
near cities.   
Finally, one of the most recent method for estimating air pollution involves the 
use of satellite measurements of optical depth, referred to as aerial optical depth 
measurements.  In this measurement technique the optical depth as measured by 
satellites corresponds to the amount of matter between that satellite and the Earth.  By 
combining this data with data from land use regression as well as fixed monitoring sites 
once can construct a very fine scaled model of air pollution (Al-Saadi et al. 2005; Kloog 
et al. 2011).   
Before choosing any one of these measurement techniques for a particular study 
researchers must consider both the time and expertise necessary for a particular 
measurement method as well as the appropriateness of the method for the air pollution 
type targeted as well as the time scale desired.  For my dissertation I chose to focus on 
distance to major roadways as a proxy for traffic-related air pollution (TRAP).  Distance 
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to roadways is highly correlated with traffic generated particulate matter (Hagler et al. 
2009b; Zhu et al. 2002b) and is a commonly used metric for TRAP.  This metric has the 
advantages of being easy to measure and readily available for any individuals for whom 
address information is available.  Additionally it is a good proxy for long-term exposure 
to traffic-related air pollution which is what would primarily affect the chronic 
cardiovascular diseases that will be covered here.  This is in contrast to studies involving 
acute coronary outcomes, where daily or hourly air quality values may be needed.  A 
disadvantage of this method is that it does not give any specific details on the sources or 
components of the air pollution exposure as well as it may be confounded with stress or 
noise exposures that can be difficult to deconvolute from the desired traffic-related air 
pollution. 
1.4 Gene-Environment Interaction Studies 
Both genetics and environmental exposures have been associated with 
cardiovascular disease risk (Ambrose and Barua 2004; Brook et al. 2010; Feero et al. 
2011).  In addition to affecting cardiovascular disease risk air pollution and smoking can 
have direct effects on epigenetic markers (Baccarelli et al. 2009; Breitling et al. 2011; 
Tarantini et al. 2009), and gene expression (Charlesworth et al. 2010; Huang et al. 2011; 
Yamawaki and Iwai 2006).  These associations between air pollution and genomic data 
as well as cardiovascular disease highlight the potential for gene-air pollution and gene-
smoking interactions to shed light on at-risk subsets of the population as well as inform 
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on the potential genetic mechanisms that may mediate the effects of these exposures on 
the cardiovascular system.   
The majority of gene-air pollution interaction studies to date have focused on 
candidate genes and examined one or a few potential interactions at a time (Zanobetti et 
al. 2011).  There are multiple reasons for this focus on smaller scale studies.  One reason 
is the estimated lower power of interaction studies relative to studies of the main effect 
of genotypic variation on cardiovascular outcomes.  Despite our lower power to detect 
interactions, gene-environment interaction studies may provide a key clue to the 
missing heritability of cardiovascular disease (Zuk et al. 2012).    Some studies estimate 
that it may take 5,000 or more samples to conduct a gene-environment interaction study 
at a genome-wide scale, with the appropriate Bonferroni p-value correction, give modest 
estimates for effect size of the gene-environment interaction term (Hunter 2005); 
however gene-environment interaction studies with a more modest size have yielded 
valuable insights into cardiovascular disease (Zanobetti et al. 2011).   Additionally well 
founded models for gene-environment interactions have been established for several 
years (Ottman 1996; Ottman and Rao 1990).    These models for gene-environment 
interactions are important because they explain the conditions under which an 
interaction may be detected and also give clues as to the best statistical framework to use 
in order to increase power.  Just as the assumption of an additive model in modeling the 
main effect may reduce power to detect over-dominance or other genetic models of 
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association, not fully considering the appropriate model for the gene-environment 
interaction can cause important interactions to be obscured.  Considerations of whether 
an interaction is synergistic or antagonistic as well as whether an additive or 
multiplicative scale is appropriate can have important considerations for study design 
and estimation and interpretability of the odds ratio risk ratio (Yang and Khoury 1997).  
Another advantage of properly considering the gene-environment interaction model is 
that it gives a framework for understanding interactions when there is not genetic main 
effect.  This can be a difficult scenario and will be missed in studies where interactions 
are only examined for variants that show a strong main effect on either the genetic or 
environmental side (Cornelis et al. 2012; Thomas 2010).  However, when researchers 
properly consider the relevance of genetic models that do not require a main effect 
(Ottman and Rao 1990) the relevance of gene-environment interactions with main effects 
can be evaluated.  Given the wealth of models and techniques developed for gene-
environment interaction studies, careful study design and statistical model and method 
choice may be able to greatly increase the power to detect interactions (Murcray et al. 
2011; Ottman and Rao 1990; Thomas 2010) 
To date most of these studies have relied on candidate gene approaches when 
incorporating air pollution as the exposure, thus leaving open the question of the role of 
novel genes in gene-by-air pollution interactions.  Gene-environment interaction studies 
have significant potential to uncover novel genes associated with complex outcomes 
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(Gauderman et al. 2013; Lanktree and Hegele 2009), and genome-wide interaction 
studies (GWIS) will extend the candidate gene interaction studies that have dominated 
the field thus far.  Similar to genome-wide association studies (Deloukas et al. 2013; 
McCarthy et al. 2008; Schunkert et al. 2011) these studies will take advantage of 
correlation within the genome to use a subset of single nucleotide polymorphisms 
(SNPs) as genetic markers for wider variation across the genome.  A disadvantage of this 
approach to tagging variation across the genome is that it focuses on common variation 
and may not fully capture rare variation that could be the source of many of the 
causative mutations.  Though this disadvantage cannot be denied give the rarity of these 
variants we would expect little to no power to detect interactions with them even if we 
were to genotype these rare variants in large cohorts.  An advantage of using the same 
tagging chips used for genome-wide association studies is that this allows us to build 
upon established genetic models and to answer questions regarding the role of common 
genome-wide variation in gene-environment interaction models of cardiovascular 
disease.  Similar to GWAS, in gene-environment interaction studies care must be taken 
to insure proper genotype calls as well as avoid confounding from population 
stratification (Hunter 2005).  Additionally if using a case-only study design, which can 
increase power, care must be taken that the genotype and environmental exposure are 
independent to avoid bias (Albert et al. 2001; Gatto et al. 2004).  Despite these challenges 
of genome-wide gene-environment interaction studies I believe that they can become an 
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important cornerstone of air pollution and genetics research and that we can learn much 
about the underlying genetic and biological basis for the cardiovascular effects of air 
pollution from these studies. 
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2. Gene-smoking interactions in multiple Rho-GTPase 
pathway genes in an early-onset coronary artery disease 
cohort 
2.1 Introduction 
Coronary artery disease (CAD) is the leading cause of death in the United States 
(Lopez et al. 2006).  Despite the many studies using cohort, family-based, and 
case/control designs to address the genetic etiology of CAD (Franchini M 2008; 
Musunuru and Kathiresan 2010; Samani et al. 2007; Schunkert et al. 2011)  and common 
CAD risk factors (Heard-Costa et al. 2009; Lemaitre et al. 2011; Schunkert et al. 2011; 
Smith et al. 2010), there remains lack of knowledge concerning how genetic variation 
mediates and/or modifies the links between CAD and its common risk factors like 
hyperlipidemia, obesity, and smoking.  Further work is needed in this area. 
We previously reported a genetic linkage peak on chromosome 3q13 for CAD in 
families with an early-age-of-onset (EOCAD) (Hauser ER 2004), which was subsequently 
replicated in the Diabetes Heart Study (DHS) (Bowden et al. 2006).  Fine-mapping of this 
linkage peak in a case-control sample from the CATHGEN study revealed several 
associations between CAD and SNPs in this region (Wang et al. 2007).  Replication of the 
11 most significant SNPs in the case-control series from the Intermountain Heart 
Collaborative Study (IHCS) was only possible when the analysis was restricted to 
smokers (Horne et al. 2009). Further examination revealed a difference between the 
prevalence of smoking in the two datasets with smoking more prevalent in CATHGEN 
 18 
 
than IHCS (41% vs. 11% in controls, 74% vs. 29% in cases).  Significant gene-smoking 
interactions were found for SNPs in KALRN and ARHGAP31/CDGAP, and a second 
analysis in the Diabetes Family Heart Study (DFHS) noted additional gene-smoking 
interactions in KALRN (Rudock RE 2011).  Given that smoking is a well-established risk 
factor for CAD (Ambrose and Barua 2004; Kannel et al. 1987)  discovering genetic 
variants differentially associated with CAD in smokers may uncover mechanistic factors 
connecting genes, smoking and CAD.  We hypothesized that using APL-OSA as a test of 
gene-smoking interactions would reveal several SNPs that are significantly more 
associated with CAD in families with greater smoking exposure, measured by mean 
pack-years.  We also hypothesized that the Rho-GTPase pathway would be enriched 
among the significant associations, based on its previously noted importance (Wang et 
al. 2007).  
2.2 Methods 
2.2.1 Subjects 
The Genetics of Early Onset Cardiovascular Disease study (GENECARD) is 
comprised of families with at least two siblings diagnosed with early onset coronary 
artery disease.  Early onset coronary artery disease was defined on the basis of a 
medically documented acute coronary syndrome (unstable angina or myocardial 
infarction), a revascularization procedure, or a positive functional imaging study at or 
before the age of 50 years in men or 55 years in women.  Risk factor history was collected 
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via in person interviews in a location convenient for the subject.  A blood sample was 
also collected during the interview (Hauser et al. 2003).  Pack-years were calculated as 
pack of cigarettes smoked per day multiplied by total years spent smoking.  A pack of 
cigarettes was defined as 20 cigarettes.  People with zero pack-years were defined as 
those responding “NO” when asked if they smoked at least 100 cigarettes.  We used 
pack-years because it is a measure of lifetime smoking and is well documented in the 
GENECARD dataset.  A total of 2,434 individuals had sufficient information to calculate 
pack-years the rest were considered as missing and did not contribute to family specific 
means. 
Genotypes were generated in the Center for Human Genetics Molecular Genetics 
Core.  All studies conformed to the same laboratory-wide quality control (QC) standards 
(Crosslin et al. 2009; Shah et al. 2009; Wang et al. 2007).  Genotyping was done using 
either Taqman from Applied Biosystems or Golden Gate assay platform from Illumina.  
Applied Biosystems genotyping was done using the 7900HT Taqman SNP genotyping 
system and Illumina BeadStation genotyping was done on the 500G system.  Six quality 
control samples were included on each quadrant of a 384-well plate.  All SNPs were 
successfully genotyped for 95% of the individuals and checked for the absence of any 
Mendelian inconsistencies and deviations from HWE both in their respective studies 
and the combined set of studies.  Error rate estimates for SNPs meeting QC benchmarks 
were <0.2%.  Any SNP typed on fewer than 100 individuals was removed from analysis, 
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a total of 3,516 individuals were sampled during the GENECARD study, of which 3,061 
contributed genotypes these analyses.  A total of 430 SNPs were analyzed across the 
chromosome 3q13 region in 1,360 nuclear families.  All 11 SNPs analyzed by Horne et al 
were genotyped on these families (Horne et al. 2009).  
2.2.2 Statistical Methods 
There are several family-based association tests each with its own strengths and 
weaknesses (Chung et al. 2006; Horvath et al. 2001; Martin et al. 2003; Spielman et al. 
1993).  We used the APL-OSA method. APL-OSA is a method that implements the APL 
test to detect increased evidence for association in the tail of a covariate distribution 
(Chung et al. 2008).  Simulation studies show that APL has the same, or better, power as 
other tests without type I error inflation (Martin et al. 2003), even in regions with strong 
linkage (Chung et al. 2007).    The APL-OSA detects increased association in the tails of a 
covariate distribution, and is an effective test for SNP-smoking interactions because if 
there is truly an interaction between a SNP and smoking we expect people with both the 
risk allele and higher cigarette smoking exposure to be at much greater risk of 
developing CAD, thus increasing the strength of the association in the upper extreme of 
the smoking distribution.  We used pack-years as a measure of lifetime smoking and a 
dominant genetic model as the inheritance pattern for the putative CAD disease locus.  
The APL test is based on a test statistic which compares the number of alleles observed 
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in affected sib-pairs to the number expected under the null hypothesis of no association 
conditioned on the parental genotypes.   
   
∑   
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Z, the APL test statistic, has mean 0 and variance 1 under the null hypothesis, s is 
the number of families in the dataset.  Ti is the difference between the observed number 
of alleles in affected sib-pairs and the expected number of alleles given parental 
genotypes.  In APL-OSA the APL test is calculated iteratively as each family is entered 
into the analysis.  The analysis procedure is described in the following paragraph. 
First the mean pack-years xi for each family i is calculated.  For this calculation 
only the affected siblings are used.  As the GENECARD study is an affected sibling pair 
design many families only have affected siblings and pack-years is well measured 
amongst the affected individuals within GENECARD.  Thus we chose to only use the 
pack-years for the affected siblings to estimate the family-specific means of pack-years.  
Additionally, the family-specific associations are calculated based on the observed 
versus expected alleles in affected individuals, thus it is their exposure that will 
determine any gene-environment interactions.  Since smoking increases the risk of CAD, 
the families are ordered by xi starting with the highest value of average pack-years.  For 
exposures that decrease risk we would order the families low-to-high according to xi.  
Starting with a small subset of families c (c = 20 for our analyses), where c <  the total 
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number of families (S), the APL test statistic, Z, is calculated as indicated above, and 
proceeding in order of xi  each family is added into the set and  the APL test statistic is 
recalculated.  If two or more families have the same xi value they are added at the same 
time.  Once all families have been added in, we define the maximum subset as the subset 
of families that contribute to the max |Z|, Z*.  The absolute value is taken because Z can 
be significant in either the positive or negative direction, depending on the direction of 
association.  The APL-OSA P-value for Z is calculated by permuting the xi and repeating 
the procedure k times obtaining a Z*j for each permutation j.  Finally the P-value is 
calculated as ∑         
     , where I is the indicator function with I(X) = 1 if X true 
and 0 otherwise. 
Since the P-value is computed via permutation, to reduce computing time for the 
initial analysis 500 permutations (k = 500) are used.  Then SNPs with a P-value less than 
0.15 were selected for a second stringent analysis.  In this analysis the number of 
permutations was increased, k = 1000, to provide a more precise P-value estimate.  While 
the use of a permutation procedure increases computational demands it also provides a 
natural correction for multiple testing by comparing the observed test statistic to the 
empirical null distribution of the data.  The number of bootstrap iterations used to 
calculate     ∑   
 
   is also varied between the initial and stringent analysis, 200 initially 
and 400 in the more stringent analysis.  Despite the fact that the original linkage peak 
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was found in GENECARD,  using APL and APL-OSA to detect associations does not 
increase the type I error under the null hypothesis of no association (Chung et al. 2007).   
2.2.2.1 Meta-Analysis 
We performed a meta-analysis by examining gene-smoking interaction signals 
amongst SNPs in Rho-GTPase pathway genes that were analyzed in GENECARD, IHCS, 
or DFHS.  We excluded the study by Wang et al using CATHGEN because they did not 
report on any direct gene-smoking interactions (Wang et al. 2007), and we only report 
results for SNPs that were at least analyzed in GENECARD (the current study).  
Fischer’s method was used to compute the combined P-value for those SNPs that appear 
in 2 or more studies.  Fischer’s method computes the meta-analysis P-value (PM) from S 
independent studies as        ∑        
 
   .  Pi is the P-value of the ith study and PM 
is drawn from a Chi-squared distribution with 2S degrees of freedom.   For the gene-
based meta-analysis each gene was represented by the minimum P-value observed 
across all genetic variants within the gene after correcting for the number of SNPs in the 
gene using the Sidak combination test (Peng et al. 2009; Sidak 1967).  After collapsing 
across the genetic variants within a gene the gene-based P-values were combined using 
Fischer’s method. 
2.2.2.2 Pathway-based Analysis 
We used WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/) (Zhang et al. 2005) to 
perform the pathway-based gene set association analysis .  We applied the 
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hypergeometric test as implemented in WebGestalt to allow for the potential non-
independence of the gene sets and set of SNPs chosen for genotyping.  We used the 430 
SNPs analyzed as the reference gene set.  For significance we used a Bonferroni 
corrected cutoff of 0.05 and required that any gene sets called significant contain at least 
two genes from our list to avoid spurious associations caused by small gene sets that are 
“enriched” by only a single gene. 
2.3 Results 
GENECARD individuals have the clinical characteristics and risk factor 
distributions expected in an early-onset coronary artery disease cohort including a 
younger age of onset, more males than females, and high proportion of people 
diagnosed with hypertension and dyslipidemia (Table 1).  At 33.8% our percentage of 
smokers is higher than what was seen by Horne et al (18.8% for affected and controls 
combined) (Horne et al. 2009).  The various studies that have examined associations in 
the chromosome 3q13 region have used different definitions of smoking leading us to be 
careful when making comparisons between them.  When the smoking definition used by 
Horne et al¸ current smoker or > 10 pack-years, was applied to the CATHGEN cohort 
analyzed by Wang et al (Wang et al. 2007) the percentage of smokers in the datasets was 
60.5%, 55.2%, and 54.2% for the White Initial Dataset, White Validation Dataset, and 
African-American Dataset respectively.  All three of these datasets had a lower 
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proportion of smokers than GENECARD (61.4%) when an identical definition of 
smokers was applied. 
  
Table 1: Clinical Covariates. N is the total number of people used to calculate 
the mean/percentage. Only those individuals who contributed genotypes are included 
in the table.  Other individuals would have been included in the analysis only to 
complete the family structure 
Characteristic - N Mean (SD) / Percentage 
Sex(% Female) – 3,061 37.3% 
Age of onset – 2,010 45.2 (7.7) 
BMI  - 2,387 29.7 (6.5) 
Pack-Years  - 2,434 25.6 (27.1) 
Diabetes (%) – 2,435 19.5% 
Hypertension (%) – 2,436 53.3% 
Dyslipoprotenemia (%)  - 2,438 72.4% 
2.3.1 APL Results 
We performed the standard APL test (Martin et al. 2003) for all 430 SNPs to allow 
comparison with the APL-OSA results from the initial analysis with 200 bootstrap 
iterations and 500 permutations (Figure 1).  As in the analysis by Wang et al (Wang et al. 
2007), rs9289231 was associated with EOCAD ( p < 0.000048), and was the only 
significant SNP after Bonferroni correction for 430 tests (P < 0.00012).  Rs9289231 has 
previously been shown to be associated with high-density lipoproteins (Shah et al. 2006) 
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in addition to early onset CAD.  Twenty-three additional SNPs had unadjusted APL P-
values less than 0.05.  A comparison of all 430 SNPs in the APL-OSA (initial run with 500 
permutations, 200 bootstrap iterations) and the APL analysis is presented in Appendix 
A, Table 15. 
 
Figure 1: APL and APL-OSA Results. APL (blue open circles) and APL-OSA 
(red filled circles) results within the linkage peak region on chromosome 3.  The y-
axis is –log(p-value) and the horizontal line is the 0.05 significance line.  The x-axis is 
the location of each SNP along chromosome 3 in mega-bases. 
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2.3.2 APL-OSA Results 
Table 2 contains the APL-OSA association results.  Of the 430 SNPs, 16 had an 
APL-OSA P-value < 0.05 after completing the second stringent analysis (Table 2).  Of 
these, 12 were associated with a gene and four were intergenic SNPs.  Though no results 
met a Bonferroni corrected P-value of P < 0.00012, this cutoff may be overly conservative 
given the LD the region and the permutation procedure used to calculate empirical P-
values.  Of the 16 SNPs with P < 0.05, six were in genes associated with the Rho-GTPase 
pathway, rs870995 (PIK3CA), rs2272486 (KALRN), rs4234218 (KALRN), rs11707609 
(MYLK), rs1343700 (MYLK), rs10934651 (MYLK), rs6766899 (ARHGAP/CDGAP).  All of 
these genes fell under the chromosome 3 linkage peak (Hauser ER 2004) however there 
was low to moderate LD between the SNPs under this peak (Figure 2).  One SNP of 
particular interest is rs2272486 (P = 0.033, KALRN).  Rs2272486 is a synonymous variant 
(His -> His) and was the most significant SNP in the initial cohort analysis by Wang et al 
(P = 0.0005) (Wang et al. 2007).   
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Figure 2: APL-OSA Associations.  APL-OSA associations after restricting 
initial analyses (Fig. 1) based on a liberal P-value (P < 0.15).  It is these associations 
that are used throughout the paper as they represent our best estimation of the gene-
smoking interactions.  In the LocusZoom (Pruim et al. 2010) plot below the –log10(P-
value) is given on the y-axis and the genomic location on the x-axis.  Only the area 
under the chromosome 3 linkage peak (Hauser ER 2004) is shown.  Colors indicate the 
linkage disequilibrium with the most significant SNP in KALRN (rs4234218, shown as 
a diamond), and are based on LD within the CEU HapMap population.  Only 
rs2272486, highlighted in green, shows even modest LD. 
 
Of the 11 SNPs analyzed by Horne et al. rs4234218 had an APL-OSA P < 0.05 (P = 
0.018, Table 2).  This SNP did not have a significant gene-smoking interaction P-value in 
any of the datasets analyzed by Horne et al, however the maximum subset for rs4234218 
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contained 249 families each of which had an average pack-years of 40.5 or greater.   The 
definition of smokers used by Horne et al was pack-years > 10.  This heterogeneity in the 
definition of the “exposed” subgroup may account for the heterogeneity in association 
results, and would indicate that a more severe smoking phenotype is needed to observe 
interactions with rs4234218. 
A meta-analysis of three gene-smoking interaction studies in the 3q13 genomic 
region revealed two SNPs with evidence for effect modification via smoking (Table, 3).  
rs12637456 (meta-analysis P = 0.044, KALRN) and rs9289231 (meta-analysis P = 0.0017) 
both showed evidence for association when information from independent cohorts was 
combined.  As independent studies often have heterogeneity in the SNPs selected for 
analysis, a gene based approach may be superior (Neale and Sham 2004).  By using 
Sidak’s combination test (Peng et al. 2009) to combine P-values across genes followed by 
a gene-based meta-analysis of three independent cohorts (GENECARD, IHCS, and 
DFHS) we observed evidence for association between EOCAD and gene-smoking 
interactions in KALRN (meta-analysis P = 0.026) and ARHGAP21 (meta-analysis P = 
0.0056, Table 3). 
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Table 2: APL-OSA Results.  Results of the APL-OSA analysis with 1000 permutations and 400 bootstrap iterations (for 
calculation of the variance).  Only those results with P < 0.05 are shown in the table. 
 
Marker Gene BP 
Location 
MAF Z* Z* p-
value 
APL-OSA p-
value 
N - Maximum Subset 
(pack-years cutoff) 
RS9289186 ILDR1 121740304 0.07 2.75 0.003 0.006 232 (41.8) 
RS6766899 ARHGAP31 119107251 0.19 2.95 0.0016 0.008 200 (45.0) 
RS1875111  112978764 0.26 3.23 0.0006 0.011 349 (9.0) 
RS2084385 PAK2 196553867 0.12 3.62 0.0001 0.014 684 (16.0) 
RS11708769 Intergenic 150075547 0.13 2.68 0.0037 0.017 88 (42.0) 
RS4234218 KALRN 123961210 0.36 2.91 0.00183 0.018 249 (40.5) 
RS1513172 Intergenic 117011888 0.33 3.54 0.0002 0.019 232 (42.0) 
RS870995 PIK3CA 178913005 0.42 3.00 0.0014 0.031 358 (6.25) 
RS2272486 KALRN 123988038 0.36 2.72 0.0032 0.033 211 (44.0) 
RS11707609 MYLK 123503423 0.42 2.41 0.008 0.034 319 (37.8) 
RS1343700 MYLK 123571753 0.38 2.47 0.0067 0.041 59 (72.0) 
RS1358087 Intergenic 126078890 0.37 2.35 0.0093 0.046 124 (56.0) 
RS10934651 MYLK 123533208 0.05 2.55 0.0054 0.047 334 (35.0) 
RS10511352 LSAMP 115643277 0.09 2.42 0.0078 0.047 653 (17.5) 
RS1394041 Intergenic 147096847 0.10 2.55 0.0054 0.048 102 (58.0) 
RS9822445 LSAMP 116161534 0.30 2.28 0.0114 0.048 24 (65.8) 
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Table 3: Gene-smoking interactions across three independent studies.  SNPs in Table 3 are located in the Rho-GTPase 
pathway and analyzed in a gene-smoking interaction model in at least two of three studies, IHCS (Horne et al. 2009), 
DFHS (Rudock RE 2011), or the current analysis (GENECARD).  Only SNPs appearing in two or more studies were 
included and the column “Meta-Analysis” is the Fisher’s combined p-value across all the studies. 
 
SNP IHCS GENECARD DFHS Meta-Analysis Gene 
rs9289231 0.07 0.282 <0.001** 0.0017 KALRN 
rs12637456 0.010 0.736  0.044 KALRN 
rs6810298 0.75 0.564 0.012** 0.10 KALRN 
rs4234218 1.00 0.018 0.515 0.15 KALRN 
rs10934490 0.019 0.156  0.20 CDGAP/ARHGAP31 
rs16834817 0.14 0.396  0.22 MYLK 
rs1444768 0.54 0.504  0.63 KALRN 
rs1444754 0.87 0.644  0.88 KALRN 
 
 54 
 
 
2.3.3 Pathway-based WebGestalt  Results 
We performed a pathway-based gene set association analysis with WebGestalt 
(Zhang et al. 2005) using the 16 significant (P < 0.05) SNPs discovered from the APL-
OSA analysis of the  430 SNPs across the chromosome 3q13 linkage region.  We used the 
hypergeometric test as a test of enrichment, and after WebGestalt restricted our initial 
list of 16 SNPs to those mapping to known human genes we were left with 11 SNPs 
mapping to seven human genes (rs1875111 mapped to a homolog of the mouse gene 
BOC).  We tested enrichment for both Gene Ontology (GO) (Ashburner et al. 2000) and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto 2000) gene sets.  
The GO gene sets cytosol (P = 0.0095) and cellular projection (P = 0.046) and the KEGG 
pathways regulation of actin cytoskeleton (P = 0.028) and renal cell carcinoma (P = 0.043) 
were enriched in the pathway analysis.  
Most of the GO and KEGG pathways are defined according to biological function 
and thus do not offer a direct test of the Rho-GTPase pathway as presented by Wang et 
al (Wang et al. 2007).  Using the UCSC Table Browser (Karolchik D 2004) we extracted 
SNPs in the coding and 3’-UTR regions for the genes within the Rho-GTPase pathway as 
depicted in (Wang et al. 2007).  We then further restricted to only those genes on 
chromosome 3 included in our peak-wide analysis.   These restrictions left 6 genes 
(CDGAP/ARHGAP31, KALRN, MYLK, PIK3CA, PIK3CB, PIK3R4) comprising 4912 SNPs.  
We used the 430 SNPs included in the analysis as the reference set and used the 
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intersection of the 4912 SNPs pulled from the UCSC Table Browser and our 430 
analyzed SNPs as the SNP set of interest (97 SNPs).  Of our 16 significant SNPs 7 were in 
the SNP set of interest, compared with 101 out of 430 when considering all genes.  This 
1.87-fold enrichment yielded a suggestive P-value of 0.055 under the hypergeometric 
test.  In order to determine the degree to which smoking drives this enrichment we 
performed the same test but used the 23 SNPs significant in the Association in the 
Presence of Linkage (APL) analysis.  APL does not take into account the influence of 
smoking on the genetic associations, and instead simply tests for an overall association 
of SNP on CAD (Martin et al. 2003).  In this analysis only 4 out of 23 significant SNPs 
were in the aforementioned Rho-GTPase SNP set, giving no evidence for enrichment (P 
= 0.855). 
2.4 Discussion 
This study used a family-based dataset, GENECARD, to validate smoking 
interactions in a linkage region, chromosome 3q13, associated with CAD (Hauser ER 
2004; Wang et al. 2007).  We continued to observe strong evidence for association in this 
region, particularly in the gene KALRN.  Previous evidence for association was more 
pronounced in smokers (Horne et al. 2009; Rudock RE 2011) leading us to believe that a 
SNP-smoking interaction may be responsible for many of the initial associations.  Using 
GENECARD, the EOCAD family-based dataset in which the original linkage was 
identified, we performed an APL-OSA analysis using pack-years as a measure of 
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smoking history and found that 16 SNPs out of 430 analyzed had an APL-OSA P-value < 
0.05 suggesting effect modification by smoking.     
2.4.1 Chromosome 3q13 associations and LD 
Among the 16 gene-smoking interactions identified via APL-OSA there were 
several SNPs not located in the Rho-GTPase pathway or associated with the identified 
KEGG or GO pathways.  LSAMP, a gene previously implicated in CAD (Wang et al. 
2008) was represented by two SNPs both located in introns, rs10511352 (p = 0.047) and 
rs9822445 (P = 0.048).  rs1394041 (P = 0.048) is an intergenic SNP previously found to be 
associated with several blood lipid phenotypes including small low-density 
lipoproteins, high-density lipoproteins, and triglycerides (Kathiresan et al. 2007).   
To examine the correlation among the signals we identified in this study we 
looked at the LD of 26 SNPs, the 16 significant gene-smoking interactions and the 10 
additional SNPs analyzed by Horne et al.  Across all 26 SNPs the LD was quite low, max 
r2 = 0.64 rs1444768 – rs1444754 (Figure 3), indicating that these analyses are identifying 
independent loci that interact with smoking.   
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Figure 3: Linkage Disequilibrium Across SNPs.  Linkage Disequilibrium (LD) Plot of 11 SNPs from Horne et al 
and 15 significant SNPs (APL-OSA p-value < 0.05) from across chromosome 3.  Boxed SNPs are the 11 analyzed by Horne 
et al(Horne et al.).  Underlined SNPs were also analyzed by Rudcock et al (Rudock RE 2011).  Plot shows the pairwise r2 
with darker cells having a higher r2 than lighter cells. 
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2.4.2 Evidence for validation 
To date analyses with four independent datasets (CATHGEN, IHCS, DHS, and 
GENECARD) have identified EOCAD associations and/or gene-smoking interactions in 
the chromosome 3q13 region.  Genome-wide analyses in GENECARD and the Diabetes 
Heart Study (DHS) were a family-based linkage analysis, both of which showed strong 
evidence of linkage in the 3q13 region (Bowden et al. 2006; Hauser ER 2004).  The more 
targeted candidate region analyses in CATHGEN identified specific genetic variants in 
KALRN and the Rho-GTPase pathway as associated with CAD (Wang et al. 2007), and 
validation studies in IHCS and the DHS (Horne et al. 2009; Rudock RE 2011) found 
evidence gene-smoking interactions in KALRN and selected Rho-GTPase genes.  Our 
study provides a further confirmation of these gene-smoking interaction signals from 
Rho-GTPase pathway genes, in particular KALRN as it contained the only exonic gene-
smoking interaction association (rs2272486).   
2.4.3 Evidence for allelic heterogeneity in KALRN 
At the SNP level there were multiple, potentially independent, associations 
within KALRN.  Out of the 11 SNPs analyzed by Horne et al., we identified one gene-
smoking interaction (rs4234218, P = 0.018).  Rs4234218 was not one of the significant 
SNPs found by Horne et al (Horne et al. 2009).   The most significant SNP found in the 
fully adjusted gene-smoking interaction model for young affecteds (most closely 
matching our EOCAD cohort) by Horne et al was rs12637456 (P = 0.010), but this SNP 
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did not have a significant APL-OSA P-value, P = 0.736.  Thus we do not have validation 
at the SNP level in GENECARD.  However, rs4234218 and rs12637456 are located in 
KALRN yet not in LD in the GENECARD dataset, r2 = 0.  Thus, KALRN may be 
important in the etiology and pathogenesis of CAD and we observe substantial allelic 
heterogeneity within the interaction associations between KALRN and CAD.  
Additional explanations for the observed heterogeneity are partial LD with an un-typed 
causal allele or a difference in the definition of smokers versus non-smokers.  While 
APL-OSA allows the data to define the best cutoff, Horne et al and Rudock et al used >10 
pack-years to define smokers.  However, identical exposure definitions still resulted in 
allelic heterogeneity.  For example, rs6810298 was significant in the Rudock et al (P = 
0.012) but not Horne et al (P = 0.75) (Horne et al. 2009; Rudock RE 2011).  Despite this 
heterogeneity the finding of multiple the gene-smoking interactions in multiple 
independent datasets in KALRN gives us confidence that these results are not due to 
random noise or confounding, but instead come from a true signal from these, or 
nearby, genetic variants.  The meta-analysis can yield some clarity by showing those 
SNPs that had the most consistent signal.  In meta-analysis we observed some 
association for replication at the SNP level with rs9289231.  However there was 
significant heterogeneity in the selection of SNPs for the three studies examined.  
Rudock et al selected 28 SNPs within KALRN using a gene tagging approach (Rudock 
RE 2011), Horne et al selected 11 SNPs based on their previous association with Rho-
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GTPase genes (Horne et al. 2009), and in our study the SNPs were selected based on 
their location on chromosome 3 and having been previously typed in the GENECARD 
cohort.  Given this SNP selection heterogeneity a gene-based approach may better 
capture the consistent gene-smoking interactions.  We see significant evidence for 
consistent associations between gene-smoking interactions in KALRN and EOCAD (P = 
0.026). 
2.4.4 Functional heterogeneity in KALRN 
In addition to the aforementioned allelic heterogeneity a literature search 
revealed that KALRN exhibits significant functional heterogeneity.  KALRN is a gene 
with multiple isoforms and multiple functional domains.  The gene was originally 
identified in the brain and has been associated with schizophrenia(Kushima et al. 2010) 
and ADHD (Lesch et al. 2008).  Among cardiovascular diseases in addition to CAD, 
KALRN has been associated with ischemic stroke (Krug T 2010), but this result was not 
replicated in an independent data set (Olsson et al. 2011).   
2.4.5 Smoking and KALRN 
KALRN is primarily known as a neuronal gene and it has several functions 
related to the protection and growth of neurons (Rabiner et al. 2005).  However, another 
important function of KALRN is its inhibition of inducible nitric oxide synthase (iNOS) 
activity through the prevention of iNOS homodimerization (Ratovitski et al. 1999).  
Research indicates that cigarette smoke induced intimia wall thickening in mice is 
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markedly greater in wild type than in iNOS deficient mice (Anazawa et al. 2004), and 
long-term survival after ischemic stroke was associated with interactions between nitric 
oxide synthase genetic variants and cigarette smoke (Oksala et al.).  Given these 
relationships between cardiovascular phenotypes and iNOS, and the evidence that 
cigarette smoke decreases iNOS expression (Hoyt et al. 2003), it is possible that the 
functional link between KALRN, smoking, and coronary artery disease is the joint 
activity of KALRN and smoking on iNOS. 
2.4.6 Rho-GTPase associations beyond KALRN and other pathway 
relationships 
In addition to KALRN, other genes in the chromosome 3q13 region demonstrated 
gene-smoking interactions.  MYLK was the most represented gene among the significant 
results having 3 SNPs with P < 0.05.  All three SNPs, rs11707609 (P = 0.034), rs1343700 (P 
= 0.041), and rs10934651 (P = 0.047) are located in introns of MYLK.  Rs6766899 (P = 
0.008)  is located in ARHGAP31, a Rho-GTPase pathway gene also noted as having a 
gene-smoking interaction by Horne et al (rs10934490, P = 0.017) (Horne et al. 2009).  
ARHGAP31 was also the most significant gene in the gene-based meta-analysis (P = 
0.0056).  Rs870995 had an APL-OSA P-value of 0.031 and is located in PIK3CA.  PIK3CA 
is the alpha subunit of phosphoinositide 3 kinase, and was implicated in a meta-analysis 
of 4 genome wide linkage studies for coronary artery disease (Chiodini and Lewis 2003).  
We compared the enrichment of Rho-GTPase pathway genes, as noted in (Wang et al. 
2007),  amongst the 16 significant SNPs from APL-OSA to those significant in APL .  The 
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16 gene-smoking interactions were suggestive for enrichment (P = 0.055), however the 23 
significant SNPs from the APL analysis, which would indicate an overall association 
with CAD independent of smoking, were not enriched Rho-GTPase pathway genes (P = 
0.855).  Thus we concluded that the enrichment of the Rho-GTPase pathway is likely due 
to gene-smoking interactions rather than than marginal genetic associations with CAD. 
In addition to specifically examining the Rho-GTPase pathway genes we 
examined the enrichment of functional KEGG and GO pathways.  The KEGG pathway 
regulation of the actin cytoskeleton was enriched (P = 0.028) in our analyses.  Regulation 
of the actin cytoskeleton may be mechanistically involved in the pathogenesis of CAD 
through its role in the migration and morphology changes of smooth muscle cells.  An 
important component of the association between smooth muscle cells and CAD is their 
differentiation from a contractile to a synthetic phenotype, where the cell can respond to 
vascular injury (Doran et al. 2008), and genetic variants associated with vascular disease 
are associated with smooth muscle cell differentiation (Milewicz et al. 2010).  Smooth 
muscle cell differentiation involves extensive morphology reorganization, implicating 
the actin cytoskeleton as an important mediator of the process.  The actin cytoskeleton 
also plays a role in cellular migration and proliferation, and proliferation of smooth 
muscle cells is proposed to be a key component in the development of atherosclerosis 
(Libby and Theroux 2005).  While other members of the regulation of the actin 
cytoskeleton pathway may be targets for future analyses, we recognize that it will take 
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careful functional studies in model systems to elucidate the causal actors.  Furthermore, 
our study suggests that these analyses will need to be augmented with careful analysis 
of environmental risk factors to understand the relationship between 
pathways/genes/genetic variants and CAD.   
 
2.5 Conclusion 
CAD is a complex disorder with a variety of genetic variants found to modify 
risk (Bis et al. 2011; Maouche and Schunkert 2012; Schunkert et al. 2011).  Functional 
relationships are elusive, perhaps due to the presence of allelic heterogeneity, genetic 
heterogeneity, and gene-environment actions.  While genome-wide association studies 
have great utility, unraveling epistasis or environmental interactions via this method can 
require sample sizes in the hundreds of thousands (Zuk et al. 2012).  Targeted gene-
environment interactions studies, along with higher level analyses at the pathway or 
functional level, are needed in order to elucidate causative links between genetic 
variants and CAD.  This study reaffirms published gene-smoking interactions in KALRN 
while identifying a novel coding variant, highlights multiple gene-smoking interactions 
under the chromosome 3q13 linkage peak, and uses pathway analyses to integrate and 
better understand the gene-smoking interactions arising from this region.  Each of these 
analyses implicates specific pathogenic mechanisms that can be followed up in 
functional studies.  KALRN and smoking are potentially mechanistically linked via their 
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inhibition of inducible nitric oxide synthase, the Rho-GTPase pathway has several 
members lying outside our chromosome 3 region of investigation that may present 
novel candidate genes for analysis, and our pathway analyses reveal global pathways 
that may be interrupted or jointly analyzed to further this work. 
 
. 
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3. Hypertension and Peripheral Arterial Disease are 
Associated with Traffic-Related Air Pollution in a Cardiac 
Catheterization Cohort 
3.1 Introduction 
Cardiovascular diseases kill millions worldwide every year.  Specific 
presentations of these diseases, e.g. ischemic heart disease, rank among the top 5 causes 
of death in developed high income countries (Ambrose and Barua 2004; Lopez et al. 
2006).  Air pollution is purported to play a large role in the pathogenesis of 
cardiopulmonary disease and may account for as much as 3% of the mortality from 
cardiopulmonary diseases making it one of the strongest risk factors for these health 
outcomes (Rudock RE 2011).  Analyses of several large cohorts designed to describe the  
the epidemiological characteristics of air pollutants have been extremely fruitful and 
informative (Karolchik D 2004; O'Donnell and Nabel 2011; Schunkert et al. 2011) (Khot et 
al. 2003).  Studies focusing on a small subset of specific outcomes have advanced the 
work of the larger epidemiological studies by highlighting the adverse effects of air 
pollution on the pulmonary and cardiovascular systems.  Recent research has shown the 
myriad of effects that air pollution can have on the cardiovascular systems, and various 
measures of air pollution have been shown to decrease heart rate variability (Heard-
Costa et al. 2009) (Chung et al. 2007), and increase blood pressure (Schmidt et al. 2006) 
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(Ashburner et al. 2000), cardiovascular hospital admissions (Bis et al. 2011; Lall R 2011), 
and mortality (Hoek et al. 2013; O'Donnell and Nabel 2011).   
Air pollution is a heterogeneous exposure and the term can refer to a variety of 
particles and gaseous compounds encountered in the ambient and indoor environment.  
These include volatile inorganic compounds such as nitrogen and sulfur dioxides, 
volatile organic compounds and elemental carbon, as well as particulate matter 
classified into various size distributions, e.g. particulates < 2.5μm in diameter (PM2.5).  
Researchers have recently begun to apportion air pollution by component or source so 
as to reduce variability and better understand the contribution each component has to 
public health (Price et al. 2006b) (Khot et al. 2003; Lesch et al. 2008).  We add to this body 
of research by focusing on indicators of traffic-related air pollution (TRAP) exposure.  
TRAP is composed of vehicular exhaust, evaporative emissions, and particulate matter 
created through brake and tire wear and resuspended road dust.  TRAP has been 
associated with a number of cardiovascular outcomes including heart rate variability 
(Helgadottir et al. 2007), deep vein thrombosis (Zuk et al. 2012), left ventricular 
hypertrophy (Van Hee et al. 2009), and myocardial infarction (Mustafić et al. 2012; Peters 
2009; Rosenlund et al. 2006).    
We used distance to roadways and traffic exposure zones (TEZs) as indicators of 
TRAP exposure.  The TEZs are six mutually exclusive zones of differing TRAP source 
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and ordered to be increasing in the severity of TRAP exposure.  Our study subjects were 
drawn from the CATHeterization GENetics (CATHGEN) cohort.  CATHGEN is a large, 
sequential cohort with participants selected from patients presenting to the Duke 
University Cardiac Catheterization Clinic between 2001 and 2011.  CATHGEN has been 
successfully used in several studies of cardiovascular disease (Wang L 2007) (Wang L 
2008) (Shah SH 2009), but the effect of environmental exposures on cardiovascular 
outcomes has not been explored in this unique cohort.   
3.2 Methods 
3.2.1 Study Population 
All individuals in this study came from the 9,334 individuals who consented to 
participate in the CATHGEN cohort.  CATHGEN participants were recruited 
continuously from 2001 – 2011 and came from 44 states and multiple US territories, 
according to address information extracted from medical records.  The majority (89%) 
resided in North Carolina (Figure 4).  Ethnically, CATHGEN is primarily composed of 
self-identified European-Americans and African-Americans.  Those who did not self-
report as European-Americans or African-American (6%) were excluded from analyses.  
A description of the CATHGEN cohort is given in Table 4. 
The CATHGEN participant addresses were geocoded by the Children’s 
Environmental Health Initiative.  Out of 9334 individuals submitted, 8017 (86%) were 
successfully geocoded, 7118 (76.3%) resided in North Carolina, and 2318 (24.8%) 
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resided in our study area of Durham, Wake, and Orange counties, North Carolina (Figure 
4).  Removal of those who did not self-report as European-Americans or African-
American (N = 64), and those residing more than two miles from a primary or secondary 
roadway based on roadway information from the North Carolina Department of 
Transportation (N = 132), left a study cohort of 2124 individuals for this analysis. 
 
Figure 4: CATHGEN Participants in Study Area. The distribution of 
CATHGEN participants within the study area of Durham, Wake, and Orange 
counties, NC is given in the figure below.  The participant locations are overlaid on a 
map of the primary and secondary roadway network as well as the traffic exposure 
zones 
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Table 4: Demographic and clinical variables   for   the study cohort and 
race/sex stratified sub-cohorts used for analysis. 
Clinical 
Covariates 
Total Male Female AA EA 
N 2124 1274 850 625 1499 
Sex (% Female) 60.0% 0.0% 100% 49.6% 64.3% 
Race (% EA) 70.6% 75.8% 62.9% 0.0% 100% 
Age 61.33 (12.2) 60.71 (11.9) 62.27 (12.6) 57.44 (11.6) 62.96 
(12.0) 
BMI 30.32 (7.36) 29.88 (6.6) 30.98 (8.33) 32.59 (8.24) 29.38 
(6.75) 
Ejection 
Fraction 
57.85 
(12.85) 
56.39 (13.02) 60.03 (12.3) 56.3 (13.7) 58.5 
(12.4) 
PVD 6.8% 7.9% 5.1% 6.9% 6.7% 
Hypertension 69.3% 67.9% 71.4% 81.3% 64.3% 
MI 8.2% 8.2% 8.1% 9.8% 7.5% 
Number of 
Diseased 
Coronary 
Vessels (% = 0) 
40.2% 31.8% 52.7% 52.5% 35.0% 
Number of 
Diseased 
Coronary 
Vessels (% = 1) 
19.3% 19.8% 18.6% 15.5% 20.9% 
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Number of 
Diseased 
Coronary 
Vessels (% = 2) 
15.4% 16.5% 9.9% 9.4% 15.7% 
Number of 
Diseased 
Coronary 
Vessels (% = 3) 
17.7% 22.7% 10.1% 13.9% 19.2% 
Distance to 
Roadways (m) 
898 (747) 918 (759) 868 (729) 784 (663) 946 
(775) 
Distance to 
Roadways - 
IQR (m) 
990 1031 929 895 1020 
TEZ 1 (%) 19.2% 20.3% 17.4% 10.1% 23.0% 
TEZ 2 (%) 36.0% 38.3% 32.6% 24.0% 41.0% 
TEZ 3 (%) 15.0% 13.7% 16.8% 15.2% 14.9% 
TEZ 4 (%) 27.4% 25.1% 30.7% 47.0% 19.2% 
TEZ 5 (%) 1.5% 1.4% 1.7% 2.4% 1.1% 
TEZ 6 (%) 0.99% 1.10% 0.82% 1.28% 0.87% 
 
 
3.2.2 Clinical Information 
We selected several cardiovascular outcomes to analyze in order to understand 
the effect of TRAP across a spectrum of measures of, and risk factors for, cardiovascular 
disease.  We analyzed the increased risk of a recorded myocardial infarction within a 
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week of the cardiac catheterization (MI) to study the association between TRAP and 
acute outcomes.  To study the extent of coronary atherosclerosis we associated TRAP 
exposure with the number of diseased coronary vessels.  This variable was created by 
clinicians after examining images from the catheterization procedure, and a diseased 
vessels is defined as a coronary vessel with >75% blockage.  This variable is encoded by 
physicians and takes into account location of lesions, left versus right dominance (as 
determined by the position of the posterior descending artery), as well as the total 
number of lesions.  While lesions in most arteries increment the variable by 1, a lesion in 
the left main carotid artery increments it by two and lesions in the right coronary artery 
or left main carotid artery increment it by 3, provided the patient is right dominant or 
left dominant respectively.  A full description of the number of diseased coronary 
vessels variable is given in Table 16 (Appendix B).  We analyzed hypertension as it is a 
strong coronary artery disease risk factor (Wilson et al. 1998), and air pollution has been 
associated with increased blood pressure (Fuks et al. 2011; Schmidt et al. 2006).  We used 
a binary indicator variable where 1 indicated the presence of clinically significant 
hypertension as documented during the health & physical exam administered prior to 
the catheterization procedure.  This indication did not necessarily depend on history of 
specific hypertension treatment but was determined by the attending physician.  Finally 
we also studied the association between Peripheral Arterial Disease (PAD) and TRAP.  
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PAD was defined according to the Charlson Comorbidity Index (Charlson et al. 1987; 
Quan et al. 2011), and documented by the physician prior to the catheterization 
procedure.  The correlation amongst all outcomes is given in Table 17 (Appendix B). 
3.2.3 Indexing of Traffic-related air pollution 
We defined our distance to roadway exposure variable as the perpendicular 
distance from a patient’s primary geocoded residence to a primary or secondary 
roadway.  Primary roadways were defined as divided, limited-access highways 
distinguishable by the presence of an interchange.  Secondary roadways were defined as 
the main inter- and intra-city arteries, and often had multiple lanes of traffic as well as 
at-grade intersections with other roads and driveways.  The roadways were classified by 
the North Carolina Department of Transportation and are available in their 4th quarter 
release of the 2010 Topologically Integrated Geographic Encoding and Referencing 
North Carolina Primary and Secondary Roads State-based shapefile.  This file is 
compatible with the ArcGIS® software suite (Hauser et al. 2003) which was used to 
visualize the data, and is available at http://dotw-
xfer01.dot.state.nc.us/gisdot/DistDOTData/LRS_ROUTE_SHP.zip.  The primary and 
secondary roadway classification used by the North Carolina Department of 
Transportation in this data release is consistent with the definition used the by United 
States Census.   The average length of time at residence was 587 days making this 
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distance to roadways measure a measure of long-term exposure to traffic-related air 
pollution.  We used an inverse logarithm transform as this was the transform implied by 
a study of ultra-fine particulate matter and distance to major roadways in North 
Carolina (Hagler et al. 2009b)  
.  Our second measure of TRAP was the Traffic Exposure Zones.   For Durham, 
Wake, and Orange counties, we constructed a hierarchy of six mutually exclusive but 
non-contiguous TEZs which categorize exposure to traffic-related air pollution:  high 
volume traffic with regular congestion-related delays (TEZ 6); other high volume traffic 
with smooth flow (TEZ 5); secondary arterials identified by mass transit routes (TEZ 4); 
high-traffic urbanized areas characterized by signal light density (TEZ 3); remainder of 
the urbanized areas as defined by the 2000 US Census (TEZ 2); and remainder of the 
study area (TEZ 1).  A 1-km buffer around the Raleigh-Durham airport was excluded 
from the study, which caused the exclusion of one individual.  In a study of wheezing in 
infants, traffic exposure zones similar to the ones created for this study yielded positive 
associations (Ryan et al. 2005). 
Traffic exposure zones 4, 5, and 6 were based on traffic data concerning 
predominant roadway usage.  For each of these zones a 200m buffer was created around 
road segments. Modeled traffic flow and actual transit route data for 2005 was supplied 
by the Institute for Transportation Research and Education (ITRE) at NC State 
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University (NCSU).  TEZ 4 was defined as road segments that constituted routes for 
three municipal transit authorities (Capital Area Transit for the Raleigh/Cary area, 
Durham Area Transit Authority, and Chapel Hill Transit) and two local universities 
(Duke and North Carolina State University).  The traffic volume zone (zone 5) was 
defined as road segments carrying >40,000 vehicles per day.  Finally, traffic delay (zone 
6) was defined as roads having a 35% reduction in transit time when compared to free 
flowing traffic.  The time period used to model the traffic flow was peak morning traffic.  
A detailed description of all TEZs is given in Appendix B, Table 18.  Only a few 
individuals in the study cohort resided in TEZ 5 (N = 32) and TEZ 6 (N = 21) thus we 
combined these zones for some analyses, and for all analyses TEZ 1 was the baseline 
exposure zone. 
3.2.4 Statistical Methods 
R v10.1(Team 2009) was the statistical software used for all analyses.  
Generalized additive models (GAMs) as implemented in the mgcv package (Wood 2008) 
were used to estimate the increased risk of our four cardiovascular outcomes from 
traffic-related air pollution.  As linear models are a subset of generalized additive 
models the GAMs are appropriate when the response is linear, allow for  model 
diagnostics through the visualization of the exposure response relationship using 
splines, and can flexibly incorporate non-linear terms using thin-plate regression splines.  
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The risks of the binary outcomes (MI, hypertension, and PAD) were estimated using a 
logistic model with a quasi-binomial link function.  A linear link function was used for 
the continuous outcomes.  Since the number of diseased coronary vessels was an ordinal 
variable we used a cumulative link model, as implemented in the R package ordinal 
with a logistic link.  This model is equivalent to the standard proportional odds 
regression model.  An inverse-exponential transform was used to better model the 
exposure-response relationship when distance to roadways was the TRAP measure.  
Associations were initially fit using a basic model which made no adjustments and then 
an adjusted model which included terms for race, sex, smoking, body mass index, and 
socioeconomic status.  Race, sex, and smoking status were binary variables.  Smoking 
status was a clinical variable extracted from the patient’s medical records where a 
positive response indicated that the patient reported smoking at least ½ pack of 
cigarettes per day.  If the patient had discontinued smoking solely due to symptoms of 
coronary artery disease then a positive response was still recorded.  Socioeconomic 
status was indexed by median home value at the census tract level.  The 2000 US Census 
was used for individuals who had their catheterization on or before July 1, 2005 and the 
2010 Census was used for all other patients.  This allowed for the use of the most 
accurate census data given the 10 year sampling of CATHGEN.  Both median home 
value and body mass index were treated as linear predictors.  Under the hypothesis that 
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air pollution increases the progression of cardiovascular disease, the age at which 
individuals receive a catheterization could be considered a function of their exposure to 
air pollution, amongst other predictors.  Thus age at catheterization was considered a 
potential alternative outcome (collider) and was thus not included in the adjusted 
model.  Associations were examined for influential points using Cook’s distance (Cook 
1977), and any points found to be overly influential were removed and the model refit. 
Race and sex specific associations were assessed via stratification.  Stratifications 
were chosen over associations because we were greatly interested in sex and race 
specific associations given the noted sex differences in associations between TRAP and 
cardiovascular outcomes (Kanehisa and Goto 2000; Peters et al. 2004; Zuk et al. 2012), as 
well as the need for greater exploration of potential sex-specific associations.   
All results are expressed in in terms of the regression coefficient (β) for linear 
outcomes or the odds ratio (OR) for outcomes using a logistic regression or cumulative 
link model.  Regression coefficients and odds ratios are presented on the scale of an 
inter-quartile range increase in the inverse exponential transformed distance to roadway 
variable or as residence in a traffic exposure zone as compared to TEZ 1 (baseline) 
depending on which exposure was being examined. 
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3.3 Results 
3.3.1 Hypertension 
We observed that hypertension was associated with distance to roadways both in 
an unadjusted model (OR = 1.21, CI: 1.06 – 1.37) and in a model adjusted for race, sex, 
smoking status, and socioeconomic status (OR = 1.17, CI: 1.03 – 1.33).  The similarity of 
the odds ratios between these two associations indicated that while some of the included 
covariates may show strong associations with hypertension, e.g. smoking status, none 
showed evidence of confounding the distance to roadway associations (Table 5, Figure 
5). 
Stratifying by race and sex revealed that the association between hypertension 
and distance to roadways is stronger in African-Americans (AA) (OR = 1.49, CI: 1.13 – 
1.97) than European-Americans (EA) (OR = 1.11, CI: 0.95 – 1.28) and stronger in women 
(OR = 1.25, CI: 1.01 – 1.55) than men (OR = 1.12, CI: 0.95 – 1.32).  These associations were 
adjusted for smoking and socioeconomic status as well as race or sex, depending on the 
stratification. 
There were no strong associations amongst the traffic exposure zones.  Though 
TEZ 5 and TEZ 6 showed increased odds ratios, 3.22 (CI: 0.85 – 12.2) and 1.97 (CI: 0.49 – 
7.96) respectively, the confidence intervals were wide and included 1.0.   
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3.3.2 Peripheral Arterial Disease 
PAD was significantly associated with distance to roadways in an unadjusted 
model (OR = 1.33, CI: 1.18 – 1.50).  This association remained in the age, race, sex, 
smoking, and socioeconomic status adjusted model with little change in the odds ratio 
indicating independence of the association from the included potential confounders (OR 
= 1.32, CI: 1.17 – 1.49, Table 5).  Stratifying by race in the adjusted model revealed 
stronger associations among the EA (OR = 1.39, CI: 1.21 – 1.61) than AA (OR = 1.15, CI: 
0.90 – 1.48), and stratifying by sex while adjusting for the remaining confounders 
revealed stronger associations in men (OR = 1.40, CI: 1.21 – 1.63) than women (OR = 1.10, 
CI: 0.87 – 1.38). 
TEZ 6 (high-speed, high volume roadways) was associated with PAD (OR = 2.60, 
CI: 1.03 – 6.54).  None of the other traffic exposure zones showed significant associations 
with PAD (Table 6, Figure 5). 
 
3.3.3 Myocardial Infarction and Number of Diseased Vessels 
Distance to roadways was not associated with an increased risk of MI within a 
week prior to the catheterization in our adjusted model (OR = 0.89, CI: 0.77 – 1.03, Table 
2).  Amongst the traffic exposure zones, residence in TEZ 2 (urbanized areas) was 
associated with increased risk of MI (OR = 1.71, CI: 1.18 – 2.48) and TEZ 3 (signal lights) 
also showed increased risk of MI (OR = 1.53, CI: 0.99 – 2.38).  Due to the small sample 
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size TEZ 5 and 6 were combined for the MI analyses though this combined traffic 
exposure zone was not associated with MI (Table 6, Figure 5). 
We used the number of diseased vessels as our measure of coronary 
atherosclerosis.  We did not observe any associations between distance to roadways the 
number of diseased coronary vessels.  We did find that TEZ 4 (transit routes) was 
associated with a decrease in the number of diseased vessels in an unadjusted 
cumulative link model (OR = 0.73, CI: 0.58 – 0.94).  However this association was absent 
in the adjusted model (OR = 0.94, CI: 0.72 – 1.21, Table 6, Figure 5).   
 
Table 5: Association between clinical outcomes and distance to roadways 
Outcome Subset  OR CI  
Hypertension Overall 1.17 1.03 - 1.33 
 Men 1.12 0.95 - 1.32 
Women 1.25 1.01 - 1.55 
EA 1.11 0.95 - 1.28 
AA 1.49 1.13 - 1.97 
 
PVD Overall 1.32 1.17 - 1.49 
 Men 1.40 1.21 - 1.62 
Women 1.10 0.87 - 1.38 
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EA 1.39 1.21 - 1.61 
AA 1.15 0.90 - 1.48 
 
MI Overall 0.88 0.76 - 1.02 
 Men 0.81 0.66 - 0.98 
Women 0.99 0.80 - 1.24 
EA 0.82 0.67 - 0.98 
AA 1.03 0.80 - 1.32 
 
Number of Diseased 
Vessels 
Overall 0.96 0.87 - 1.06 
 Men 0.98 0.87 - 1.11 
Women 0.91 0.77 - 1.08 
EA 0.99 0.88 - 1.11 
AA 0.88 0.73 - 1.08 
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Figure 5: Association Between Cardiovascular Outcomes and Distance to Roadways and the Traffic 
Exposure Zones.  Forrest plots of the association between the cardiovascular outcomes and distance to roadways 
(top) and the traffic exposure zones (bottom).  For Hypertension and MI traffic exposure zones 5 and 6 were 
combined into a single zone (TEZ 5-6).  All results from the adjusted models. 
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Table 6: Association between clinical outcomes and the traffic exposure zones 
Outcome Subset  OR CI  
Hypertension TEZ 2 0.89 0.67 - 1.18 
 TEZ 3 0.84 0.59 - 1.19 
TEZ 4 0.92 0.67 - 1.27 
TEZ 5-6 2.61 0.99 - 6.89 
TEZ Trend 1.02 0.92 - 01.12 
 
PVD TEZ 2 0.87 0.62 - 1.23 
 TEZ 3 0.92 0.61 - 1.40 
TEZ 4 1.12 0.78 - 1.60 
TEZ 5 0.81 0.29 - 2.27 
TEZ 6 2.60 1.03 - 6.55 
TEZ Trend 1.08 0.97 - 1.19 
 
MI TEZ 2 1.74 1.21 - 2.50 
 TEZ 3 1.52 0.98 - 2.34 
TEZ 4 1.32 0.88 - 1.97 
TEZ 5-6 0.95 0.37 - 2.41 
TEZ Trend 1.01 0.90 - 1.12 
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Number of 
Diseased Vessels 
TEZ 2 1.09 0.86 - 1.37 
 TEZ 3 0.97 0.73 - 1.29 
TEZ 4 0.94 0.72 - 1.21 
TEZ 5 0.61 0.30 - 1.23 
TEZ 6 0.85 0.35 - 2.10 
TEZ Trend 0.95 0.88 - 1.03 
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3.4 Discussion 
Though the association between ambient air pollution and cardiovascular 
mortality has been well-established(Brook et al. 2010; Hoek et al. 2013; Karolchik D 
2004), there is still much we have to learn about the specificity of association between 
specific air pollution exposures and cardiovascular outcomes.  Using the CATHGEN 
cohort we have shown that traffic-related air pollution is strongly associated with 
specific cardiovascular outcomes.  Our strongest associations occurred between TRAP 
and PAD.  In our analyses we saw that increased TRAP exposure was associated with a 
32% increase in the prevalence of PAD (OR = 1.32, CI: 1.17 – 1.49) in a race, sex, smoking, 
and socioeconomic status adjusted model.  In a large cohort study of urban air pollution, 
residence within 50 m of a major roadway was associated with a 77% increase in the risk 
of PAD when compared with residence greater than 200m from a roadway (OR = 1.77, 
CI: 1.01 – 3.10) (Kanehisa and Goto 2000).  In addition to validating the overall 
association with CAD we were able to expand on their analyses by incorporating racial 
stratifications.  Our results revealed a stronger association among EA (OR = 1.39, CI: 1.21 
– 1.61) than AA (OR = 1.15, CI: 0.90 – 1.48).  The implications of this racial interaction are 
unclear.  Even though we adjusted for socioeconomic status via median home value, it 
cannot be ignored that there still may be independent dimensions of SES relevant to the 
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prevalence of PAD that differ by racial subgroup.  Additionally there may be modifying 
factors, including genetic susceptibility and genetic risk variants, which may differ by 
racial subgroup.  Further study is necessary to uncover these potential modifiers. 
In addition to PAD, we found hypertension was strongly associated with 
distance to roadways.  In a large population based study a 10μg/m3 increase in PM2.5 was 
associated with a 5% increase in the risk of hypertension (OR = 1.05, CI: 1.00 – 
1.10)(Johnson and Parker 2009).   This association with PM2.5 was substantially below our 
observed association between hypertension and distance to roadways (OR = 1.17, CI: 
1.03 – 1.33).  Additionally while we noted that the association was stronger in AA (OR = 
1.49, CI: 1.13 – 1.97) than EA (OR = 1.11, CI: 0.95 – 1.28), in their study Johnson and 
Parker observed that the association between hypertension and PM2.5 was driven by 
non-Hispanic whites.  As Johnson and Parker were using self-reported hypertension 
(based on two or more physician reports of hypertension) they acknowledged that 
health access disparities between ethnicities may contribute to the differential 
associations.  However in the case of CATHGEN all individuals were sampled at Duke 
University Medical Center thus received the same level of health care.  Hypertension 
was based on a report filled out by a trained physician or medical fellow, thus we do not 
believe that differential health disparities contributed to our race specific associations.   
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Residence in TEZ 6 (roadways with high traffic delays) was associated with a 
strongly increased risk of PAD (OR = 2.60, CI: 1.03 – 6.54).  However a linear trend 
across the traffic exposure zones was not significant (Table 6).  This lack of a linear trend 
leaves open the question of whether specific sources of TRAP are differentially 
associated with PAD or if the most common sources all have similar effects.  The recent 
availability of component specific analyses should begin to answer this question. 
Exposure to traffic-related air pollution has been shown to cause an increase in 
observed MIs within 1 hour of exposure (Peters et al. 2004).  In a review of 26 articles on 
the association between air pollution and MI the associations between MI and long-term 
exposure to traffic-related air pollution were mixed (Bhaskaran et al. 2009).  Seven of the 
26 studies examined long-term exposures with 5 examining NO2 or distance to 
roadways and amongst these 2 showed no association and 3 showed an increased risk of 
MI with TRAP exposure (Bhaskaran et al. 2009).  In our studies residence in urbanized 
areas (TEZ 2) and in areas of high signal light density (TEZ 3) was associated with an 
increased risk of MI.  These associations with the traffic exposure zones were not 
replicated in our distance to roadway analyses which did not show an association with 
MI.  Though the cumulative evidence appears to point to an association between MI and 
TRAP more work needs to be done classifying the exact nature of the exposure-response 
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curve both with respect to the relevant time frame of exposure and causative 
constituents.   
To date there most studies associating air pollution with atherosclerosis burden 
have used subclinical measures such as carotid intima medial thickness (CIMT) or aortic 
calcification.  Using the Heinz Nixdorf Recall study researchers showed an association 
between subclinical atherosclerosis and long-term PM2.5 exposure(Bauer et al. 2010).   In 
a 2007 study participants living with 50m of a roadway showed increased coronary 
artery calcification compared to those living >200m from a roadway(Hoffmann et al. 
2007).  In 2010 data from clinical trials was used to conduct a longitudinal study where 
increased exposure to traffic (residence within 100m of a roadway) was associated with 
CIMT progression, however exposure to PM2.5 was not associated with increased CIMT 
progression (Künzli et al. 2010).   None of these studies focused on the progression of 
clinically significant atherosclerosis as determined by a physician.  Using our clinical 
variable number of diseased coronary vessels, which takes into account coronary 
dominance, atherosclerosis location, and degree of atherosclerosis (Appendix B, Table 
16) we did not observe associations with TRAP.  There are several possible reasons for 
this.  First we are sampling from a unique population consisting of individuals who 
have had a coronary catheterization.  For this reason the rate of coronary artery disease 
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is high.  Increased risk of coronary artery disease from TRAP exposure may be difficult 
to detect in this population due to the increased baseline risk.   
3.4.1 Strengths and Limitations 
There are several strengths and limitations to this study.  One of our primary 
limitations is our indirect measure of traffic-related air pollution.  We use distance to 
roadways as a metric for TRAP exposure however this is an indirect measure that does 
not inform on the causative actors.  Despite this, distance to roadways is strongly 
correlated with exposure to fine particle particulates (Hagler et al. 2009b) and is a widely 
used TRAP exposure metric.  An additional limitation of our study is the unique 
selection of CATHGEN.  CATHGEN was selected from patients at the cardiac 
catheterization laboratory at Duke University Medical Center.  As such it represents a 
specialized population, enriched for cardiovascular diseases.  However despite the 
unique selection criteria we are still able to replicate TRAP associations published using 
population-based cohorts.  In addition individuals with underlying cardiovascular 
disease have been noted as a population particularly at risk of air pollution related 
adverse health effects and thus worthy of in-depth study (Pope 2000). 
The main strength of CATHGEN is the large sample size.  At more than 9,000 
participants CATHGEN represents a very large clinical cohort that can be used for a 
variety of air pollution studies.  Even after our restriction to the three county study area 
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we retained enough sample size to perform meaningful stratification analyses that 
yielded informative race and sex specific associations.  Additionally the depth of clinical 
information observed in CATHGEN is a rare find for a cohort of this size.  By combining 
Duke medical records for all patients we have a large volume of relevant outcomes that 
augments the detailed cardiovascular measures made during the cardiac catheterization.  
This clinical information has been enriched with genomic information including 
genome-wide genotyping, metabolomics, proteomics, gene expression, and epigenetic 
data.  Though none of this data has been utilized in this study it can all be applied to 
understand the mechanism of environmental exposures. 
3.5 Conclusion 
In conclusion we have shown that TRAP is strongly associated with several 
cardiovascular outcomes including peripheral arterial disease and hypertension.  We 
did not find strong associations amongst some cardiac specific outcomes such as 
coronary artery disease though this may be due to the unique selection of the cohort and 
enrichment for cardiovascular disease.  These analyses replicate previously published 
findings in a cohort that may be at risk for adverse cardiovascular effects due to TRAP 
exposure and add relevant information on race and sex specific associations, while 
addressing some previous hypotheses on potential confounders of some published 
associations. 
 90 
 
 
4. Genetic variants in the Bone Morphogenic Protein 
gene family modify the association between distance to 
roadway and peripheral arterial disease in a large 
cardiovascular disease cohort. 
4.1 Introduction 
According to the Bureau of Transportation, as of 2010 there were over 250 
million registered highway vehicles in the United States, making traffic-related air 
pollution a ubiquitous environmental exposure.  Peripheral Arterial Disease (PAD) is 
characterized by blockages in the peripheral arteries, principally the lower extremities, 
and affects approximately 12% of the population (Shammas 2007).  Studies have 
associated TRAP exposure with PAD (Hoffmann et al. 2009a; Hoffmann et al.), 
identified potential genetic components to PAD (Knowles et al. 2007; Wahlgren and 
Magnusson 2011), and verified that specific genetic variants interact with air pollution to 
affect cardiovascular disease(Zanobetti et al. 2011).  However the joint effect of genetic 
variants and TRAP exposure on PAD remains to be studied.  To investigate this joint 
effect we performed race-stratified GWIS using the CATHeterization GENetics 
biorepository (CATHGEN) (http://cathgen.duhs.duke.edu) (Shah et al. 2010a).  
CATHGEN contains blood samples and clinical information from 9,334 patients 
presenting to the Duke University Cardiac Catheterization Clinic from 2001 – 2011.  We 
restricted all analyses to European-Americans (EA) and African-Americans (AA) in 
 91 
 
 
North Carolina who resided within two miles of a primary or secondary roadway (N = 
6,066, Appendix D).  Distance to primary and secondary roadways, henceforth “distance 
to roadways”, is strongly correlated with TRAP (Hagler et al. 2009b; Zhu et al. 2002b), 
and is associated with cardiovascular outcomes including left ventricular mass (Van Hee 
et al. 2009), coronary heart disease (Hoffmann et al. 2009a; Hoffmann et al. 2007), and 
PAD (Hoffmann et al. 2009b).  In our cohort an interquartile range increase in distance to 
roadways was significantly associated with a decrease in PAD prevalence in a race and 
sex adjusted logistic regression model (OR = 0.799, P = 0.044). 
4.2 Methods 
4.2.1 Study design 
The CATHGEN cohort is a large biorepository of samples from consenting 
patients that presented to the Duke University Cardiac Catheterization Clinic.  
Collection of the samples began in 2001 and was finished in 2011 with 9334 unique 
patients sampled over the 10 year period.  Sample collection included a written 
informed consent form and 50 mL of blood collected through the femoral artery.  
PAXgene RNA tubes (http://www.preanalytix.com) and EDTA tubes for DNA were 
stored at -80°C (Shah et al. 2010a).  The collection and all subsequent analyses of the 
CATHGEN cohort were approved by the Duke University Institutional Review Board. 
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Annotation of patient data with address information was performed by the 
Children’s Environmental Health Initiative (CEHI) in the Duke Nicholas School of the 
Environment.  A total of 8,071 CATHGEN participants were geocoded, of which 7,158 
resided in North Carolina (Appendix C, Figure 10).  We restricted all analyses to the 
CATHGEN participants residing in North Carolina.  Using the ArcGIS (ESRI 2011; 
Hauser et al.) software package we were able to import both the patient locations and 
locations of all primary and secondary roadways in North Carolina.  As defined 
according to the North Carolina Department of Transportation 
(http://www.ncdot.gov/it/gis/DataDistribution/DOTData/LRS_ARCS_SHP.zip), primary 
roadways are major highways distinguished by interchanges and secondary roadways 
are major intra and inter-city arterials.   Using ArcGIS we calculated the distance to the 
nearest primary or secondary roadway, known to be correlated with traffic-related air 
pollution (Hagler et al. 2009b; Zhu et al. 2002b), for each CATHGEN address and used 
this distance as a proxy for traffic-related air pollution exposure.  The binary peripheral 
arterial disease (PAD) variable, indicating the presence or absence of PAD, was collected 
from the medical records of the CATHGEN participants as entered by their attending 
physician.  The clinical covariates of the study cohort are given in Table 7. 
As the CATHGEN cohort spanned 10 years of collection there were 750 
participants with multiple addresses due to moving during the collection period.  To 
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resolve this we selected the address whose recorded start date (the date the participant 
was recorded to have moved in to that residence) was closest to the date of the cardiac 
catheterization procedure for each participant.  In the event that a participant had 
multiple addresses recorded for the same cardiac catheterization procedure we selected 
the address closest to a primary or secondary roadway.  To include the distance to 
roadway variable in our genetic model we scaled the distance in miles to the 
interquartile range, and included this scaled distance variable in the model as its own 
term as well as in a multiplicative term with an additive coding of the genotype.   
Table 7: Clinical covariates for the CATHGEN cohort (a), air pollution study 
cohort (b), and GWIS cohort (c) 
1a.  CATHGEN 
Clinical Covariates 
All (N = 9334) PAD cases (N = 709) PAD Controls (N 
= 8625) 
Age (SD) 60.8 (12.0) 65.5 (10.2) 60.4 (12.1) 
BMI (SD) 30.0 (7.19) 29.1 (6.61) 30.1 (7.24) 
Sex (% Female) 37.8 31.7 38.3 
Race (% Caucasian) 74.8 77.9 74.5 
Smoking (% Ever 
Smoke) 
47.6 70.9 45.6 
Diabetes (% Yes) 28.3 41.5 27.2 
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Hypertension (% 
Yes) 
67.3 81.0 66.1 
Dyslipidemia (% Yes) 59.5 76.5 58.1 
1b.  Air Pollution Study Cohort 
 All (N = 6066) PAD cases (N = 478) PAD Controls (N 
= 5588) 
Age (SD) 61.0 (12.0) 64.7 (10.7) 60.6 (12.1) 
BMI (SD) 30.1 (7.29) 29.3 (7.26) 30.2 (7.29) 
Sex (% Female) 38.5 29.1 39.3 
Race (% Caucasian) 77.5 79.5 77.4 
Smoking (% Ever 
Smoke) 
48.6 73.6 46.4 
Diabetes (% Yes) 28.8 41.0 27.8 
Hypertension (% 
Yes) 
68.4 83.3 67.1 
Dyslipidemia (% Yes) 60.3 78.0 58.8 
1c.  GWIS Cohort 
 All (N = 2177) PAD cases (N = 138) PAD Controls (N 
= 2039) 
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Age (SD) 60.0 (12.0) 65.2 (10.4) 59.6 (12.0) 
BMI (SD) 30.4 (7.34) 29.9 (7.29) 30.4 (7.35) 
Sex (% Female) 43.0 35.5 43.5 
Race (% Caucasian) 74.6 75.4 74.5 
Smoking (% Ever 
Smoke) 
48.3 70.3 46.8 
Diabetes (% Yes) 30.6 47.1 29.4 
Hypertension (% 
Yes) 
68.5 83.3 67.5 
Dyslipidemia (% Yes) 59.1 79.0 57.7 
 
4.2.2 Genotyping 
Genotyping was performed on 3,512 CATHGEN participants using the Illumina 
HumanOmni 1-Quad_v1-0_C array.  The selection of patients for genotyping was done 
irrespective of their geocoded location yielding a total of 2,177 individuals residing in 
North Carolina and possessing genome-wide genotype data.  We restricted our analyses 
to the 1623 European-Americans (EA) and 554 African-Americans (AA) out of the 2,177.  
Quality control was performed prior to all analyses and included removal of related 
individuals, low quality genotypes, SNPs with a call frequency < 98%, individuals with a 
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call rate < 98%, and individuals whose genotypic gender did not match the recorded 
self-reported gender. 
4.2.3 Statistical methods 
The statistical analysis consisted of three stages.  The first stage was a race 
stratified analysis of the EA and AA cohorts.  Case-control logistic regression was used 
to calculate the odds ratio on the gene-distance to roadway interaction term and a Score 
test (Bera and Bilias 2001) was used to calculate the significance of this odds ratio.  An 
additive genetic model was used for all analyses and for the EA cohort the model was 
adjusted for age, sex, and four principle components calculated using Eigenstrat (Price et 
al. 2006b) to remove any racial substructure.  For the AA cohort the model was also 
adjusted for age and sex however an examination of the scree plots for the AA principle 
components from Eigenstrat revealed that only two principle components were needed 
to remove the influence of racial substructure.  A clinical covariate adjusted model was 
also used which added body mass index and binary indicators for hypertension, 
smoking, diabetes, and dyslipidemia was also analyzed however the addition of these 
covariates did not affect the odds ratio as compared to the previous model and thus 
results from the age, sex, and racial principle components model are reported.  Both 
models included terms for the additively coded genotype and the distance to nearest 
major roadway (which was scaled to the interquartile range), as well as the SNP-by-
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distance to roadway interaction term.  After viewing the plots of the expected p-value 
distribution versus the observed distribution (QQ plots) it was clear the AA GWIS 
required further adjustment for genomic inflation, while the EA GWIS did not show 
evidence of significant inflation requiring adjustment.  To adjust for the inflated p-values 
in the AA GWIS the genomic control method was used using the F-test (GCF) to 
generate the adjusted p-values based on the chi-squared statistic from the Score test.  
This is the method recommended for large-scale analyses where a small P is 
required(Devlin et al.).  As the SNP set was fixed on the GWAS chip specific “null” 
SNPs were not pre-identified.  Instead 103,196 SNPs not in LD were used to calculate the 
median of the Score test statistic was then used to calculate the inflation (λm  = 1.22).  
The median provided a better adjustment than the mean.  The Score test statistic was 
then adjusted by λm and an F-test with 100 degrees of freedom, the best performance 
with a stringent correction at our sample size in(Devlin et al.), was used to calculate the 
new P for each SNP.   
 The last two stages of the analysis involved a meta-analysis of the results 
generated from each cohort in the first stage.  First a meta-analysis was performed using 
the METAL software (Willer et al. 2010).  This package was used in order to insure 
direction of effect was taken into account as well as the precise allele used as the 
reference allele as the minor allele can change due to differing allele frequencies among 
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racial groups.   The second stage was an examination of each of the top 10 results from 
the race stratified gene-environment interaction GWAS performed in stage 1.  This 
allowed us to examine the concordance of effects for the top results to see if any of these 
results replicated.  The third stage was an examination of the top 10 results from the 
meta-analysis independent of their significance in the race stratified analyses.  After 
performing these three stages the results were checked for their statistical stability and 
biological significance.  The check for statistical stability was done by examining plots of 
the fitted residuals and estimated probabilities for each logistic regression analysis.  
Potential outliers were identified and removed and the analyses were rerun.  Significant 
changes in the odds ratio or p-value after removal of outliers was considered evidence of 
statistical instability.  The biological significance of each SNP was investigated by 
examining their location within the genome and the potential regulatory function of the 
sequence surrounding significant SNPs, e.g. CpG sites important for regulation via 
methylation and open chromatin regions.  These genomic location and sequence 
analyses were carried out using information from the NCBI dbSNP database (Sherry et 
al. 2001) and information on DNaseI hypersensitivity sites from the ENCODE project 
(Thurman et al. 2012).  Data on DNaseI hypersensitivity sites from the Duke University 
contributions to the ENCODE project are summarized at 
http://dnase.genome.duke.edu/. 
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4.3 Results 
For the EA GWIS rs755249, located in the 3’-untranslated region (UTR) of 
BMP8A, achieved genome-wide significance (P = 2.29x10-8, Table 8).  Investigation of the 
ten most significant interactions revealed eight of the top ten results were within 1Mb of 
BMP8A  including four intronic and two missense SNPs in MACF1 (Table 8).   The 
strong linkage disequilibrium (LD) across BMP8A and MACF1 limits our ability to 
identify independent signals within the region using only the EA cohort (Figure 6). 
There were 781,727 SNPs for the AA cohort that passed quality control and the minor 
allele frequency cutoff.  None of the AA results reached genome-wide significance after 
using GCF to correct for bias and removing results that showed statistical instability. 
Examination of the ten most significant meta-analysis results revealed an 
additional BMP8A SNP (rs710913, meta-analysis P = 6.70x10-6, 3’-UTR BMP8A, Table 9).  
Of the 20 SNP-TRAP interactions identified from the AA and EA cohorts, 18 were 
analyzed in the meta-analysis and three showed consistent direction of association with 
rs2989314 (meta-analysis P = 1.14x10-4) the most significant of the consistent meta-
analysis results from the top EA and AA GWIS interactions (Table 10). 
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Figure 6: LocusZoom (Pruim et al.) plots of the BMP8A region.  LocusZoom 
reveals strong LD between rs755249 in BMP8A and multiple SNPs in MACF1 among 
the European-Americans (top).  This region has a much lower level of LD in the 
African-American cohort (bottom). 
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Table 8: The top 10 SNP-TRAP Interactions for the EA (1a) and AA (1b) cohorts after filtering for statistical 
stability.  The 10 strongest interactions (lowest P) for the EA and AA cohorts.  SNPs were restricted to a minor allele 
frequency (MAF) of > 0.05 for the race specific results, however for the sake of reporting the paired result from the other 
race, e.g. the AA result for SNPs in the top 10 of the EA analysis, is listed independent of the MAF.  Blank cells for the 
odds ratio, standard error, and P indicate that the model did not converge. Results marked with a superscript “U” (U) are 
those where stability analyses caused us to exclude the results due to statistical instability (rs3755899, rs1638665, and 
rs9567406).  DHS = DNaseI Hypersensitivity sites.  Rs9409787 was in a site designated as a DNaseI hypersensitivity site in 
retinal endothelial cells.  *bonferroni significant.  **P < 0.05 in EA and AA analyses and consistent direction of effect in 
meta-analysis. 
 
8a.  EA Top 10 Interactions 
CHR BP PROBE OR 
(EA) 
P (EA) MAF 
(EA) 
OR 
(AA) 
P (AA) MAF (AA) LOCUS 
1 39995074 rs755249 * 3.45 2.29E-08 0.24 0.04 0.32 0.04 BMP8A 
9 97261572 rs9409787 4.93 6.87E-08 0.13 0.46 0.15 0.26 DHS 
1 40035686 rs17513135 3.34 1.33E-07 0.23 0.05 0.34 0.04 PAPBC4 
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1 39731550 rs4660214 3.08 1.26E-06 0.22 0.12 0.31 0.04 MACF1 
1 39913351 rs2296173 3.08 1.28E-06 0.22 0.12 0.32 0.04 MACF1 
1 39835817 rs2296172 3.08 1.28E-06 0.22 0.12 0.33 0.03 MACF1 
1 39880319 rs3768302 3.08 1.28E-06 0.22 0.12 0.33 0.03 MACF1 
1 39815143 rs16826093 3.07 1.33E-06 0.22 0.12 0.32 0.04 MACF1 
1 39797055 rs16826069 2.99 1.35E-06 0.22 0.66 0.64 0.04 MACF1 
1 40050568 rs7539279 2.81 1.41E-06 0.34 0.94 0.85 0.49  
8b. AA Top 10 Interactions 
CHR BP PROBE OR (AA) P (AA) 
MAF 
(AA) 
OR (EA) P (EA) MAF (EA) LOCUS 
2 77088598 rs13389599U  22.26 5.33E-08 0.09   0.00091 LRRTM4 
13 44877318 rs9567406 U 68.32 9.83E-08 0.11 0.66 0.27 0.13  
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10 1.19E+08 rs1638665 U 506.92 2.67E-07 0.09   0.0015  
2 1.62E+08 rs634138  6.1 7.67E-07 0.08 0.44 1.0 0.0012  
4 39529700 rs3755899 U 1789.83 1.92E-06 0.08 1.18 0.64 0.058  
16 78805200 rs2161719* 5.76 2.72E-06 0.18 0.86 0.60 0.14 WWOX 
21 21812972 rs2989314* 9.79 2.90E-06 0.12 2.21 0.08 0.07  
16 27270607 rs9940555* 7.72 3.03E-06 0.17 1.59 0.58 0.016 NSMCE1 
6 1.51E+08 rs9397365 21.07 4.46E-06 0.09 0.37 0.0054 0.15 MTHFD1L 
10 1.01E+08 rs11190074 7.36 4.97E-06 0.09 0.69 0.37 0.085 CNNM1 
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Table 9: Meta-Analysis for the top 10 EA and top 10 AA SNPs from Table 8.  Rs13389599 and rs1638665 were 
excluded from the meta-analysis because they did not converge in the EA logistic regression.  * Neither rs3755899 nor 
rs9567406 were considered stable AA or meta-analysis results.   
 
CHR Probe Locus 
P (Meta-
Analysis) Direction 
MAF 
(EA) 
OR 
(EA) P (EA) 
MAF 
(AA) 
OR 
(AA) P (AA) 
1 rs755249 BMP8A 1.45E-05 -/+ 0.26 3.45 2.29E-08 0.04 0.04 3.39E-01 
1 rs17513135 PABPC4 4.54E-05 -/+ 0.23 3.34 1.33E-07 0.04 0.05 3.50E-01 
1 rs7539279 
 
4.60E-05 -/+ 0.34 2.81 1.41E-06 0.49 0.94 8.65E-01 
9 rs9409787 
 
6.76E-05 -/+ 0.13 4.93 6.87E-08 0.26 0.46 1.86E-01 
1 rs16826069 MACF1 7.74E-05 +/- 0.22 2.99 1.35E-06 0.04 0.66 6.70E-01 
21 rs2989314 
 
1.14E-04 +/+ 0.07 2.21 8.36E-02 0.1245 9.79 2.90E-06 
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1 rs2296172 MACF1 2.19E-04 +/- 0.22 3.08 1.28E-06 0.03 0.12 3.41E-01 
1 rs3768302 MACF1 2.19E-04 +/- 0.22 3.08 1.28E-06 0.03 0.12 3.41E-01 
1 rs2296173 MACF1 2.32E-04 +/- 0.22 3.08 1.28E-06 0.04 0.12 3.27E-01 
1 rs16826093 MACF1 2.39E-04 +/- 0.22 3.07 1.33E-06 0.04 0.12 3.27E-01 
1 rs4660214 MACF1 2.44E-04 +/- 0.22 3.08 1.26E-06 0.04 0.12 3.12E-01 
16 rs9940555 NSMCE1 4.47E-03 +/+ 0.02 1.59 5.77E-01 0.17 7.72 3.03E-06 
4 rs3755899 * 
 
4.86E-03 +/+ 0.06 1.18 6.38E-01 0.08 1789.83 1.92E-06 
2 rs634138 
 
1.25E-02 +/- 0.001 0.44 9.98E-01 0.08 6.10 7.67E-07 
16 rs2161719 WWOX 5.48E-02 +/- 0.14 0.86 6.01E-01 0.18 5.76 2.72E-06 
13 rs9567406 * 
 
8.13E-02 -/+ 0.13 0.66 2.68E-01 0.11 68.32 9.83E-08 
10 rs11190074 CNNM1 1.27E-01 -/+ 0.09 0.69 3.64E-01 0.09 7.36 4.97E-06 
6 rs9397365 MTHFD1L 8.80E-01 +/- 0.15 0.37 4.15E-03 0.09 21.07 4.46E-06 
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Table 10: Top 10 SNPs from Meta-Analysis of EA and AA GWIS 
CHR PROBE Loucs P Direction MAF 
(AA) 
MAF 
(EA) 
OR 
(AA) 
P (AA) OR 
(EA) 
P (EA) 
5 rs256811  2.54E-06 -/- 0.11 0.03 3.87 5.44E-06 10.80 1.68E-03 
5 rs7448169  3.78E-06 -/- 0.28 0.45 2.80 9.03E-03 2.26 6.42E-05 
1 rs12024301 RGL1 4.84E-06 +/+ 0.07 0.05 5.05 7.56E-06 3.63 2.53E-03 
1 rs710913 BMP8A 6.70E-06 +/+ 0.31 0.36 2.11 4.54E-02 2.42 3.04E-05 
5 rs6879255  7.76E-06 -/- 0.27 0.29 1.69 2.12E-01 2.68 6.06E-06 
13 rs1411500 GPC6 1.07E-05 -/- 0.12 0.03 2.96 4.79E-02 14.78 4.81E-05 
6 rs4074661  1.21E-05 -/- 0.37 0.41 0.37 2.38E-02 0.41 1.01E-04 
4 rs4340770  1.25E-05 +/+ 0.44 0.50 1.87 8.53E-02 0.41 3.20E-05 
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1 rs755249 BMP8A 1.45E-05 -/+ 0.04 0.24 0.04 2.88E-01 3.45 2.29E-08 
5 rs256809  1.48E-05 -/- 0.10 0.03 3.77 2.32E-04 10.22 1.78E-03 
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Given the strong interactions seen in BMP8A, we examined results from other 
SNPs in genes in the Bone Morhphogenic Protein (BMP) family.  Genes in the BMP 
family have been shown to be regulators of muscle mass (Sartori et al. 2013), affect 
vascular smooth muscle cell progression (Chung et al. 2012), promote vascular, aortic, 
and smooth muscle cell calcification (Hruska et al. 2005; Liberman et al. 2011; Yao et al. 
2010) , and are associated with atherosclerosis (Derwall et al. 2012; Yao et al. 2010) and  
angiogenesis (David et al. 2009; Smadja et al. 2008).  In addition to examining genes 
belonging to the BMP family, we looked for additional interactions in n MACF1 and 
PABPC4, two genes near BMP8A with strong interaction signals.  No interactions in 
MACF1 or PABPC4 had a P < 0.05, a nominal level of significance, in the AA cohort.  
Coupled with the lack of strong meta-analyses associations from these genes, we 
interpret this as evidence that LD with SNPs in BMP8A may be the reason for the 
observed MACF1 and PABPC4 interactions.  Unlike MACF1 and PABPC4, the BMP 
family genes BMP8A and BMP2 showed evidence for interactions in both cohorts 
(Appendix C, Table 19).   
An examination of BMP8A revealed five gene-environment interaction 
associations in addition to rs755249 in the EA cohort: the intronic SNPs of rs710913 (P = 
3.04x10-5) and rs2004330 (P = 5.73x10-4) as well as rs1180341 (P = 1.24x10-4), rs1180343 (P = 
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1.73x10-4), and rs3738676 (P = 1.51x10-6), all in the 3’-UTR.  The distance to roadway-
rs710913 interaction was the most consistent association out of all of the SNPs in BMP 
family genes (P = 0.073 AA, P = 4.04x10-6 meta-analysis).  As shown in Appendix C 
Figures 11 and 12, the LD between the typed BMP8A SNPs and rs755249 was modest in 
the EA, r2 between 0.23 and 0.55.  In the AA cohort there was very little LD in this 
region, with rs755429 and rs710913 having the highest LD (r2 = 0.08).   
To date BMP8A has been primarily implicated in spermatogenesis and 
development of the epididymis (Loveland et al. 2007; Zhao et al. 1998).  Methylation is 
proposed to be an important regulator of BMP8A (Mahoney et al. 2012; Pollard et al. 
2008).  Five of the six BMP8A SNPs with P < 0.05 in the EA cohort altered a CpG site.  In 
particular the genome-wide significant rs755249 interrupted a CpG dimer, CGCG -> 
CGCA, while rs710913 removed a CpG site, CGGA -> TGGA.  Given the evidence that 
traffic-related air pollution alters DNA methylation status (Baccarelli et al. 2009; 
Madrigano et al. 2011; Nawrot and Adcock 2009) and the link between DNA 
methylation and vascular diseases (Castro et al. 2003; Dong et al. 2002),  it may be that 
the causal pathway linking TRAP, BMP8A, and PAD runs through DNA methylation 
status.   
BMP2 gene expression increases in vascular endothelial cells after exposure to 
black carbon, a by-product of incomplete combustion in diesel engines(Yamawaki and 
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Iwai).  Additionally BMP2 is involved in calcification in vascular cells(Chung et al.), 
making it a strong candidate gene linking TRAP and PAD.  Among EA there were five 
SNPs in BMP2 with an interaction P < 0.05:  a missense variant, rs235768 (R -> S, P = 
7.27x10-3); a synonymous variant, rs1049007 (S -> S, P = 0.011); and three intronic SNPs, 
rs235764 (P = 0.020), rs235767 (P = 0.018), and rs7270163 (P = 0.034).  Of these five SNPs 
two had P < 0.05 in the AA cohort and consistent direction of association under meta-
analysis, rs7270163 (AA P = 0.0025, meta-analysis P = 7.98x10-4) and rs235764 (AA P = 
0.018, meta-analysis P = 6.36-4).  None of the remaining BMP family genes had SNPs with 
P < 0.05 and consistent direction of association in both cohorts.  Table 19 (Appendix C) 
lists the interaction P-values for all analyzed SNPs in BMP family genes. 
None of the AA results achieved genome-wide significance after correcting for 
genomic inflation and statistical instability.  The most significant SNP was rs13389599 (P 
= 5.33x10-8) located in an intron of LRRTM4.  In silico investigations revealed that four 
SNPs of the top 10 SNPs were within genes, all in introns (Table 7).  Examinations of the 
intergenic SNPs, rs634138 (P = 7.67x10-7) and rs2989314 (P = 2.90x10-6), revealed that only 
rs2989314 was located near genes (pseudo-genes KRT18P2 and RPS3AP1).  Examination 
of DNAseI hypersensitivity sites from multiple tissues, http://dnase.genome.duke.edu/ 
(Thurman et al. 2012), did not indicate that either SNP was in a putative regulatory 
region as defined by DNAseI hypersensitivity sites. 
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4.4 Conclusion 
In summary we have observed that decreased distance from patient residence to 
primary and secondary roadways is associated with increased prevalence of PAD, and 
this association is modified by genetic variants.  The rs755249-by-traffic related air 
pollution interaction was associated with PAD at a genome-wide significant level.  The 
lack of replication of this interaction in the AA GWIS may have been caused by the 
relatively small sample size and low minor allele frequency (MAF=0.04) in the AA 
cohort.  In addition to rs755249, we observed multiple additional associations in BMP8A, 
including rs710913 the most significant SNP in the BMP family of genes under meta-
analysis.  An examination of the sequence surrounding rs755249 and rs710913 revealed 
that they both alter CpG sites.  BMP2 had previous evidence of differential regulation 
with TRAP exposure (Yamawaki and Iwai 2006), and there were multiple interactions in 
BMP2 with P < 0.05 in both the EA and AA cohorts with consistent direction of 
association.  The potential role for gene family or pathway level associations and 
epigenetic modification in the pathological process for TRAP induced PAD highlights 
the need for additional experimental and statistical models to examine the functional 
genetic processes connecting traffic-related air pollution and PAD. 
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5. Race-stratified genome-wide interaction study and 
trans-ethnic meta-analysis reveals interactions between 
traffic-related air pollution and variants in PIGR and 
SAMSN1 that are associated with coronary 
atherosclerosis burden 
5.1 Introduction 
The significance of air pollution as a risk factor for cardiovascular disease has 
been well-established by the research community (Brook RD 2009).  As air pollution is 
one of the most ubiquitous environmental exposures and cardiovascular disease is the 
number one cause of death in developed nations (Lopez et al. 2006) understanding the 
link between them is of great importance to public health.    
Cardiovascular disease refers to a collection of chronic diseases that affect the 
heart and related vasculature.  Here we will focus on coronary artery disease, the most 
common form of cardiovascular disease that is responsible for millions of deaths each 
year (Lopez et al. 2006).  Coronary artery disease (CAD) is characterized by lesions in the 
coronary artery which form from insult or injury to the artery.  These lesions can grow 
into the lumen, obstructing blood flow to the heart and in some cases rupturing and 
releasing prothrombic factors which can completely occlude blood flow resulting in a 
myocardial infarction (Tabas 2011).  Over the years cohort studies and animal models 
have revealed much about the pathophysiology of coronary artery disease.  Well known 
risk factors for coronary artery disease include family history (Myers et al. 1990; Shea et 
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al. 1984; Wilson et al. 1998), body mass index (Romero-Corral et al. 2006), stress (Krantz 
et al. 2000; Strike and Steptoe 2004), hypertension/endothelial dysfunction (Al Suwaidi 
et al. 2000; Sowers et al. 2001), and elevated triglycerides among others (Miller et al. 
2011; Wilson et al. 1998).  Large scale genome-wide association studies have repeatedly 
shown that genetic variants are associated with coronary artery disease (Deloukas et al. 
2013; Schunkert et al. 2011).  Though CAD is highly heritable the known genetic variants 
explain relatively little of the heritability (Peden and Farrall 2011; So et al. 2011).  It is 
possible that interactions between genetic variants and environmental exposures are 
masking part of the heritability and thus play a role in explaining CAD risk (Zuk et al. 
2012).  Environmental exposures associated with CAD include both smoking (Ambrose 
and Barua 2004) and air pollution (Brook RD 2009).   
Air pollution is a heterogeneous mixture of suspended particles and volatile 
organic and inorganic compounds.  The particles are most often classified into various 
size ranges though increasing effort is being put into classifying particles by the 
chemical species adsorbed onto them.  Common volatile and gaseous organic and 
inorganic components of air pollution include elemental carbon, carbon dioxide, ozone, 
nitrates, and sulfates among others.  In addition to having multiple components air 
pollution is generated by a variety of industrial, agricultural, and residential/traffic 
sources.  In our analyses we will focus on traffic-related air pollution (TRAP), which is 
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generated by tailpipe emissions, resuspended road dust, and evaporative emissions.  
Some of the common components of TRAP are nitrates, black carbon, CO2, and 
particulate matter less than 2.5μm in diameter (PM2.5).  Many of these components of 
traffic-related air pollution have been individually associated with coronary artery 
disease (CAD) (Zanobetti et al. 2009), and summary measures of TRAP, such as distance 
to major roadways, have also been associated with CAD (Hoffmann et al. 2009a; 
Rosenlund et al. 2008).  We use distance to major roadways as a summary measure for 
TRAP.  Studies have shown that the distance to major roadways closely correlates with 
air pollution emitted by traffic sources (Hagler et al. 2009a; Zhu et al. 2002a).   
As many studies have been devoted to investigating the direct association 
between air pollution and CAD incidence, prevalence, and burden (Brook RD 2009; 
Hoffmann et al. 2009a) we chose to expand upon these associations by investigating 
gene-by-TRAP interaction associated with CAD burden.  That genetic variants are 
associated with CAD is a well-founded and uncontroversial idea (Deloukas et al. 2013; 
Feero et al. 2011; Maouche and Schunkert 2012), supported by genome wide analyses 
(Davies et al. 2012; O'Donnell et al. 2011; Schunkert et al. 2011).  However there have 
been relatively few studies that have attempted to understand gene-environment 
interactions, particularly with air pollution as the environmental exposure.  There have 
been a few gene-environment interaction studies linking smoking, genetic variants, and 
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cardiovascular disease.  These include both candidate gene (Breitling 2013; Ward-
Caviness et al. 2013) and genome-wide interaction studies (Polfus et al. 2013).  However 
with respect to air pollution the few studies that have been performed have primarily 
been candidate gene studies and have shown some promise in linking inflammation and 
detoxification related genes to air pollution and cardiovascular disease (Zanobetti et al. 
2011). 
Gene-environment interactions are purported to play a large role in 
cardiovascular disease (Lanktree and Hegele 2009), and understanding gene-
environment interactions can yield insight into the biological pathways that link inhaled 
particulate matter to the heart and related vasculature.  While oxidative stress is a strong 
candidate further refinement is necessary.  As previously stated, to date the vast 
majority of the gene-air pollution interaction studies performed have been candidate 
gene studies focusing on detoxification genes, such as GSTM1, or genes related to 
inflammatory pathways / inflammation response (Zanobetti et al. 2011).  While these 
candidate gene studies have greatly informed us about genetic factors that may modify 
or mediate the association between air pollution and CAD they lack the ability to 
uncover novel genes.  For this reason we chose to take a genome-wide approach that 
would allow us to investigate known and novel genetic targets for gene-by-TRAP 
interactions in an unbiased fashion.  We utilize the CATHeterization GENetics 
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(CATHGEN) cohort for our genome-wide gene-environment interaction studies (GWIS) 
as it has the necessary sample size, environmental exposure data, genome-wide 
genotyping, and breadth of clinical information to make a study such as this possible 
(Shah et al. 2010b).  Also CATHGEN has the racial diversity to allow us to utilize race-
stratified cohorts, allowing for internal replication of results, an essential feature of any 
genome-wide analysis and particularly important when considering interactions.  
Though the often low power of gene-environment interaction studies has been well 
publicized (Hunter 2005; Murcray et al. 2009) we believe that through careful use of 
statistics, screening of results, and trans-ethnic replication biologically relevant 
interactions can be uncovered that can inform on the underlying mechanisms linking air 
pollution exposure to CAD. 
5.2 Methods 
5.2.1 Study Population 
We used the CATHGEN cohort for our interaction studies.  CATHGEN is a large 
(N = 9,334) cardiac catheterization cohort collected at Duke University from 2001 – 2011.  
All patients were recruited through the Duke University cardiac catheterization 
laboratory and provided written informed consent before enrolling in the CATHGEN 
biorepository.  Patients were administered a Health & Physical examination as part of 
the standard procedure before any catheterization by a trained medical professional.  In 
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addition patients provided blood samples for storage and later used for genomic, 
proteomic, and metabolomic studies(Shah et al. 2010b).  All of the patient collection and 
data analyses associated with CATHGEN were approved by the Duke University 
Institutional Review Board. 
We had residential address information for 8,071 CATHGEN participants, and 
we restricted our study population to those participants residing in North Carolina (N = 
7,158).  Of these CATHGEN North Carolina residents 2,177 had genome-wide 
genotyping data and thus comprised our study cohort. 
5.2.2 Clinical Information 
All clinical information used in this study came from the Health & Physical 
examination performed as standard procedure before the catheterization.  A wealth of 
information is collected during this examination and stored in secure databases at Duke 
University Medical Center for clinical and research access.  From this database we 
extracted the clinical variables age, race, sex, smoking status, hypertension, 
hyperlipidemia, diabetes, and body mass index.  Race was a self-identified ethnicity 
variable used to eliminate any individuals not reporting as self-identified African-
Americans (AA) or European-Americans (EA).  Sex, smoking status, hypertension, 
hyperlipidemia, and diabetes were all binary variables.  Hypertension, hyperlipidemia, 
and diabetes were all defined as an indication for these outcomes on this or any 
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previous Health & Physical examination.  Body mass index was defined as the height in 
meters squared divided by the weight in kilograms.  All clinical information is detailed 
in Table 1.  We used the number of diseased coronary vessels (number of diseased 
vessels) as a measure of coronary atherosclerosis burden.  The number of diseased 
vessels is a clinician annotated clinical variable that gives the number (0 – 3) of major 
coronary vessels with significant (> 75%) blockage. 
Table 11: Clinical Covariates for Number of Diseased Vessels GWIS 
GWIS Cohort  All (N = 2177) EA (N = 1623) AA (N = 554) 
Age (SD) 60.0 (12.0) 61.2 (11.9) 56.3 (11.4) 
BMI (SD) 30.4 (7.34) 29.8 (7.02) 32.1 (7.99) 
Sex (% Female) 43.0 39.4 53.6 
Race (% Caucasian) 74.6 100 0 
Smoking (% Ever Smoke) 48.3 50.2 42.6 
Diabetes (% Yes) 30.6 26.4 42.8 
Hypertension (% Yes) 68.5 64.4 80.5 
Dyslipidemia (% Yes) 59.1 60.8 54.0 
Number of Diseased Vessels - 
mean (SD) 
1.11 (1.18) 1.18 (1.18) 0.90 (1.18) 
# With 0 Diseased Vessels 933 (42.9%) 639 (39.4%) 294 (53.1%) 
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# With 1 Diseased Vessel 421 (19.3%) 325 (20.0%) 96 (17.3%) 
# With 2 Diseased Vessels 332 (15.3%) 274 (16.9%) 58 (10.5%) 
# With 3+ Diseased Vessels 414 (19.0%) 324 (20.0%) 90 (16.2%) 
Distance to Roadways (km) 
(SD) 
0.90 (0.79) 0.94 (0.82) 0.78 (0.71) 
 
5.2.3 Distance to Roadway 
Traffic-related air pollution particulate matter is highly correlated with the 
distance to major roadways (Hagler et al. 2009b; Zhu et al. 2002b).  For this study we 
defined major roadways as primary and secondary roadways.  Primary roadways are 
major highways often distinguished by their interchanges while secondary roadways 
are multi-lane intra and inter-city arterials.  These roadways were defined by the North 
Carolina Department of Transportation.  Using ArcGIS (ESRI 2011) we imported both 
the patient locations and North Carolina primary and secondary roadway map.  Then 
using tools provided by the ArcGIS software we calculated the perpendicular distance to 
the nearest primary or secondary roadway, which we simple call the distance to 
roadways.   
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5.2.4 Genotyping 
A total of 3,512 CATHGEN participants were genotyped on the Illumina 
HumanOmni 1-Quad_v1-0_C array though only 2,177 of them resided within North 
Carolina.  Of these 2,177 genotyped individuals 1623 were European-American and 554 
were African-American.  Rigorous quality control was performed on the genotype data 
and consisted of removal of related individuals, low quality genotypes, SNPs with a call 
frequency < 98% and any individuals with a call rate of < 98%.  Additionally we 
removed any individuals whose genotypic gender differed from their self-reported 
gender. 
5.2.5 Statistical Methods 
For our race-stratified GWIS we used cumulative link model implemented in the 
clm package in R (Team 2009) in order to properly account for the ordinal nature of the 
number of diseased vessels variable.  This model is equivalent to a proportional odds 
model and takes into account information from all levels of the variable unlike 
stratifying and using a logistic regression model.  The model was adjusted for age, sex, 
body mass index, hypertension, smoking, hyperlipidemia, and diabetes.  Additionally 
principle components calculated using Eigenstrat(Price et al. 2006a) were used to adjust 
for racial substructure within each of the race-specific GWIS.  For the EA cohort a total of 
four principle components were used while two principle components were sufficient to 
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adjust for racial substructure in the AA cohort.  Results from the cumulative link model 
are reported in terms of an odds ratio signifying the increased risk of incrementing the 
number of diseased vessels by one for a one unit increase in exposure.  One unit of 
exposure was defined as an interquartile range (1.4km) increase in distance to roadways.   
We took advantage of the racial diversity in CATHGEN by utilizing race-
stratified cohorts.  Our independent AA and EA cohorts allowed us to use them for 
internal replication of results.  These cohorts are particularly well suited for replication 
because they were both collected from the same site (Duke University Medical Center) 
and ascertained under identical criteria.  Additionally all lab procedures, including 
clinical measures and genotyping, were performed identically for both cohorts making 
them excellent technical replicates and allowing us to combine the results using a meta-
analysis procedure to increase power.  For the meta-analysis we used the METAL 
software package (Willer et al. 2010).  We used METAL to take advantage of its 
computational efficiency as well as its ability to adjust for the reference allele in each 
cohort to truly insure that the direction of effect was consistent between the two cohorts.  
As the minor allele can change when comparing populations of different ethnicities it is 
necessary to consider the reference allele to insure that the correct conclusions are 
reached.   
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Given the often low power of interaction studies(Hunter 2005; Murcray et al. 
2009) we did not purely rely on attempting to observe interactions that were genome-
wide significant.  Instead we investigated the 10 most significant interactions from the 
race-specific cohorts as well as the meta-analysis.  We examined the 10 most significant 
race-specific results to see if they replicated in the other cohort (P < 0.05 and consistent 
direction of association).  Similarly we examined the 10 most significant meta-analysis 
results to insure that they were not due to inclusion of unstable results from the race-
stratified analyses.  From all analyses we removed any results with inflated odds ratios 
(OR >50) as these were more likely to be due to statistical instability rather than a true 
association.     
We investigated the biological significance of each SNP identified through either 
the race-stratified analyses or the meta-analysis.  We examined the sequence 
surrounding each SNP to identify variants with potential regulatory or epigenetic 
implications, e.g. CpG sites.  We also examined intergenic variants to identify if there 
were in open chromatin regions defined as DNAseI hypersensitivity sites.  Finally all 
variants were examined for prior associations with cardiovascular disease or other 
outcomes.  These genomic location, prior association, and sequence analyses were 
performed using information from the NCBI dbSNP database(Sherry et al. 2001) and the 
ENCODE project(Sheffield et al. 2013; Thurman et al. 2012). 
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5.3 Results 
We restricted our analyses to SNPs with a minor allele frequency > 0.05.  A total 
of 756,588 SNPs with a minor allele frequency > 0.05 converged in the AA model and a 
total of 674,795 SNPs converged in the EA model.   
5.3.1 EA Results 
There were no genome-wide significant interactions in the EA analysis though 
multiple exceeded the threshold for suggestive evidence of association (P < 1x10-5) 
(Figure 7).  The most significant association was rs2822693 (P = 2.2x10-6), an intergenic 
SNP on chromosome 21 located near loci the gene SAMSN1 (Table 12).  Investigation of 
the top 10 associations in the EA cohort revealed that none of them involved SNPs 
located within genes, and none of them were near genes that had previously been 
implicated in gene-air pollution interaction studies.  Five of the ten most significant 
associations in the EA GWIS came from the same region on chromosome 18.  The LD 
between these chromosome 18 variants is substantial with all of the top variants in this 
region having an r2 > 0.8 with the most significant chromosome 18 variant, rs1108775 
(Appendix D, Figure 13).  As all of the top EA interactions were intergenic we examined 
all of them to see if they were in DNAse I hypersensitivity sites (DHS) which would 
indicate a potential regulatory role.  Rs2822693 was the only SNP located in a DNAse I 
hypersensitivity site present in hematopoetic stem cells.  SAMSN1 expression was 
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highest in hematopoetic stem cells and the DNAse I hypersensitivity site containing 
rs2822693 was highly correlated with SAMSN1 expression (dnase.genome.duke.edu 
(Sheffield et al. 2013)).  
Though none of the top EA interactions replicated in the AA cohort, there were 
several interactions where the direction of association was consistent between the two 
cohorts (Table 13).  Of the top EA interactions three had a more significant association 
under meta-analysis indicating that the AA GWIS added information supporting the 
association: rs10830090 (EA P = 1.3x10-5, AA P = 0.067, meta-analysis P = 9.9x10-7), 
rs1035208 (EA P =1.3x10-5 , AA P = 0.17, meta-analysis P = 6.5x10-6), and rs176139 (EA P = 
1.0x10-5, AA P = 0.28, meta-analysis P = 9.9x10-6). 
Table 12: Top variants from race-stratified genome-wide interaction study.  
Bolded results indicate differing minor alleles for the race-stratified cohorts.  Odds 
ratios for these results should be flipped before comparing them due to the differing 
reference group. 
a. EA GWIS 
CHR BP SNP LOCUS OR P MAF 
21 15856974 rs2822693 SAMSN1 DHS 0.45 2.25E-06 0.11 
11 34019537 rs12285326 CAPRIN1 0.61 5.39E-06 0.29 
18 62767789 rs1108775  1.55 7.85E-06 0.48 
18 62781618 rs176139  0.65 1.01E-05 0.48 
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18 62749752 rs597579  1.53 1.14E-05 0.49 
18 62814767 rs1179815  1.52 1.14E-05 0.50 
8 3427306 rs17395021 CSMD1  0.51 1.17E-05 0.13 
10 129273673 rs10830090  1.52 1.25E-05 0.44 
18 62821954 rs1035208  1.52 1.25E-05 0.50 
2 10349858 rs17267630  0.62 1.25E-05 0.31 
b. AA GWIS 
CHR BP SNP LOCUS OR P MAF 
1 207143422 rs1856746 FCAMR  2.96 2.31E-06 0.15 
1 207153881 rs2791713 FCAMR-PIGR 3.00 2.37E-06 0.16 
1 207110936 rs291096 PIGR (V -> V) 2.97 2.67E-06 0.16 
7 22601127 rs17366136  2.47 8.08E-06 0.27 
10 20970477 rs11012265  0.46 9.11E-06 0.38 
8 90022416 rs7827828  3.79 1.06E-05 0.10 
1 151015868 rs12068365 BNIPL (S -> N) 0.35 1.34E-05 0.13 
1 193929977 rs642668  0.46 1.36E-05 0.39 
1 151293147 rs12076626 PI4KB  0.30 1.44E-05 0.10 
1 193917413 rs6680840  0.44 1.79E-05 0.27 
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5.3.2 AA Results 
Similar to the EA there were no genome-wide significant interactions found in 
the AA GWIS (Figure 8).  However unlike the EA GWIS several interactions associated 
with the number of diseased vessels involved SNPs that were within genes and 
replicated in the EA cohort (Table 12).  The FCAMR-PIGR locus accounted for the three 
most significant interactions in the AA GWIS with the most significant interaction 
occurring in an intron of FCAMR (rs1856746, P = 2.3x10-6).  The second most significant 
SNP occurred in the intergenic region between FCAMR and PIGR (rs2791713, P = 
2.3x106), and the third most strongly associated SNP was a synonymous variant in PIGR 
(rs291096, P = 2.7x10-6, V -> V).  Of the remaining variants 5 were in intergenic regions, 
one was in a gene intron (rs12076626, P = 1.4x10-5, PI4KB), and one was a 
nonsynonymous variant in BNIPL (rs10268365, P = 1.3x10-5, S->N).   
FCAMR and PIGR are located within 11.5kb of each other on chromosome 1.  
Both genes are involved in the inflammation process  by mediating the actions of the J-
chain immunoglobulins, immunoglobulin A (IgA) and immunoglobulin G (IgG) (Barratt 
et al. 2004; Wines and Hogarth 2006) making them very plausible candidate genes for 
involvement in the pathophysiological pathway linking TRAP exposure and coronary 
atherosclerosis burden.  Isoforms of BNIPL have been shown to induce apoptosis in 
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human breast cancer cells (Zhu et al. 2002b), and can suppress the enzymatic activity of 
Cdc42GAP (Qin et al. 2003).   
To check the consistency of these interactions we looked for their association in 
the EA cohort.  Both the FCAMR variant rs1856746 (EA P = 0.048) and the PIGR variant 
rs2791713 (P = 0.022) replicated in the EA cohort having a P < 0.05 and consistent 
direction of association.  The coding variant rs291096 narrowly missed our replication 
threshold having a consistent direction of association between the EA and AA GWIS 
however the P-value was not <0.05 (P = 0.086). 
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Figure 7: Manhattan plot of interaction P-values for the EA GWIS.  Though no interactions achieved genome-wide 
significance (red line) interactions on chromosome 11 (CAPRIN1), 18, and 21 (SAMSN1 open chromatin region) 
exceeded the suggestive significance threshold (blue line). 
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FCAMR-PIGR 
 
 
Figure 8: Manhattan Plot of Interaction P-values for AA GWIS
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5.3.3 Meta-analysis 
We used METAL (Willer et al. 2010) to perform a meta-analysis of the EA and 
AA cohorts.  METAL can weight the results by sample size and properly take into 
account the reference allele to insure consistent associations.  Only consistent 
associations with a minor allele frequency > 0.05 in both cohorts were considered in 
these results. 
The most significant interaction in the meta-analysis was rs10830090 (meta-
analysis P = 9.9x10-7).  Rs10830090 was among the most significant associations in the EA 
cohort (Table 12).  With an odds ratio of 1.35 (P = 0.067) and 1.52 (P = 1.3x10-7) for the AA 
and EA cohort respectively we can see that we have very consistent odds ratios for the 
effect of the SNP-by-TRAP interaction.  Rs10830090 is located in an intergenic region on 
chromosome 10 and is not located in any DNAseI hypersensitivity sites according on a 
query performed via dnase.genome.duke.edu (Sheffield et al. 2013).  An examination of 
the top interactions under meta-analysis revealed that in addition to rs10830090 there 
was one intronic variant with a suggestive P-value (P < 1x10-5): rs6900057 (RARS2, AA P 
= 0.02, EA P = 5.5x10-4, meta-analysis P = 7.3x10-6).  Other variants residing in genes 
among the top meta-analysis results included rs7020508 (DAB2IP, AA P = 0.047, EA P = 
3.1x10-5, meta-analysis P = 1.2x10-5) and rs3862089 (MTUS1, AA P = 0.095, EA P = 4.2x10-5, 
meta-analysis P = 1.5x10-5) (Table 13).  We did not extend this examination beyond the 10 
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most significant meta-analysis as the association signal was already below our 
suggestive level. 
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Table 13: Top SNP-by-TRAP Interactions Under Meta-Analysis.  Bold results indicate differing minor alleles for 
the race-stratified cohorts.  Odds ratios for these results should be flipped before comparing due to the differing reference 
groups. 
Chr Probe P Direction OR (AA) P (AA) OR 
(EA) 
P (EA) MAF 
(AA) 
MAF 
(EA) 
10 rs10830090 9.88E-07 +/+ 1.35 6.68E-02 1.52 1.25E-05 0.39 0.44 
10 rs4363506 1.24E-06 -/- 1.35 6.70E-02 1.52 1.63E-05 0.39 0.44 
18 rs17078595 3.09E-06 -/- 1.83 9.32E-02 2.59 2.72E-05 0.07 0.05 
5 rs6894083 3.73E-06 -/- 0.55 1.61E-04 1.39 4.23E-03 0.38 0.20 
5 rs890710 6.06E-06 -/- 0.63 7.24E-03 0.67 3.70E-04 0.28 0.28 
18 rs1035208 6.48E-06 +/+ 0.81 1.71E-01 1.52 1.25E-05 0.42 0.50 
6 rs6900057 7.28E-06 +/+ 0.58 2.04E-02 0.46 5.47E-04 0.14 0.05 
18 rs176139 9.91E-06 -/- 1.18 2.83E-01 0.65 1.01E-05 0.43 0.48 
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9 rs7020508 1.24E-05 -/- 0.53 4.73E-02 0.66 3.12E-05 0.09 0.37 
8 rs3862089 1.48E-05 -/- 0.73 9.52E-02 0.61 4.19E-05 0.32 0.20 
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5.4 Discussion and Conclusion 
We have described several gene-environment interactions uncovered in a race-
stratified genome-wide interaction study.  Though none of these interactions achieved 
genome-wide significance the replication that we observed combined with the strong 
prior evidence for some of the genes indicates that these associations are worth of 
further study. 
5.4.1 SAMSN1 Associations 
SAMSN1 (also called HACS1) encodes a 441 amino-acid protein, with SAM and 
SH3 domains which can indicate adaptor or scaffolding functions (Claudio et al. 2001).  
SAMSN1 was discovered via a screen for genes expressed in multiple myloma and lies 
in a region often disrupted in multiple myelomas (21q11.2).  Expression of SAMSN1 has 
been detected in several tissues including the brain, lung, and heart and appears 
restricted to hematopoetic cells (Claudio et al. 2001).  Studies have shown that SAMSN1 
expression is up-regulated in B cell activation signaling cascades (Zhu et al. 2004). In the 
EA cohort we found suggestive evidence that a rs2822693 (located in an open chromatin 
region upstream of SAMSN1) was associated with the number of diseased coronary 
vessels observed during the cardiac catheterization in a gene-by-traffic related air 
pollution model (P = 2.2x10-6).  The open chromatin region was determined by a DNAse 
 135 
 
 
I hypersensitivity assay and signifies a nucleosome free region of DNA that would be 
open for regulatory factors to bind.  This region of DNA was open in hematopoetic cells, 
and the gene expression of SAMSN1 was highly correlated with this hypersensitivity 
site (Sheffield et al. 2013).   
5.4.2 FCAMR-PIGR Associations 
We observed multiple associations between variants in the FCAMR-PIGR locus 
on chromosome 1.  None of these associations achieved genome-wide significance 
however we did observe a coding variant in PIGR that was associated with the number 
of diseased coronary vessels in our interaction model at our suggestive P-value cutoff 
(rs291096, P = 2.3x10-6).  The association signal from this exonic variant combined with 
the replication of the two most significant variants from the AA GWIS, both of which 
were in the FCAMR-PIGR locus, prompted us to further investigate this locus.  Though 
the only coding variants observed were located in PIGR given the proximity of the two 
genes, their similar functions, and LD structure (Figure 9) we cannot completely 
disregard that potentially both PIGR and FCAMR are involved in mediating the effects 
of traffic-related air pollution on coronary artery atherosclerosis.   
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Figure 9: LocusZoom Plot of FCAMR-PIGR locus for African-Americans 
 
Further investigation of the FCAMR locus revealed a total of 8 variants that were 
typed within the gene.  In addition to rs1856746 which had a P < 0.05 in both cohorts 
(and P < 1x10-5 in the AA GWIS) there was on additional intronic variant with P < 0.05 in 
the AA GWIS, rs11119925 (AA P = 0.019, EA P = 0.034).  No additional variants had P < 
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0.05 in the EA cohort.  Similar to FCAMR, the interaction between TRAP and variants in 
PIGR was much stronger in the AA GWIS than in the EA.  There were 13 variants in 
PIGR represented in our GWIS.  No interactions achieved a P < 0.05 in the EA cohort 
however six variants had interaction P-values < 0.05 in the AA GWIS.  The most 
significant was the synonymous variant rs291096 (P = 2.7x10-6).  Of the remaining 5 
interactions with P < 0.05 there were 2 intronic variants, two synonymous variants, and 
one missense variant (rs291102, A->V, AA P = 1.2x10-4, Table 14).  The LD amongst these 
coding variants was low however the strong LD between the top PIGR variant and 
FCAMR variant impedes disentangling these interaction association signals. (Figure 9) 
Both FCAMR and PIGR are related to the immune response.  FCAMR is a 
receptor for the Fc fragments of immunoglobulin molecules.  Studies have shown that 
FCAMR can be cloned from mesangial cell total RNA and is upregulated by IL1A 
(McDonald et al. 2002).  PIGR is a poly-Ig receptor that mediates the transport of 
polymeric immunoglobulin molecules (Hood et al. 1985), and is primarily primarily 
found in the mucosal epithelium (Wines and Hogarth 2006).  PIGR and FCAMR 
recognize J-chain containing immunoglobulins, i.e. IgA and IgM (Barratt et al. 2004; 
Wines and Hogarth 2006), and both genes play an important role in the immune 
response of mucosal cells.  PIGR is primarily found in the mucosal epithelium 
(particularly the gut) while FCAMR is widely expressed and has been detected in the 
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kidney, intestine, heart, and lung (Wines and Hogarth 2006).  Both PIGR and FCAMR 
has also been implicated in IgA nephropathy, a condition where IgA immune complexes 
are deposited in the glomerular mesangium (Barratt et al. 2004; McDonald et al. 2002).  
Like many chronic and progressive kidney diseases the rate of vascular diseases is much 
higher in individuals with IgA nephropathy as compared to controls (Myllymäki et al. 
2006).  Though neither PIGR nor FCAMR has been associated with air pollution a 2006 
study showed elevated plasma PIGR levels in smokers as compared to non-smokers 
indicating that plasma PIGR can be regulated by an inhaled pollutant (Ohlmeier et al. 
2011). 
 
Table 14: FCAMR-PIGR Locus Associations.  Bold results indicate differing 
minor alleles for the race-stratified cohorts.  Odds ratios for these results should be 
flipped before comparing due to the differing reference groups. 
a. PIGR Associations 
BP Probe OR (AA) OR (EA) P (AA) P (EA) MAF 
(AA) 
MAF 
(EA)  
207102008 rs11283 NA 1.03 NA 0.93 NA 0.02 
207102290 rs17017942 0.77 NA 0.38 NA 0.08 0 
207102293 rs13190 0.93 1.17 0.76 0.1 0.19 0.44 
207105641 rs908702 1.01 1.17 0.98 0.11 0.19 0.45 
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207106444 rs172361 0.5 0.95 9.24E-05 0.87 0.37 0.03 
207106478 rs291102 0.5 0.99 1.22E-04 0.98 0.35 0.03 
207107696 rs908701 0.58 0.91 1.37E-03 0.79 0.44 0.03 
207107806 rs7542760 0.83 14.81 0.36 0.07 0.22 0.01 
207109116 rs2275531 1.04 1.18 0.87 0.09 0.22 0.45 
207110888 rs291097 0.54 1.01 4.52E-04 0.99 0.4 0.03 
207110936 rs291096 2.97 0.85 2.67E-06 0.09 0.16 0.46 
207114037 rs291090 0.53 0.91 3.94E-04 0.78 0.4 0.03 
b. FCAMR Associations 
BP Probe OR 
(AA) 
OR (EA) P (AA) P (EA) MAF 
AA 
MAF 
(EA) 
207133774 rs34478566 0.64 NA 0.45 NA 0.02 0.002 
207134410 rs3813953 NA NA NA NA NA 0.001 
207135991 rs11119925 0.66 1.11 0.02 0.34 0.36 0.27 
207137338 rs2000059 0.53 1.3 0.17 0.1 0.03 0.11 
207139046 rs11576146 0.69 1.14 0.12 0.32 0.18 0.18 
207140440 rs11119933 0.71 1.16 0.06 0.26 0.31 0.18 
207141876 rs17018470 0.93 NA 0.71 NA 0.2 0.004 
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207143422 rs1856746 2.96 0.83 2.31E-06 0.05 0.15 0.46 
 
5.4.3 Conclusion 
In this study we use a race-stratified genome-wide interaction study design to 
investigate the role of genetic variants in modifying or mediating the association 
between traffic related air pollution and coronary artery disease.  We use the number of 
diseased coronary vessels as a measure of coronary artery disease and use a cumulative 
link model in our GWIS to properly account for the ordinal nature of our variable.  
While genome-wide significance eluded us due to the large sample sizes estimated to be 
necessary for genome-wide interaction studies (Hunter 2005) it is possible this was 
limited more by sample size than by a true lack of associated variants.  For this reason 
we investigated variants at the suggestive P < 1x10-5 significance level and used our race 
stratified design and meta-analysis to identify variants that replicated or had consistent 
associations.  Using this approach we were able to identify several novel candidate 
genes that may play a role in linking air pollution and coronary atherosclerosis. 
Candidate gene interaction studies have added much to our knowledge of air pollution 
and coronary atherosclerosis (Zanobetti et al. 2011) and our results add to these studies 
by implicating additional inflammation response related genes (PIGR and FCAMR).  We 
also extend the class of genes implicated in these interactions though our uncovering of 
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an interaction associated with SAMSN1, a gene expressed almost exclusively in 
hematapoetic cells.  Future studies to expand upon these associations will include 
candidate gene replication studies as well as gene expression studies particularly given 
the possible regulatory role of rs2822693. 
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6. A method for the constrained maximization of the 
correlation between a multivariate outcome and high-
dimensional set of predictors 
6.1 Introduction 
The recent explosion of high-dimensional genomic and metabolomic data in the 
health sciences has fueled a number of novel discoveries (Dunn et al. 2011; Hindorff et 
al. 2009; West et al. 2006).  Gene expression arrays, high-throughput proteomics and 
metabolomics, and others all have contributed to entirely new methods of discovery and 
increased the potential for genomic solutions to a variety of human diseases.  The 
drawbacks of high-dimensional data include the necessary multiple testing corrections 
to maintain an acceptable Type I family-wide error rate and the often correlated nature 
of the data that can decrease the interpretability of any result.  Data reduction 
techniques are often employed to counter the difficulties of multiple comparison testing 
and interpretability that individual association test on each predictor in a high-
dimensional data set.  Data reduction techniques often operate on the assumption that a 
high-dimensional data set can be efficiently summarized by a smaller set of possibly 
correlated predictors.  Dimension reduction techniques can be divided into two realms: 
linear dimension reduction and non-linear dimension reduction.  In linear dimension 
reduction one assumes that the reduced dimensions are a linear combination of the 
input variables while in non-linear dimension reduction this linear combination restraint 
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is relaxed (Fodor 2002).  While non-linear dimension reduction techniques are gaining in 
popularity, the relative computational simplicity and ease of interpretation of linear 
dimension reductions techniques means they remain the primary class used in data 
analysis (Carreira-Perpinan 1997; Fodor 2002) 
Two of the common linear dimension reduction techniques are principle 
component analysis (PCA) and canonical correlation analysis (CCA).  PCA is perhaps 
the most popular dimension reduction technique (Carreira-Perpinan 1997) and is often 
used in high-dimensional genomic studies, particularly to address population 
substructure in genome-wide association studies (Price et al. 2006b).  PCA uses the 
covariance structure of the data to construct uncorrelated PCA factors which capture all 
of the information in the input data.  By taking the first L factors researchers have a 
lower dimensional projection of the data that is in many ways a best approximation of 
the input data (Carreira-Perpinan 1997; Fodor 2002).  Canonical correlation analysis 
creates a pair of canonical variates (x and y) that describe the best linear combination to 
maximize the correlation between two matrices (Hotelling 1936; Weenink 2003).    
 While both PCA and CCA play important roles in data dimension reduction and 
summarizing correlations within and between datasets, each has limitations.  Though 
PCA has contributed much to our ability to properly analyze genomic data and 
understand the physiological basis of chronic disease (Bhattacharya et al. 2014; Lakka et 
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al. 2002; Price et al. 2006b; Shah et al. 2012) the method only summarizes information 
from one high-dimensional matrix, which may limit future associations with outcomes 
as well as the interpretability of the factors.  For example PCA can be effectively used to 
summarize gene expression data (Raychaudhuri et al. 2000), however in a study design 
to associate lower dimension gene expression factors with cardiovascular outcomes PCA 
may not create factors that best summarize the relationship between the gene expression 
and outcomes.  Instead PCA will summarize the covariance of the gene expression as 
best it can with no consideration for the directions that may be most important in a 
future study.  In CCA while the “outcome” is taken into consideration it is exchangeable 
with the predictors as both matrices are treated equally.  While in the study of human 
disease it is often the case that a multi-dimensional outcome can be constructed it is rare 
that researchers want it treated in the same way as a high-dimensional set of predictor 
variables.  Often times the set of outcomes has been carefully selected and curated to 
provide relevant information on the disease state of the individual that can be disrupted 
by rotating and combining them into canonical correlation vectors, and also there may 
be previous associations with some or all of the outcomes in an analysis that would be 
eliminated by rotating the matrices.  For this reason I have developed a method called 
constrained CCA (cCCA) which combines some of the elements of PCA and CCA in an 
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effort to increase associations with the outcome matrices as well as the interpretability of 
the factors created from the predictors.   
6.2 Concept of cCCA 
In this method PCA and CCA are combined according to a convex combination 
so that a weighting can be used to maximize the correlation between two matrices while 
limiting the degree that one of them (which we designate the outcome matrix) is rotated.  
The degree of preservation of outcome matrix is determined by the weighting parameter 
(δ).  By varying delta users can control the degree to which the rotation of the outcome 
matrix is constrained, and at the limits of 0 and 1 the solution recapitulates CCA and 
PCA respectively. 
Both PCA and CCA have their defined frameworks and work very well within 
them however I believe that there is a growing need for a method that combines these 
two techniques.  Often researchers find themselves attempting to predict a structured, 
multivariate outcome with a high-dimensional set of predictors.  Additionally 
researchers may have several measures representing an endophenotype of a complex 
disease, i.e. several lipid measures representing lipid metabolism endophenotype for 
coronary artery disease.  Researchers may want to know which factors of a 
metabolomics or gene expression array best correlate with these measures and thus 
create an “endophenotype factor” that can give an understanding of the genetic or 
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metabolomic pathways that underlie the lipid metabolism endophenotype of coronary 
artery disease.  Constrained canonical correlation analysis combines PCA and CCA 
precisely to assess the correlation of a high-dimensional set of predictors with a 
multivariate outcome and to potentially create these “endophenotype factors” which 
give the directions of variation of the predictor matrix along an endophenotype for a 
complex disease of interest.  In this way cCCA combines PCA and CCA to give 
potentially novel results that can advance the study of human disease. 
6.3 Derivation of cCCA 
To begin the derivation of cCCA we start with several definitions: 
Ax, Ay = data matricies (centered) 
x, y = directions of optimal correlation 
zx = Axx, zy = Ayy 
A’yAx = Σyx 
A’yAy = Ayy = Σyy 
A’xAy = Σxy 
A’xAx = Σxx 
 
Given these definitions with respect to (x,y) we seek to maximize over 
 
(1 - δ)y’Σyxx + δy’Σyyy 
 
subject to the following three constraints  
 
1) x’Σxxx = 1, 
2) 0 ≤ δ ≤ 1, and 
3) when δ > 0.5 then y’y = 1 else when δ ≤ 0.5 then y’Σyyy = 1 
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Given these definitions and constraints I will now solve for x and y in the case where δ ≤ 
0.5.  The derivation follows a similar pattern when δ > 0.5 and is given in the Appendix.  
Thus given the three constraints 
C1) x’Σxxx = 1, 
C2) 0 ≤ δ ≤ 1, and 
C3) y’Σyyy = 1 
I derive the following Lagrangian 
 
L(ρx, ρy, ρν1, ρν2, x, y, δ) = (1 – δ)y’Σxyy + δy’Σyyy – ρx(x’Σxxx – 1) – ρy(y’Σyyy – 1) – ν1δ – ν2(1 
– δ) 
Taking the partial derivative of the above Lagrangian with respect to x, y and δ yields 
E1) ∂L/∂x = (1 – δ)Σxyy - 2ρxΣxxx = 0 
E2) ∂L/∂y = (1 – δ)Σyxx + 2δΣyyy - 2ρyΣyyy = 0 
E3) ∂L/∂δ = -y’Σyxx + y’Σyyy – ν1 + ν2 = 0 
From E3 get 
E4) y’Σyxx + ν1 – ν2 = y’Σyyy 
Taking y’∂L/∂y – x’∂L/∂x yields 
(1 – δ)y’Σyxx + 2δy’Σyyy - 2ρyy’Σyyy – (1 – δ)x’Σxyy + 2ρxx’Σxxx = 0 
By E4 and the fact that y’Σyxx = x’Σxyy we can let ν3 = ν1 – ν2 and derive 
E5) 2δ(y’Σyxx + ν3) - 2ρyy’Σyyy + 2ρxx’Σxxx = 0 
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By imposing C1 and C3 on E5 can get  
E6) 2δ(y’Σyxx + ν3) - 2ρy + 2ρx = 0 
Thus when δ = 0, ρy = ρx as observed in CCA (Weenink). 
To derive a generalized eigenvalue problem that can be used to solve for y assume Σxx is 
invertible and use E1 to get 
E7) x = (1 – δ)Σxx-1Σxyy / (2ρx) 
Via substitution of E7 into E2 and rearranging terms can derive 
E8) [(1 – δ)2ΣyxΣxx-1Σxy / (2ρx) + (2δ - 2ρy)Σyy]y = 0 
Which is a generalized eigenvalue problem of the form Ay = Bλy with A = ΣyxΣxx-1Σxy 
and B = Σyy, and λ = [2ρx + (2δ - 2ρy)] / (1 – δ)2.  Now to solve for x assume Σyy is invertible 
and use E2 to solve for y 
E9) y = (1 – δ)Σyy-1Σyxx / (ρy / 2 - 2δ) = 0 
By substituting E9 into E1 yields 
E10) [(1 – δ)2ΣxyΣyy-1Σyx / (ρy / 2 - 2δ) – ρxΣxx / 2]x = 0 
Like E8, E10 is also a generalized eigenvalue problem with A = ΣxyΣyy-1Σxy, B = Σxx and λ 
= ρx(ρx / 2 - 2δ) / 2(1 – δ)2 
Both E8 and E10 reduce to the standard generalized eigenvalue problems 
observed in CCA when δ = 0 (and thus ρy = ρx) except with a scaling factor of 4 for E8 
and a scaling factor of ¼ for E10.   
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Now for when δ > 0.5 we still seek to maximize (1 - δ)y’Σyxx + δy’Σyyy with respect to 
(x,y) however now the constraints are 
C4) x’Σxxx = 1, 
C5) 0 ≤ δ ≤ 1, and 
C6) y’y = 1 
C4 and C5 are identical to C1 and C2 however C6 has changed and this will alter the 
generalized eigenvalue solutions for x and y as well as insure that the solution replicates 
what we would observe in PCA when δ = 1.  The new constrains lead to the Lagrangian 
 
L(ρx, ρy, ν1, ν2, x, y, δ) = (1 – δ)y’Σyxx + δy’Σyyy – ρx(x’Σxxx – 1) – ρy(y’y – 1) – ν1δ – ν2(1 – δ) 
 
Taking the partial derivative with respect to x, y, and δ yields 
E11) ∂L/∂x = (1 – δ)Σxyy - 2ρxΣxxx = 0 
E12) ∂L/∂y = (1 – δ)Σyxx + 2δΣyyy - 2ρyy = 0 
E13) ∂L/∂δ = -y’Σyxx + y’Σyyy – ν1 + ν2 = 0 
Similar to as we did with δ < 0.5 we begin by assuming Σxx is invertible and derive an 
expression for x using E11 
E14)  x = (1 –δ) Σxx-1Σxyy / (2ρx) 
By substituting E14 into E12 we can derive  
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E15)  (1 – δ) ΣyxΣxx-1Σxyy / (2ρx) + 2δΣyyy - 2ρyy = 0 
E15 is a generalized eigenvalue problem (simply move the term 2δΣyyy to the right hand 
side and factor out y to observe this).  Furthermore when δ = 1 we observe the following 
E16) δ = 1 -> 2Σyyy - 2ρyy = 0 -> Σyyy = ρyy  
E16 is the exact eigenvalue problem solved in PCA.  Thus we observe that when δ = 1 we 
recapitulate PCA. 
 
To solve for x we assume Σyy is invertible as we did before.  Via E12 we can derive an 
expression for y in terms of x and the input data matrices 
E17) y = (1 – δ) Σyy-1Σyxx / (2δ - 2ρy) 
By substituting E17 into E11 we can derive a generalized eigenvalue problem that we 
can use to solve for x 
 
E18) (1 – δ)2ΣyxΣyy-1Σxyx / (2δ - 2ρy) - 2ρxΣxxx = 0 
 
6.4 Implementation of cCCA 
As the solutions for x and y are given by generalized eigenvalue problems they 
can be solved for using standard statistical software.  I will use the R packages cancor 
and CCA (Team 2009) to solve for x and y.  Though this solution implies that the input 
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matrices are non-singular (and thus invertible) there exist generalized solutions to both 
PCA and CCA that utilize the pseudo-inverse to avoid this constraint (Hua and Liu 
1998; Wu 2009).  If necessary these solutions will be examined and the derivation of 
cCCA adjusted, though historically PCA and CCA have often been used to great effect 
without relaxing their initial assumptions of non-singular input matrices.  The solutions 
for x and y will give interpretable factors that describe how a centered matrix of 
predictors (Ax) best correlates with a centered matrix of outcome variables (Ay) under 
varying levels of constraint on the rotation of the outcome variables (δ).  I hope that 
cCCA fills a missing space in the factor analysis / dimension reduction field by 
combining aspects of CCA and PCA in a way that can offer more interpretable factors, 
that can inform on endophenotype factors (factors aligned to specific endophenotypes of 
complex diseases), that may have stronger associations with the outcome of interest than 
the factors generated by PCA and CCA.  Future work will include implementing and 
optimizing the method as well as simulation studies to determine the best approaches to 
selecting δ as well as determining how the association between factors and outcome 
varies as δ is varied. 
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7. Conclusion 
The associations and methods presented in this dissertation reflect a significant 
addition to the field of computational biology specifically as it relates to environmental 
epidemiology, cardiovascular disease, and genetics.  In Chapter 2 I present a candidate 
gene analysis of a linkage peak on chromosome 3.  This linkage peak had previously 
been implicated in cardiovascular disease (Wang L 2007) however replication proved 
difficult potentially due to the presence of gene-smoking interactions that had 
previously masqueraded as main effects (Horne et al. 2009).  In order to verify that the 
original chromosome 3 linkage peak and subsequent SNP-CAD associations were in fact 
driven by gene-smoking interactions I directly tested for interactions using the APL-
OSA statistical package.  I additionally tested for pathway relationships and performed 
a meta-analysis to see which genes showed the greatest evidence for gene-smoking 
interactions across multiple studies. 
The conclusion of these efforts was to verify that there were in fact gene-smoking 
interactions that were driving the association between the chromosome 3q13 region and 
coronary artery disease.  The KALRN gene contained the most strongly associated SNP-
smoking interactions and this was confirmed after a meta-analysis of four independent 
cohorts.  KALRN is located in the Rho-GTPase pathway and it was previously 
hypothesized that this pathway was overrepresented amongst interactions in this 
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chromosomal region.  I was able to verify that there was an excess of smoking 
interaction association signals in genes within this pathway and that these signals were 
driven by the gene-smoking interactions and not by the marginal association between 
the SNPs and CAD.  This is an important step for the field and gives a strong genetic 
basis to the well-established link between smoking and CAD.   
Though these studies of KALRN and gene-smoking interactions are important 
and lay a good foundation there are a few next steps that could be taken to further 
elucidate the functional importance of KALRN and the Rho-GTPase pathway in smoking 
mediated CAD.  One important step would be animal studies.  Though a complete 
knockout of KALRN in mice seems to be embryonic lethal (personal communications) 
mice strains heterozygous for a KALRN knockout could present an important 
comparison group to understand the joint effect of smoking and KALRN on 
cardiovascular disease.  Additionally I believe a sequencing study could add important 
information to our association studies.  Given that gene-smoking interaction were 
observed for coding variants, it is possible that sequencing studies will yield even more 
interactions due to their ability to capture rare variation that is not well represented on 
genotyping arrays.  Finally given the link between KALRN and iNOS (Ratovitski et al. 
1999) as well as smoking and iNOS (Hoyt et al. 2003), expanding the scope of analysis 
beyond chromosome three to include genes related to iNOS may produce invaluable 
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results that can help identify functional relationships and pave the way for future 
studies. 
In Chapter 3 I explore the relationship between distance to roadways, an index 
for TRAP, and cardiovascular disease outcomes.  This chapter both advances the field of 
environmental epidemiology and lays important groundwork for analyses to come in 
Chapters 4 and 5.   
Though the relationship between TRAP and cardiovascular disease has been 
established on several occasions [Sources] many of these have been observational 
cohorts drawn from the general population.  Understanding the effect of air pollution on 
vulnerable populations, e.g. the elderly or those at risk for cardiovascular events, is an 
important step for the field of environmental epidemiology.  I advanced the field in this 
direction by utilizing the CATHGEN cohort for my analyses. This cohort is drawn from 
individuals undergoing a cardiac catheterization procedure, thus enriching the cohort 
for individuals with cardiovascular disease.  A second direction that my studies take to 
advance the field is to jointly study the effect of a single exposure on several related 
outcomes as well as race and sex stratified sub-cohorts.  Race and sex specific differences 
can be very important to our understanding of those populations most at risk for cardiac 
complications due to air pollution exposure.  Understanding the relationship between 
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TRAP and related cardiovascular outcomes allows us to better understand the pathways 
that link TRAP exposure and cardiovascular disease. 
My studies in this area indicated that TRAP is most strongly associated with 
systemic cardiovascular disease in the CATHGEN cohort with associations between 
PVD and hypertension being the strongest.  While there were some race and sex specific 
differences the overall associations were strong and resistant to modification by 
including potential confounders in the model.  As TRAP is composed of several different 
types of air pollution the next studies should break down the components to better 
understand which specific components of TRAP are contributing to the observed 
associations.  Additionally animal models or gene-environment interaction studies can 
begin to place a biological basis behind these observed associations and move the field 
closer to a potential intervention. 
The third and fourth chapters of my dissertation center on a common theme: the 
feasibility and utility of genome-wide interaction studies.  While researchers have 
recognized the importance of gene-environment interactions, the most common study 
design is a candidate gene study focusing on one or a small group of genes.  This 
approach maximizes power at the expense of finding novel associations.  In contrast, 
genome-wide interaction studies must contend with lower power to detect significant 
interactions than candidate gene studies but gain the ability to uncover novel 
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associations that can point to previously unknown biological links between 
environmental exposures and health outcomes.  I overcame the power limitations of 
genome-wide interaction studies by implementing novel statistical methods and 
intensive follow-up of the most significant interactions.  By overcoming these limitations 
and forging ahead with two genome-wide interaction studies I was able to uncover 
novel biological links between TRAP and CVD. 
In Chapter 4 I performed a GWIS to understand the potential role of SNP-TRAP 
interactions in explaining PVD prevalence.  I used race-stratified cohorts which allowed 
me to internally replicate interaction in independent populations.  I implemented the 
Score test rather than the traditionally used Wald test to increase power in my studies.  
Using the Score test meant writing the GWIS software in R, traditionally a slow 
programming language, which I overcame by parallelizing the analysis which 
substantially decreased the runtime.  Using this approach I was able to successfully 
uncover a genome-wide significant interaction in the BMP8A gene.  Though genes in the 
bone morphogenic protein family had previously been linked to cardiovascular disease 
(Derwall et al. 2012; Yao et al. 2010)  this study represents the first time BMP8A was 
implicated and the first study linking BMP genes, air pollution, and PVD.  A follow-up 
analysis that examined other BMP family genes revealed that BMP2, which has been 
shown to be regulated by black carbon exposure (Yamawaki and Iwai 2006), shows 
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evidence that coding variants are involved in interaction with TRAP and associated with 
PVD prevalence.  A sequence analysis of BMP8A revealed that the most significant 
associations interrupted or introduced CpG sites which may implicate methylation as an 
important mediator of these associations.   
The results of the GWIS I performed in Chapter 4 point towards several 
potentially fruitful experiments that could greatly further the field.  Further analysis of 
the BMP family of genes, in particular BMP2 and BMP8A, would potentially be very 
fruitful.  Animal studies where BMP knockout or knockdown mice are put into 
chambers and exposed to TRAP could reveal some of the physiological changes that 
result from disruption of BMP family genes and exposure to air pollution.  Further 
cohort studies could focus on more rare variation than is captured on the genotyping 
array used in this GWIS and can also investigate the importance of methylation in 
mediating the effect of TRAP exposure and variation in BMP8A.  Additionally gene 
expression studies may provide a relatively easy method to link these SNP-TRAP 
interactions to molecular phenotypes that can reflect the regulatory potential of these 
interactions. 
In Chapter 5 we again performed a GWIS however in this instance we used the 
number of diseased coronary vessels as the outcome.  This is an ordinal variable, 
ranging from 0 – 3, that counts the number of diseased major coronary vessels seen 
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during the cardiac catheterization procedure.  Continuing the theme of implementing 
novel methods to increase power in these genome-wide interaction studies, I 
implemented a cumulative link model to properly model the number of diseased 
vessels.  Traditional analyses would either use a linear model or convert the categorical 
variable into a binary variable.  The linear model imposes the overly stringent constraint 
that the difference between each level of the variable be the same, which is not true in 
the case of the number of diseased vessels.  The binary variable model imposes an 
artificial cutoff in an attempt to create a set of cases and controls.  The cumulative link 
model is flexible in that it allows for variable spacing between levels of the number of 
diseased vessels variable and still manages to use all the information encoded in each 
level of the variable.  This GWIS represents the first time that a cumulative link model 
has been used in a genome-wide association study or genome-wide interaction study 
and thus represents and important advance within the field. 
The results from the GWIS run with a cumulative link model were very 
promising.  We observed a suggestive, P < 1x10-5, interaction in PIGR in the AA cohort 
that replicated in the EA cohort.  PIGR is an immungloublin receptor involved in cellular 
signaling pathways.  Additionally PIGR has been shown to be upregulated after 
exposure to cigarette smoke, demonstrating its responsiveness to inhaled pollutants 
[Source].  In addition to PIGR I observed a strong interaction signal on chromosome 21 
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in a DHS upstream of SAMSN1.  The precise function of SAMSN1 is currently unknown 
but the presence of SH3 binding domains indicates that it may be involved in cellular 
signaling pathways.  The DHS upsteream of SAMSN1 was highly correlated with 
SAMSN1 expression which mainly originates from hematopoetic cells (Sheffield et al. 
2013).  These strong and biologically plausible associations open up a wealth of potential 
follow-up studies to expand upon them.  Collaborations with researchers from the 
ENCODE project could shed more light on link between SAMSN1 and the nearby DHS.  
Given the wealth of cell lines available in ENCODE, one can imagine treating these cell 
lines with diesel exhaust extract after introducing mutations in the DHS upstream of 
SAMSN1 to look for any phenotypic changes.  Gene expression studies in these cells, or 
even in cohort studies, can identify the potential for regulation of SAMSN1 by DHS 
variants and TRAP.  With PIGR the most fruitful experiments may again be animal 
studies given the wealth of immunocompromised mice strains available.  In all of these 
functional studies, separating out air pollution components may be a very fruitful step 
that can isolate effects and help to identify the precise mediators of the effects of TRAP 
exposure.  These component models can even be run in advance of any animal studies 
given the increased focus of the air pollution epidemiology community on learning how 
to accurately model the constitutes of a given air pollution mixture given 
meteorological, land use, and emissions data. 
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In the final chapter I developed a method, constrained Canonical Correlation 
Analysis, that I believe can be useful in high dimensional data analysis.  Particularly 
with complex diseases, e.g. CAD, it is becoming increasingly common for researchers to 
deal with both a multivariate outcome and set of predictors.  While techniques exist to 
summarize one or the other very few techniques exist to take advantage of correlation 
structure within both high dimensional data sets and then use that correlation structure 
to make predictions about all axes of variation in the outcome dataset.  Canonical 
Correlation Analysis is one method however it fails to properly differentiate between 
outcome and predictors and simply treats the matrices equivalently as it seeks to 
maximize correlations.  However constrained Canonical Correlation Analysis combines 
Principle Components Analysis with CCA in order to create a method that has the 
advantages of both.  cCCA is able to extract a sequence of factors that detail the 
directions of variation within the predictor dataset that best correlate with the variation 
in the outcome dataset.   The advance that cCCA brings is the parameter δ which gives 
the level of constraint to be imposed on the outcome dataset.  With δ = 0 no constraint is 
imposed and both predictor matrix and outcome matrix are treated equivalently as in 
CCA.  With δ = 1 PCA is performed on the outcome matrix with no consideration of the 
predictors.  However with 0 < δ < 1 the user is able to tune the degree of constraint on 
the outcome matrix so that the factors extracted from the predictor matrix explain 
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variation within the outcome matrix, and not vice versa as with CCA.  The advantage 
over PCA is that the correlation structure of both matrices is considered when 
maximizing the correlation.  A PCA only approach would be to perform PCA on both 
matrices and then try and associate the set of PCA factors from the predictors with the 
PCA factors from the outcomes.  This is less than ideal as it does not fully leverage the 
correlation structure to try and find the best explanatory directions of variation.  For this 
reason cCCA may present a marked improvement over both PCA and CCA in the field 
of high-dimensional data analysis when researchers have both a multivariate outcome 
and many potentially correlated predictors. 
In conclusion this dissertation demonstrates the power of interaction studies to 
both provide relevant information on previous associations (Chapter 2) as well as 
identify novel genes associated with cardiovascular disease through genome-wide 
interaction studies (Chapters 4 and 5).  In Chapter 3 this dissertation adds to the 
literature establishing a link between cardiovascular disease and traffic-related air 
pollution.  Finally Chapter 6 outlines a new method for the analysis of a multifactorial 
outcome with a high-dimensional set of predictors.  
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Appendix A – Chapter 2 Supplemental Materials 
Table 15: APL and APL-OSA Results.  P-values for all 431 SNPs analyzed via 
APL and APL-OSA.  500 permutations and 200 bootstrap iterations were used to 
generate these results to reduce computation time. 
 
SNP APL P APL-OSA P CHROM BP  LOCUS 
RS12167 0.524082 0.88 3 33013187 GLB1 
RS3772398 0.405529 0.562 3 47886731 MAP4 
RS8179164 0.430587 0.864 3 49372288 RHOA 
RS1987628 0.176367 0.868 3 49374263 RHOA 
RS17595772 0.538286 0.13 3 49384708 RHOA 
RS7631908 0.442424 0.176 3 49400711 RHOA 
RS6792911 0.677527 0.166 3 49404860 RHOA 
RS9757181 0.940161 0.154 3 49416851 RHOA 
RS11717485 0.755135 0.966 3 49419517 RHOA 
RS6997 0.152083 0.766 3 49428838 TCTA 
RS1477848 0.589047 0.276 3 112300672 PVRL3 
RS1477844 0.353312 0.648 3 112312521 PVRL3 
RS1351049 0.246805 0.176 3 112324966 PVRL3 
RS2221065 0.894083 0.87 3 112737083 CD96 
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RS1553970 0.064038 0.214 3 112805801 CD96 
RS6786655 0.693106 0.616 3 113146618 PHLDB2 
RS3177104 0.492121 0.288 3 113177814 PHLDB2 
RS774763 0.118516 0.162 3 113203019 TAGLN3 
RS4682356 0.522828 0.668 3 113290445 TTMP 
RS1492486 0.067987 0.164 3 113330219 GCET2 
RS2029638 0.072254 0.928 3 113337262 GCET2 
RS2029636 0.653152 0.776 3 113404462 SLC9A10 
RS2272022 0.373353 0.312 3 113546540 CD200 
RS11708769 0.820186 0.006 3 113569632 CD200 
RS3889123 0.700193 0.884 3 114208132 C3ORF17 
RS3732812 0.88818 0.982 3 114345717  
RS1875111 0.498476 0.02 3 114461454 BOC 
RS11929640 0.622608 0.996 3 114771120 SIDT1 
RS13096064 0.126685 0.982 3 115077959 ZDHHC23 
RS4682145 0.547479 0.226 3 115097030 ZDHHC23 
RS974702 0.295942 0.102 3 115116649 ZDHHC23 
RS9870411 0.205477 0.108 3 115128548 ZDHHC23 
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RS3765114 0.044324 0.164 3 115137897 ZDHHC23 
RS11921691 0.260557 0.722 3 115155815 ZDHHC23 
RS324555 0.055638 0.66 3 115212798 KIAA1407 
RS6438191 0.565076 0.868 3 115438010 ZNF80 
RS3732780 0.491556 0.816 3 115438510 ZNF80 
RS1316642 0.661295 0.53 3 115506753 FLJ39873 
RS13067741 0.796381 0.154 3 115646846 ZBTB20 
RS17681395 0.799446 0.506 3 115878663 ZBTB20 
RS3732481 0.4046 0.384 3 115966103 ZBTB20 
RS6804032 0.357447 0.514 3 116031161 ZBTB20 
RS1506024 0.277707 0.22 3 116257652 ZBTB20 
RS3821560 0.342472 0.864 3 117054054 LSAMP 
RS10511352 0.469269 0.12 3 117125967 LSAMP 
RS1920384 0.687696 0.484 3 117250752 LSAMP 
RS6776244 0.615903 0.124 3 117251989 LSAMP 
RS7641464 0.293387 0.618 3 117368960 LSAMP 
RS1870709 0.391649 0.968 3 117435489 LSAMP 
RS10934326 0.663583 0.23 3 117469033 LSAMP 
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RS1461131 0.948493 0.108 3 117483362 LSAMP 
RS9822445 0.748476 0.024 3 117644224 LSAMP 
RS10934345 0.30623 0.994 3 117692305 LSAMP 
RS9834065 0.189251 0.422 3 117730574 LSAMP 
RS1795293 0.202031 0.274 3 117761199 LSAMP 
RS1467213 0.08718 0.626 3 117805164 LSAMP 
RS9847048 0.859111 0.344 3 117838700 LSAMP 
RS10934364 0.827523 0.49 3 117896600 LSAMP 
RS1106851 0.48185 0.138 3 117943999 LSAMP 
RS1835856 0.954191 0.324 3 117974362 LSAMP 
RS6785331 0.530169 0.068 3 117990316 LSAMP 
RS6803436 0.262965 0.792 3 118005909 LSAMP 
RS7433070 0.587259 0.608 3 118042925 LSAMP 
RS6438359 0.890315 0.1 3 118071957 LSAMP 
RS2037009 0.238141 0.738 3 118110689 LSAMP 
RS1133603 0.93172 0.926 3 118133470 LSAMP 
RS1589182 0.442622 0.968 3 118186282 LSAMP 
RS1518898 0.009549 0.186 3 118211238 LSAMP 
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RS4855909 0.593237 0.408 3 118212508 LSAMP 
RS938115 0.159984 0.982 3 118257964 LSAMP 
RS1850719 0.345109 0.754 3 118284215 LSAMP 
RS7633227 0.254979 0.378 3 118313302 LSAMP 
RS733527 0.737718 0.798 3 118347424 LSAMP 
RS6788787 0.369832 0.14 3 118353538 LSAMP 
RS1915585 0.261331 0.904 3 118391522 LSAMP 
RS4855900 0.546672 0.972 3 118477957 LSAMP 
RS1513172 0.146235 0.016 3 118494578 LSAMP 
RS6438389 0.652004 0.722 3 118532507 LSAMP 
RS1513156 0.044592 0.426 3 118549311 LSAMP 
RS11716267 0.943449 0.834 3 118586537 LSAMP 
RS1398626 0.509511 0.794 3 118616293 LSAMP 
RS1513162 0.093551 0.548 3 118617776 LSAMP 
RS4075039 0.778469 0.528 3 118645474 LSAMP 
RS7427839 0.150715 0.458 3 118648013 LSAMP 
RS6790819 0.854601 0.458 3 118659480 LSAMP 
RS4356827 0.972513 0.948 3 118661434 LSAMP 
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3P0352 0.604141 0.404 3 118664719 LSAMP 
RS2927275 0.462299 0.254 3 118666759 LSAMP 
RS1698042 0.117094 0.882 3 118667838 LSAMP 
3P0353 0.536757 0.286 3 118670015 LSAMP 
3P0354 0.378453 0.286 3 118670801 LSAMP 
RS1501881 0.491621 0.498 3 118672530 LSAMP 
RS1910040 0.087763 0.46 3 118673682 LSAMP 
RS1354152 0.832272 0.968 3 118675868 LSAMP 
RS1698041 0.588529 0.766 3 118682441 LSAMP 
RS45458507 0.70522 0.06 3 118699111 LSAMP 
RS11713954 0.437652 0.052 3 118699690 LSAMP 
RS2055426 0.509761 0.574 3 118703034 LSAMP 
RS2937675 0.506591 0.664 3 118706580 LSAMP 
RS45530132 0.371125 0.336 3 118709990 LSAMP 
RS1875518 0.076401 0.714 3 118712470 LSAMP 
RS2937673 0.527036 0.762 3 118715077 LSAMP 
RS1676232 0.005631 0.682 3 118717529 LSAMP 
RS4855952 0.235973 0.676 3 118717715 LSAMP 
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3P0358 0.507696 0.812 3 118718327 LSAMP 
RS1501874 0.90126 0.33 3 118720007 LSAMP 
RS2937670 0.555677 0.71 3 118720251 LSAMP 
RS1979868 0.742579 0.298 3 118722031 LSAMP 
RS16827091 0.407503 0.308 3 118722980 LSAMP 
3P0360 0.43622 0.196 3 118723379 LSAMP 
RS1381801 0.952916 0.292 3 118723585 LSAMP 
3P0361 0.519792 0.78 3 118727468 LSAMP 
RS2937666 0.581625 0.886 3 118729388 LSAMP 
RS4855955 0.72981 0.682 3 118738784 LSAMP 
RS6794425 0.812169 0.954 3 118742620 LSAMP 
RS6778437 0.316049 0.682 3 118746628 LSAMP 
RS6795971 0.996778 0.944 3 118751683 LSAMP 
RS1466416 0.505971 0.628 3 118753496 LSAMP 
RS2869787 0.342186 0.704 3 118791508 LSAMP 
RS869851 0.567688 0.214 3 118804008 LSAMP 
RS2904196 0.350272 0.952 3 118829308 LSAMP 
RS11707500 0.289124 0.648 3 118849432 LSAMP 
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RS4404477 0.106767 0.978 3 118857458 LSAMP 
RS6784348 0.329197 0.684 3 118892675 LSAMP 
RS7646668 0.493811 0.426 3 118914350 LSAMP 
RS6438404 0.157908 0.766 3 118918128 LSAMP 
RS4367097 0.216331 0.174 3 118922408 LSAMP 
RS9861188 0.272336 0.904 3 118932645 LSAMP 
RS7647501 0.835015 0.674 3 118939388 LSAMP 
RS4687991 0.122914 0.706 3 118947921 LSAMP 
RS4687996 0.683649 0.986 3 118956667 LSAMP 
RS6796552 0.962924 0.568 3 118967152 LSAMP 
RS4687889 0.679704 0.842 3 119020129 LSAMP 
RS7427162 0.07385 0.586 3 119069371 LSAMP 
RS1378834 0.335603 0.364 3 119102092 LSAMP 
RS1456186 0.397566 0.818 3 119110095 LSAMP 
RS817508 0.03771 0.888 3 119168266 LSAMP 
RS17723301 0.18097 0.69 3 119198278 LSAMP 
3P0500 0.28256 0.43 3 119198885 LSAMP 
RS843855 0.743059 0.298 3 119239225 LOC389142 
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RS705260 0.133803 0.296 3 119503622  
RS779609 0.881391 0.746 3 119539208  
RS1392271 0.449722 0.74 3 119550500 LOC389142 
RS1401956 0.360734 0.738 3 119674809  
RS4687959 0.083981 0.816 3 120106104 IGSF11 
RS6782002 0.957143 0.858 3 120107321 IGSF11 
RS1468738 0.847224 0.516 3 120114311 IGSF11 
RS6779428 0.741266 0.648 3 120122314 IGSF11 
RS2192365 0.354673 0.756 3 120126099 IGSF11 
RS2903250 0.894162 0.23 3 120131750 IGSF11 
RS9837571 0.39496 0.63 3 120138354 IGSF11 
RS1347448 0.329942 0.364 3 120305831 IGSF11 
RS4687841 0.137088 0.252 3 120436259 B4GALT4 
RS7627301 0.740647 0.278 3 120502771 CDGAP 
RS10934490 0.771303 0.156 3 120513650 CDGAP 
RS12497738 0.828855 0.16 3 120513752 CDGAP 
RS6799733 0.838476 0.096 3 120515237 CDGAP 
RS7650193 0.531589 0.174 3 120517446 CDGAP 
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RS2044621 0.874847 0.368 3 120533422 CDGAP 
RS17281577 0.843972 0.956 3 120534679 CDGAP 
RS9289128 0.840451 0.282 3 120538237 CDGAP 
RS10511387 0.60624 0.112 3 120549318 CDGAP 
RS7614907 0.727883 0.626 3 120559179 CDGAP 
RS7616603 0.505991 0.234 3 120564555 CDGAP 
RS17203055 0.803133 0.05 3 120567021 CDGAP 
RS12636459 0.032835 0.52 3 120570524 CDGAP 
RS17203069 0.671142 0.902 3 120578502 CDGAP 
RS9837853 0.902929 0.652 3 120581739 CDGAP 
RS729411 0.542509 0.206 3 120585148 CDGAP 
RS10049044 0.945017 0.866 3 120586270 CDGAP 
RS6766899 0.302568 0.014 3 120589942 CDGAP 
RS2241994 0.611864 0.548 3 120592696 CDGAP 
RS2873688 0.259335 0.722 3 120593647 CDGAP 
RS9831023 0.383339 0.28 3 120594452 CDGAP 
RS2121994 0.46087 0.846 3 120594473 CDGAP 
RS935616 0.971641 0.356 3 120595249 CDGAP 
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RS6776994 0.560746 0.554 3 120602026 CDGAP 
RS4687851 0.37784 0.09 3 120607892 CDGAP 
RS11922594 0.851599 0.43 3 120608512 CDGAP 
RS4687852 0.328316 0.742 3 120612810 CDGAP 
RS9855065 0.92493 0.804 3 120612831 CDGAP 
RS6796981 0.419288 0.75 3 120613146 CDGAP 
RS12639070 0.497736 0.394 3 120614010 CDGAP 
RS3732413 0.413151 0.634 3 120615873 CDGAP 
RS3732414 0.311873 0.692 3 120617081 CDGAP 
RS1132200 0.319887 0.65 3 120633526 TMEM39A 
HCV387937 0.695074 0.798 3 120727283 CD80 
RS483349 0.148667 0.556 3 120827383 PLA1A 
RS334559 0.363965 0.918 3 121292295 GSK3B 
RS1621291 0.980592 0.298 3 121588392 FSTL1 
RS2488 0.581383 0.148 3 121595976 FSTL1 
RS1057231 0.505005 0.256 3 121596093 FSTL1 
RS13709 0.669205 0.322 3 121596818 FSTL1 
RS1515577 0.426237 0.244 3 121611630 FSTL1 
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RS2272515 0.651711 0.096 3 121617573 FSTL1 
RS1123897 0.901523 0.402 3 121639724 FSTL1 
RS1259333 0.70868 0.392 3 121646977 FSTL1 
RS1147707 0.490121 0.32 3 121651938 FSTL1 
RS17140284 0.462857 0.136 3 121797081 NDUFB4 
RS4505627 0.546755 0.744 3 122273022 STXBP5L 
RS2030531 0.830629 0.538 3 122637888 POLQ 
RS2877516 0.231517 0.94 3 122716563 POLQ 
RS12485719 0.124733 0.788 3 122772189 ARGFX 
RS1873645 0.726922 0.126 3 122831189 HCLS1 
RS2070180 0.240779 0.696 3 122834028 HCLS1 
RS6807963 0.427399 0.052 3 122835944 HCLS1 
RS3772126 0.138477 0.906 3 122837273 HCLS1 
RS3772127 0.532526 0.258 3 122837615 HCLS1 
RS11716984 0.051969 0.528 3 122845097 HCLS1 
RS9818194 0.620187 0.292 3 122855983 HCLS1 
RS1169 1 0.264 3 122864894 GOLGB1 
RS1574115 0.633592 0.822 3 122951915 GOLGB1 
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RS1920309 0.708583 0.902 3 123148169 SLC15A2 
RS9289186 0.642487 0.046 3 123222994 ILDR1 
HCV1412358 0.855301 0.05 3 123399376 CASR 
RS13095172 0.212358 0.176 3 123472947 CASR 
RS12635478 0.213858 0.39 3 123491243 CASR 
RS3817040 0.568693 0.508 3 123737459 PARP9 
RS35989119 0.511029 0.152 3 124153771 SEMA5B 
RS9422 0.011046 0.438 3 124815030 MYLK 
RS860224 0.015286 0.198 3 124820104 MYLK 
RS820447 0.110258 0.198 3 124830869 MYLK 
RS820463 0.462879 0.182 3 124839727 MYLK 
RS1254392 0.216769 0.498 3 124850703 MYLK 
RS820371 0.533251 0.214 3 124887401 MYLK 
RS11717814 0.562237 0.134 3 124891241 MYLK 
RS40305 0.96642 0.122 3 124894279 MYLK 
RS820335 0.289591 0.546 3 124898204 MYLK 
RS820336 0.614086 0.3 3 124898471 MYLK 
RS3732487 0.758145 0.206 3 124902263 MYLK 
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RS3732485 0.193992 0.54 3 124902472 MYLK 
RS7641248 0.604305 0.79 3 124909674 MYLK 
RS820329 0.751874 0.42 3 124927475 MYLK 
RS4678047 0.817145 0.744 3 124935528 MYLK 
RS3796164 0.187814 0.748 3 124935751 MYLK 
RS9840993 0.259514 0.538 3 124940583 MYLK 
RS3085179 0.90648 0.36 3 124941794 MYLK 
RS11718105 0.756765 0.286 3 124946398 MYLK 
RS11707609 0.848819 0.084 3 124986114 MYLK 
RS7639329 0.532426 0.946 3 124993625 MYLK 
RS28497577 0.862135 0.944 3 124995317 MYLK 
RS9846863 0.799724 0.486 3 124996168 MYLK 
RS4678060 0.659869 0.866 3 124998930 MYLK 
RS11714297 0.257852 0.43 3 125002269 MYLK 
RS2124508 0.379292 0.11 3 125009601 MYLK 
RS10934651 0.57429 0.062 3 125015899 MYLK 
RS16834774 0.501031 0.344 3 125017283 MYLK 
RS9289225 0.528788 0.136 3 125018733 MYLK 
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RS7652269 0.375067 0.14 3 125018872 MYLK 
RS3911406 0.913348 0.944 3 125021533 MYLK 
RS9829784 0.068668 0.356 3 125022826 MYLK 
RS36025624 0.444588 0.366 3 125024094 MYLK 
RS2682215 0.317301 0.94 3 125027266 MYLK 
RS2700358 0.208104 0.752 3 125039169 MYLK 
RS7628376 0.669334 0.14 3 125045246 MYLK 
RS1343700 0.175386 0.118 3 125054444 MYLK 
RS16834817 0.363267 0.396 3 125060723 MYLK 
RS12495918 0.796684 0.066 3 125065904 MYLK 
RS2682218 0.076038 0.314 3 125066569 MYLK 
RS4118366 0.313185 0.434 3 125066921 MYLK 
RS16834826 0.770146 0.056 3 125067178 MYLK 
RS13096686 0.510087 0.416 3 125072942 MYLK 
RS2700408 0.414163 0.072 3 125078122 MYLK 
RS2682229 0.180386 0.636 3 125084440 MYLK 
RS2700410 0.327039 0.7 3 125085087 MYLK 
RS1920221 0.959158 0.296 3 125089642 MYLK 
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RS2682248 0.38034 0.718 3 125099763  
RS2700373 0.449792 0.198 3 125116736 FLJ12892 
RS6810298 0.424641 0.564 3 125177665 ROPN1 
RS17376453 0.155154 0.516 3 125179139 ROPN1 
RS7434266 0.233125 0.85 3 125188532 ROPN1 
RS7613868 0.040454 0.288 3 125224719  
RS12634530 0.906764 0.26 3 125227160  
RS12637456 0.030826 0.736 3 125227353  
RS1316463 0.014454 0.856 3 125236375 LOC731323 
RS9289231 0.0014 0.492 3 125256768  
RS13075202 0.040685 0.762 3 125304977 KALRN 
RS1950091 0.702977 0.53 3 125383007 KALRN 
RS1444768 0.926127 0.504 3 125406612 KALRN 
RS1444754 0.955386 0.644 3 125420907 KALRN 
RS4234218 0.564469 0.006 3 125443900 KALRN 
RS11929003 0.135597 0.708 3 125462011 KALRN 
RS2272486 0.731804 0.086 3 125470729 KALRN 
RS12496156 0.420288 0.23 3 125478341 KALRN 
 178 
 
 
RS9289235 0.413761 0.742 3 125636850 KALRN 
RS2289843 1 0.072 3 125678784 KALRN 
RS1867647 0.684711 0.586 3 125719519 KALRN 
RS2713655 0.679068 0.086 3 125756597 KALRN 
RS1513289 0.589757 0.354 3 125802018 KALRN 
RS333284 0.302317 0.266 3 125894843 KALRN 
RS7621976 0.145425 0.138 3 125904695 KALRN 
RS1801019 0.290454 0.118 3 125939432 UMPS 
RS13146 0.575585 0.06 3 125945498 UMPS 
RS2291088 0.080135 0.926 3 125998199 ITGB5 
RS2979310 0.887098 0.544 3 126871199 OR7E29P 
RS1868121 0.362581 0.06 3 127388343 ALDH1L1 
RS4459845 0.800354 0.602 3 127400318  
RS7622890 0.046322 0.196 3 127540372 KLF15 
RS938390 0.588958 0.58 3 127541239 KLF15 
RS13077029 0.62774 0.614 3 127541327 KLF15 
RS938389 0.150011 0.652 3 127541452 KLF15 
RS6783805 0.222064 0.44 3 127542648 KLF15 
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RS7615776 0.066042 0.486 3 127543307 KLF15 
RS9850626 0.307931 0.732 3 127551469 KLF15 
RS1358087 0.900817 0.028 3 127561580 KLF15 
RS7636709 0.083541 0.114 3 127562684 KLF15 
RS951739 0.635693 0.448 3 127908351 CHCHD6 
RS11714878 0.923318 0.194 3 128056685 CHCHD6 
RS4408834 0.32914 0.818 3 128535551  
RS2217628 0.210049 0.42 3 129134319 KLHDC6 
RS9857492 0.677209 0.548 3 129246212 SEC61A1 
RS7632756 0.333257 0.494 3 129300198 RUVBL1 
RS11711710 0.754479 0.374 3 129355196 SELB 
RS2811478 0.750857 0.31 3 129382314 SELB 
RS2955095 0.568976 0.468 3 129460355 SELB 
RS2955103 0.74393 0.504 3 129497926 SELB 
RS2713594 0.525774 0.756 3 129679190 GATA2 
RS2713579 0.139734 0.496 3 129680794 GATA2 
RS45463895 0.686826 0.36 3 129681670 GATA2 
RS45437196 0.388554 0.628 3 129681855 GATA2 
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RS45463801 0.898636 0.55 3 129682006 GATA2 
RS3803 0.312782 0.318 3 129682070 GATA2 
RS45479594 0.274812 0.088 3 129682142 GATA2 
RS10934857 0.264591 0.774 3 129682352 GATA2 
RS45598538 0.02521 0.262 3 129682369 GATA2 
RS2713604 0.042704 0.284 3 129683149 GATA2 
RS2713603 0.457807 0.43 3 129683224 GATA2 
RS11717152 0.492904 0.834 3 129683703 GATA2 
RS2659689 0.552573 0.51 3 129685696 GATA2 
RS2659691 0.234702 0.28 3 129686390 GATA2 
RS2713601 0.947063 0.806 3 129686426 GATA2 
RS2335052 0.042435 0.406 3 129687641 GATA2 
RS1573858 0.91373 0.752 3 129688550 GATA2 
RS2860228 0.882986 0.374 3 129692357 GATA2 
RS9851497 0.822532 0.468 3 129695216 GATA2 
RS6439129 0.58669 0.524 3 129695463 GATA2 
RS6776756 0.830683 0.784 3 129698511 GATA2 
RS2713600 0.135578 0.374 3 129779758 C3ORF27 
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RS9880192 0.453838 0.382 3 129780259 C3ORF27 
HCV11237369 0.602167 0.952 3 130014560 RAB7 
RS2625967 0.383867 0.882 3 130749949 PLXND1 
RS2245285 0.376366 0.616 3 130769103 PLXND1 
RS2255703 0.030901 0.924 3 130775946 PLXND1 
RS2285373 0.023851 0.1 3 130790899 PLXND1 
RS6439193 0.685607 0.982 3 130901631 TMCC1 
RS13095825 0.252467 0.994 3 131549247  
RS12488457 0.513705 0.388 3 131599386 FLJ35880 
RS9883988 0.678739 0.838 3 131645085 FLJ35880 
RS819086 0.51001 0.902 3 131655482 FLJ35880 
RS819091 0.623459 0.872 3 131678260 FLJ35880 
RS9836961 0.253587 0.564 3 131769576 LOC131873 
RS6439249 0.806557 0.9 3 131783340 LOC131873 
RS9823913 0.101556 0.662 3 131829269 LOC131873 
RS11710068 0.573936 0.398 3 131877537 PIK3R4 
RS900989 0.380125 0.392 3 131902071 PIK3R4 
RS10934954 0.482762 0.436 3 131910836 PIK3R4 
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RS10934955 0.657711 0.308 3 131933044 PIK3R4 
RS11711283 0.923122 0.584 3 131944000 PIK3R4 
RS4527350 0.867393 0.94 3 132023659  
RS2669869 0.726513 0.782 3 132100157 ATP2C1 
RS2685193 0.368188 0.78 3 132158994 ATP2C1 
RS218481 0.726535 0.964 3 132204893 ATP2C1 
RS190067 0.513179 0.724 3 132213054 ATP2C1 
RS16835847 0.435774 0.71 3 132309572 NEK11 
RS885076 0.062483 0.466 3 132406524 NEK11 
RS2033182 0.051336 0.674 3 132481398 NEK11 
RS11914980 0.196519 0.42 3 132575137 NUDT16 
RS7638101 0.483049 0.392 3 132662820 MRPL3 
RS1486230 0.287778 0.498 3 132678443 MRPL3 
RS1385969 0.729289 0.24 3 132725192 CPNE4 
RS995840 0.902888 0.934 3 132836338 CPNE4 
RS6802186 0.606244 0.906 3 132916949 CPNE4 
RS1463518 0.120751 0.432 3 133070463 CPNE4 
RS1870713 0.49868 0.52 3 133157217 CPNE4 
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RS1950079 0.702227 0.058 3 133240262 CPNE4 
HCV1513476 0.148946 0.352 3 133369678  
RS1809997 0.596457 0.984 3 133450259  
RS3749269 0.647641 0.124 3 133550719 ACPP 
RS11918232 0.885367 0.542 3 133589619  
RS1500112 0.085442 0.792 3 133666783 DNAJC13 
RS12488259 0.837653 0.37 3 133759046 FLJ12592 
RS2369832 0.955244 0.936 3 133920080 NPHP3 
RS2049149 0.730158 0.26 3 134259591 MGC3040 
RS1124217 0.823698 0.908 3 134437992 MGC3040 
RS2370409 0.682561 0.716 3 134492504 TMEM108 
RS3732572 0.53545 0.618 3 134592159 MGC3040 
RS2276737 0.211077 0.368 3 134650053 BFSP2 
RS1842155 0.564152 0.372 3 134771371 CDV3 
RS1051772 0.602551 0.698 3 134810147 TOPBP1 
RS11914965 0.189514 0.376 3 134895319  
RS3811656 0.187038 0.63 3 134957018 TF 
RS12635289 0.714693 0.046 3 146882839  
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RS2177300 0.074396 0.896 3 146884214 GM2AP 
RS1394041 0.571255 0.02 3 148579537  
RS2638362 0.0542 0.964 3 149903206 AGTR1 
RS5182 0.579725 0.354 3 149942085 AGTR1 
RS5186 0.86495 0.542 3 149942678 AGTR1 
RS275645 0.482748 0.792 3 149947144 AGTR1 
RS9849625 0.622961 0.428 3 150022844 AGTR1 
RS870995 0.055656 0.001 3 180395700 PIK3CA 
RS1356413 0.251837 0.624 3 180426595 PIK3CA 
RS6141 0.831169 0.966 3 185572960 THPO 
RS6142 0.756442 0.328 3 185573843 THPO 
RS2162188 0.024665 0.302 3 188873673 SST 
RS34357956 0.617825 0.43 3 196730876 PPP1R2 
RS823518 0.128127 0.948 3 196751367 PPP1R2 
RS823526 0.5888 0.994 3 196759585 PPP1R2 
RS36002025 0.405578 0.664 3 196759644 PPP1R2 
RS9886993 0.029554 0.836 3 196786481 APOD 
RS7629772 0.117495 0.36 3 196789692 APOD 
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RS13303036 0.00841 0.146 3 196800304 APOD 
RS7627090 0.605327 0.616 3 197949151 PIGX 
RS1357287 0.101798 0.276 3 197969364 PAK2 
RS1798619 0.021838 0.808 3 197970248 PAK2 
RS2948170 0.095449 0.158 3 197976928 PAK2 
RS6809369 0.622974 0.922 3 197978358 PAK2 
RS6798777 0.844968 0.788 3 197987214 PAK2 
RS9325377 0.115344 0.888 3 197990550 PAK2 
RS12634982 0.09022 0.966 3 197990836 PAK2 
RS11923075 0.046261 0.734 3 197999729 PAK2 
RS7646247 0.499205 0.594 3 198003606 PAK2 
RS6583176 0.127788 0.854 3 198009975 PAK2 
RS4916555 0.214444 0.584 3 198023045 PAK2 
RS2084382 0.356413 0.618 3 198031843 PAK2 
RS2166799 0.823441 0.612 3 198031935 PAK2 
RS9829778 0.753669 0.678 3 198033486 PAK2 
RS7432972 0.446595 0.986 3 198033993 PAK2 
RS2084385 0.151769 0.022 3 198038264 PAK2 
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RS9222 0.176961 0.388 3 198040880 PAK2 
RS15614 0.390747 0.322 3 198043346 PAK2 
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Appendix B – Chapter 3 Supplemental Materials 
Table 16: Description of Clinical Outcomes 
Outcome Clinical Definition 
Hypertension Clinically significant hypertension by history.  This 
does not necessarily depend upon a history of 
treatment; documentation by blood pressure 
determination is not required. 
MI Documented myocardial infarction within one week 
prior to the catheterization procedure 
Number of Diseased 
Coronary Vessels 
Number of vessels with significant occlusion (greater 
than 75%)  
For right dominant patients, a lesion in the left main 
counts as 2 diseased vessels.  A lesion in the right 
coronary artery would increase the number of 
diseased vessels to 3.  If the left main is not 
significantly diseased then the LAD, RCA, and LCA 
will result in an increment of 1 to number of disease 
vessels.  If the patient is left dominant, then the LMC 
counts as 3 diseased vessels if stenosed.  The LAD also 
contributes 1 diseased vessel if diseased.  The RCA 
does not contribute to the calculation of number of 
disease if left dominant.  Patients who are neither right 
nor left dominant (balanced) are counted as right 
dominant.  The dominance is determined by the 
position of the posterior descending artery.  The 
coding of this variable is determined by physician 
judgment. 
PVD PVD as defined according to the Charleson 
Comorbidities (Quan et al. 2011) 
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Table 17: Correlations between cardiovascular outcomes. The correlation 
between cardiovascular outcomes is given below.  For binary outcomes a phi-
coefficient is given (a).  For the ordinal number of diseased vessels outcome the other 
outcomes are tabulated with respect to each level (b-d). 
 
a.  Correlations between binary variables 
 PVD Hypertension MI  
PVD 1 0.086 0.008  
Hypertension  1 0.002  
MI   1  
b.  PVD vs Number of Diseased Vessels 
 Number of Diseased Vessels 
PVD 0 1 2 3 
0 831 377 267 329 
1 22 33 27 46 
c. Hypertension vs Number of Diseased Vessels 
 Number of Diseased Vessels 
Hypertension 0 1 2 3 
0 302 121 61 71 
1 551 289 233 304 
d. MI vs Number of Diseased Vessels 
 Number of Diseased Vessels 
MI 0 1 2 3 
0 813 360 261 331 
1 40 50 33 44 
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Table 18: Traffic Exposure Zones Description 
Traffic Exposure 
Zone 
Count Description 
1 407 Baseline study zone composed of areas 
within the Durham, Wake, Orange county 
study region and not in any higher traffic 
exposure zone 
2 765 Urbanized Areas traffic exposure zone 
composed of urbanzied areas as definied by 
the 2000 US Census 
3 318 Signal light density traffic exposure zone.   
The attribute data for the traffic demand 
model contains data for the roadways on 
signal light density in lights per mile. The 
segments with traffic lights were imported 
to the Manifold System GIS version 6.5 
(manifold.net, 2011). The segments were 
generalized to points 100 m apart keeping 
the signal light density variable. Isotropic 
kriging using Manifold’s ‘Auto’ option and 
the 25 nearest neighbors was employed on a 
grid of 200 m cells to generate a signal light 
density surface. The use of the ‘auto’ option 
lets the software pick the best model for the 
semivariogram. This was filtered with a 5x5 
median cross filter; an integer function was 
applied to reduce values to the nearest 
integer.  Finally, cells that were less than 
one were set to null. A contour function was 
applied to convert the surface to polygons 
representing the signal light density zone, 
which was exported and brought back into 
ArcGIS.  Areas with greater than 3 traffic 
lights per mile were classified as high signal 
light density zones 
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4 581 Transit route zone composed of the transit 
routes for the cities of Cheapel Hill, Raleigh, 
and Durham as well as for the universities 
of University of North Carolina - Chapel 
Hill and North Carolina State University 
(located in Raleigh).  A 200m buffer around 
these transit routes composed the exposure 
zone. 
5 32 Traffic Volume exposure zone composed of 
road segments with a minimum traffic of 
40,000 vehicles per day.  A 200m buffer 
around these roadway segments composed 
the exposure zone 
6 21 Traffic Delay exposure zone composed or 
road segemetns with 35% or greater delay 
during morning peak traffic as estimated for 
a general day in the Fall or Spring of 2005 
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Appendix C – Chapter 4 Supplemental Materials 
Supplementary Tables for Chapter 4: 
Table 19: Interaction results for all loci tested in the bone morphogenic protein 
family of genes (BMP1, BMP2, BMP4, BMP7, BMP8A, BMP9, BMP10, and BMPER). 
BMP1 
CHR BP PROBE OR 
(EA) 
P (EA) MAF 
(EA) 
OR 
(AA) 
P (AA) MAF 
(AA) 
8 22024523 rs10096505 1.06 7.84E-01 0.48 0.84 7.24E-01 0.36 
8 22025644 rs7812993 1.16 5.68E-01 0.22 0.71 4.85E-01 0.29 
8 22029129 rs10095410 0.00 9.75E-02 < 0.01 1.04 9.44E-01 0.09 
8 22033435 rs11777932 1.08 8.59E-01 0.08 0.29 4.81E-01 0.03 
8 22038952 rs7838961 1.16 5.00E-01 0.49 1.04 9.27E-01 0.36 
8 22042151 rs7819541 0.61 4.34E-01 0.07 1.33 4.93E-01 0.46 
8 22042197 rs4507761 1.12 7.68E-01 0.08 1.24 9.99E-01 0.01 
8 22046829 rs11994254    1.48 5.85E-01 0.04 
8 22048790 rs12114940 1.01 9.70E-01 0.43 0.94 9.11E-01 0.26 
8 22049780 rs3924231 0.88 7.25E-01 0.17 0.89 7.94E-01 0.47 
8 22049892 rs3924229 1.11 8.10E-01 0.11 0.61 3.32E-01 0.23 
8 22051849 rs6997623 0.52 9.99E-01 0.00 0.60 4.52E-01 0.16 
8 22053123 rs4075478 1.01 9.74E-01 0.38 1.02 9.59E-01 0.41 
8 22054197 rs12675993 1.16 7.22E-01 0.10 1.21 7.78E-01 0.11 
8 22055348 rs3857979 1.07 7.69E-01 0.48 1.07 8.81E-01 0.33 
8 22057449 rs7827382 0.58 7.27E-02 0.22 1.36 5.55E-01 0.22 
8 22058122 rs11775186 0.78 5.69E-01 0.09 1.03 9.63E-01 0.09 
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8 22058904 rs11784926 0.34 2.51E-01 0.04 0.02 2.60E-01 0.02 
8 22059363 rs11996036 0.80 6.45E-01 0.06 0.93 9.19E-01 0.09 
8 22059413 rs28710878 0.00 7.24E-02 < 0.01 1.64 3.60E-01 0.10 
8 22062432 rs10107545 0.93 9.98E-01 < 0.01 1.07 9.43E-01 0.09 
8 22063438 rs6983732 0.50 3.87E-02 0.13 1.25 5.80E-01 0.27 
8 22067769 rs4242430 0.79 3.83E-01 0.31 0.84 8.30E-01 0.09 
8 22067774 rs4076873 0.92 7.25E-01 0.24 1.08 8.63E-01 0.47 
8 22069018 rs11778448 0.94 8.00E-01 0.24 1.74 1.94E-01 0.34 
BMP2 
CHR BP PROBE OR 
(EA) 
P (EA) MAF 
(EA) 
OR 
(AA) 
P (AA) MAF 
AA 
20 6751034 rs1049007 0.56 1.10E-02 0.38 0.39 2.54E-01 0.12 
20 6751316 rs7270163 1.87 3.44E-02 0.11 3.56 2.51E-03 0.31 
20 6754246 rs235764 1.71 1.98E-02 0.27 3.58 5.46E-03 0.41 
20 6755598 rs235767 1.68 1.84E-02 0.39 3.66 1.59E-02 0.48 
20 6756148 rs1005464 1.10 7.21E-01 0.22 0.26 2.24E-01 0.10 
20 6759115 rs235768 0.54 7.28E-03 0.39 0.13 1.28E-01 0.06 
20 6759980 rs15705 1.38 2.10E-01 0.22 1.28 6.51E-01 0.23 
20 6760201 rs3178250 1.40 2.22E-01 0.19 1.53 4.29E-01 0.21 
20 6760431 rs170986 1.37 2.35E-01 0.17 2.49 2.97E-02 0.31 
BMP4 
CHR BP PROBE OR 
(EA) 
P (EA) MAF 
(EA) 
OR 
(AA) 
P (AA) MAF 
(AA) 
14 54417522 rs17563 1.36 1.72E-01 0.44 0.66 4.30E-01 0.24 
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14 54418411 rs2071047 0.66 7.58E-02 0.41 0.97 9.56E-01 0.39 
14 54420653 rs10140018 1.01 9.90E-01 0.01 0.38 7.42E-01 0.03 
BMP7 
CHR BP PROBE OR 
(EA) 
P (EA) MAF 
(EA) 
OR 
(AA) 
P (AA) MAF 
(AA) 
20 55743905 rs12438 1.26 2.98E-01 0.49 2.10 6.22E-02 0.25 
20 55744499 rs6014947 1.21 3.82E-01 0.49 1.87 1.27E-01 0.21 
20 55749781 rs6025422 1.20 4.08E-01 0.50 1.77 1.46E-01 0.39 
20 55753082 rs6025427 0.14 3.88E-01 < 
0.01 
1.12 8.64E-01 0.14 
20 55754110 rs3787380 1.03 8.82E-01 0.39 0.63 3.23E-01 0.22 
20 55754239 rs13037653 0.50 1.48E-01 0.07 0.13 3.79E-01 0.01 
20 55755170 rs3787382 1.05 8.53E-01 0.19 0.87 7.29E-01 0.49 
20 55756841 rs6099488 0.82 9.99E-01 < 
0.01 
3.22 3.53E-01 0.03 
20 55756881 rs6025428 1.82 9.98E-01 < 
0.01 
0.68 4.85E-01 0.13 
20 55758655 rs6070015 0.99 9.80E-01 0.05 1.25 5.54E-01 0.48 
20 55760567 rs6064508 0.77 2.84E-01 0.37 0.52 2.72E-01 0.16 
20 55761285 rs1318379 1.12 8.13E-01 0.06 1.03 9.36E-01 0.36 
20 55762947 rs6123674 1.24 3.53E-01 0.42 1.19 6.98E-01 0.21 
20 55763739 rs6099492 0.50 4.04E-01 0.03 1.49 3.97E-01 0.14 
20 55764104 rs6064509 1.24 7.71E-01 0.02 5.78 9.99E-01 0.00 
20 55772683 rs230191 1.37 1.57E-01 0.49 0.57 2.59E-01 0.24 
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20 55776447 rs230198 0.67 7.28E-02 0.46 2.02 9.51E-02 0.38 
20 55785618 rs6123677 1.39 1.41E-01 0.49 0.76 6.00E-01 0.14 
20 55786811 rs6025446 0.99 9.79E-01 0.42 1.04 9.17E-01 0.46 
20 55787622 rs12481628 0.63 3.66E-02 0.44 1.12 7.90E-01 0.33 
20 55788009 rs10470036 0.55 8.04E-01 < 
0.01 
3.20 7.46E-03 0.08 
20 55789914 rs3764677 0.58 1.91E-02 0.42 1.49 3.10E-01 0.35 
20 55790147 rs6025447 0.56 1.26E-02 0.40 0.53 4.38E-01 0.16 
20 55791348 rs6123679 2.50 1.75E-01 0.03 0.49 7.02E-01 0.01 
20 55792300 rs1002432 1.07 9.09E-01 0.03 1.21 6.30E-01 0.37 
20 55794749 rs46995 0.63 3.97E-02 0.43 0.38 1.99E-01 0.20 
20 55797057 rs6127972 0.58 1.62E-02 0.41 0.52 3.90E-01 0.19 
20 55800039 rs172983 1.42 2.47E-01 0.11 0.59 3.90E-01 0.17 
20 55802736 rs162311 1.38 2.70E-01 0.13 0.56 1.71E-01 0.42 
20 55802858 rs162312 1.49 1.38E-01 0.17 0.67 3.99E-01 0.34 
20 55803687 rs17404303 1.28 2.66E-01 0.41 1.66 3.34E-01 0.12 
20 55805127 rs2180782 1.43 1.68E-01 0.17 0.53 1.59E-01 0.43 
20 55806280 rs6127973 0.77 4.39E-01 0.15 0.00 1.27E-01 0.03 
20 55806340 rs186659 0.59 2.08E-02 0.40 0.32 2.63E-01 0.11 
20 55807110 rs6014959 1.75 7.61E-02 0.13 1.24 6.16E-01 0.45 
20 55809072 rs1028644 1.71 2.34E-02 0.25 1.00 9.93E-01 0.31 
20 55811812 rs6025456 2.41 6.22E-01 0.01 1.58 2.42E-01 0.25 
20 55812058 rs7273197 1.01 9.81E-01 0.31 1.79 2.84E-01 0.13 
20 55816734 rs4361186 3.91 4.10E-01 0.01 1.68 1.97E-01 0.33 
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20 55824475 rs6127983 1.23 3.54E-01 0.35 0.88 7.61E-01 0.42 
20 55824533 rs182784 0.64 3.98E-02 0.48 0.28 4.04E-02 0.28 
20 55824760 rs6127985 1.26 4.10E-01 0.16 0.70 4.82E-01 0.24 
20 55830151 rs6025468 1.04 8.85E-01 0.19 2.31 2.93E-02 0.29 
20 55834657 rs7269453    1.14 9.07E-01 0.07 
BMP9 
CHR BP PROBE OR 
(EA) 
P (EA) MAF 
(EA) 
OR 
(AA) 
P (AA) MAF 
(AA) 
10 48413273 rs3740297 0.89 9.98E-01 0.01 0.68 8.25E-01 0.01 
BMP10 
CHR BP PROBE OR (EA) P (EA) MAF 
(EA) 
OR 
(AA) 
P (AA) MAF 
(AA) 
2 69092621 rs10173546    1.34 6.48E-01 0.12 
2 69093312 rs2231344 2.37 2.26E-
02 
0.07 0.60 3.28E-01 0.25 
2 69095152 rs2312078 1.11 6.25E-
01 
0.39 0.73 4.75E-01 0.45 
2 69097862 rs3817368 1.12 6.08E-
01 
0.39 0.32 6.96E-02 0.27 
2 69097953 rs6760348 1.65E+49 8.80E-
02 
< 0.01 0.61 5.77E-01 0.09 
BMP8A 
CHR BP PROBE OR (EA) P (EA) MAF 
(EA) 
OR 
(AA) 
P (AA) MAF 
(AA) 
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1 39963873 rs2004330 0.46 5.74E-04 0.44 1.39 
5.11E-
01 0.25 
1 39965761 rs698141 0.98 9.63E-01 0.06 0.80 
8.16E-
01 0.08 
1 39966718 rs6656934 0.78 4.95E-01 0.11 1.04 
9.11E-
01 0.47 
1 39972874 rs11206218 0.43 3.73E-01 0.03 1.68 
3.35E-
01 0.18 
1 39973646 rs782869 0.91 9.37E-01 < 0.01 0.40 
1.91E-
01 0.14 
1 39975894 rs1180327 0.11 9.98E-01 < 0.01 0.02 
4.10E-
01 0.04 
1 39989012 rs11584399 0.90 7.55E-01 0.09 0.91 
9.13E-
01 0.05 
1 39989926 rs710913 2.42 3.04E-05 0.36 2.11 
7.33E-
02 0.31 
1 39991588 rs3738676 2.81 1.51E-06 0.36 0.66 
3.47E-
01 0.34 
1 39992537 rs1180340 0.57 9.98E-01 < 0.01 1.91 
1.58E-
01 0.12 
1 39992808 rs1180341 0.44 1.24E-04 0.46 0.82 
6.37E-
01 0.32 
1 39993432 rs1180343 0.43 1.74E-04 0.45 1.50 
4.29E-
01 0.24 
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1 39995074 rs755249 3.45 2.29E-08 0.24 0.04 
3.39E-
01 0.04 
BMPER 
CHR BP PROBE OR (EA) P (EA) MAF 
(EA) 
OR 
(AA) 
P (AA) MAF 
(AA) 
7 33949959 rs7801918 0.88 6.56E-01 0.23 0.97 
9.49E-
01 0.26 
7 33957895 rs4720146 0.21 6.13E-01 < 0.01 0.13 
3.15E-
01 0.01 
7 33959239 rs1427483 0.72 1.39E-01 0.37 1.27 
6.24E-
01 0.28 
7 33967085 rs13221600 0.60 3.63E-02 0.25 0.53 
4.24E-
01 0.12 
7 33971904 rs2016770 2.19 1.12E-03 0.34 1.57 
3.20E-
01 0.42 
7 33972999 rs747664 1.04 9.99E-01 0.00 0.13 
4.99E-
01 0.02 
7 33973653 rs10253162 2.38 4.29E-04 0.34 1.26 
5.95E-
01 0.45 
7 33977757 rs10247996 0.70 1.18E-01 0.46 0.81 
6.71E-
01 0.31 
7 33979694 rs10486624 2.96 9.98E-01 < 0.01 1.72 
3.79E-
01 0.09 
7 33984313 rs1427481 0.85 4.87E-01 0.45 0.88 7.59E- 0.49 
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01 
7 33991109 rs13233238 0.57 2.06E-02 0.28 1.36 
4.96E-
01 0.46 
7 33991875 rs10270579 0.57 1.79E-02 0.29 1.53 
3.15E-
01 0.47 
7 33992983 rs1365889 0.77 5.16E-01 0.12 0.58 
6.29E-
01 0.03 
7 33996948 rs12155213 0.63 4.78E-02 0.31 1.44 
3.75E-
01 0.47 
7 33998587 rs4723343 1.32 2.16E-01 0.42 2.76 
3.25E-
02 0.37 
7 34000224 rs9639688 1.41 1.37E-01 0.23 0.25 
5.17E-
02 0.17 
7 34009946 rs10265207 1.05 8.28E-01 0.47 1.96 
8.42E-
02 0.38 
7 34012829 rs1365888 0.71 3.80E-01 0.12 0.60 
6.02E-
01 0.08 
7 34013178 rs13243958 1.20 3.99E-01 0.35 0.50 
1.25E-
01 0.42 
7 34017577 rs10276432 1.07 7.57E-01 0.35 0.67 
3.75E-
01 0.42 
7 34021755 rs12701341 0.91 6.63E-01 0.40 0.66 
3.50E-
01 0.46 
7 34022301 rs10486625 1.12 6.06E-01 0.37 0.54 1.28E- 0.49 
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01 
7 34024288 rs6951556 
   
0.06 
3.33E-
01 0.01 
7 34035784 rs6948650 1.17 6.87E-01 0.07 0.45 
3.40E-
01 0.09 
7 34036618 rs9986855 0.81 4.76E-01 0.15 0.45 
4.62E-
01 0.03 
7 34038414 rs17169617 0.90 7.04E-01 0.17 0.40 
1.39E-
01 0.22 
7 34043348 rs10951405 0.59 7.34E-02 0.18 0.91 
8.86E-
01 0.14 
7 34046002 rs974937 1.37 1.96E-01 0.22 0.63 
3.21E-
01 0.40 
7 34074661 rs12670628 0.94 7.83E-01 0.31 0.61 
2.30E-
01 0.47 
7 34087546 rs17169630 0.95 8.91E-01 0.08 0.78 
6.00E-
01 0.34 
7 34088690 rs17823423 0.86 5.51E-01 0.23 0.45 
6.11E-
01 0.04 
7 34089823 rs7806522 0.93 7.73E-01 0.30 0.57 
1.88E-
01 0.47 
7 34090734 rs13244436 0.96 8.66E-01 0.23 0.54 
4.23E-
01 0.09 
7 34094687 rs17169636 1.09 8.19E-01 0.07 1.14 8.17E- 0.15 
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01 
7 34103553 rs1420328 0.75 4.71E-01 0.10 2.08 
1.20E-
01 0.22 
7 34107393 rs1362457 0.98 9.32E-01 0.22 0.58 
4.31E-
01 0.13 
7 34111660 rs961652 0.85 4.65E-01 0.48 1.18 
7.19E-
01 0.29 
7 34117136 rs759417 1.23 3.46E-01 0.29 1.51 
3.01E-
01 0.48 
7 34121829 rs2160308 1.14 5.65E-01 0.29 0.81 
6.86E-
01 0.17 
7 34125622 rs10249320 1.21 9.98E-01 0.01 
   
7 34126782 rs7790026 1.23 3.45E-01 0.30 1.36 
4.31E-
01 0.49 
7 34128156 rs11973757 0.24 9.99E-01 < 0.01 7.18 
4.26E-
03 0.06 
7 34132131 rs1420331 1.09 7.32E-01 0.27 0.59 
2.82E-
01 0.28 
7 34132727 rs1420332 1.08 7.39E-01 0.27 1.38 
4.51E-
01 0.50 
7 34133050 rs973766 1.76 1.32E-02 0.31 0.17 
2.71E-
01 0.06 
7 34133861 rs10261012 1.09 7.29E-01 0.27 0.64 
3.50E-
01 0.32 
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7 34134582 rs1420333 1.09 7.13E-01 0.27 1.11 
8.11E-
01 0.39 
7 34135625 rs12701343 1.09 7.26E-01 0.23 0.16 
1.69E-
01 0.08 
7 34137529 rs6948894 1.12 6.50E-01 0.27 0.62 
3.31E-
01 0.32 
7 34137970 rs12701344 1.25 9.98E-01 < 0.01 2.67 
2.89E-
01 0.07 
7 34138717 rs1946146 1.03 8.93E-01 0.23 0.54 
4.49E-
01 0.11 
7 34140513 rs1420335 0.96 8.51E-01 0.31 1.27 
5.95E-
01 0.39 
7 34140927 rs6462526 0.96 8.72E-01 0.31 0.99 
9.89E-
01 0.47 
7 34143378 rs1420339 0.38 9.98E-01 0.00 1.12 
9.02E-
01 0.06 
7 34147159 rs10271544 1.06 7.81E-01 0.40 0.79 
5.89E-
01 0.40 
7 34151057 rs757640 1.27 3.37E-01 0.19 1.14 
7.62E-
01 0.34 
7 34153768 rs918038 1.08 7.03E-01 0.39 0.79 
5.69E-
01 0.44 
7 34156746 rs2080372 1.20 4.78E-01 0.19 0.81 
7.00E-
01 0.19 
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7 34157300 rs17169653 2.64 9.98E-01 < 0.01 0.63 
6.71E-
01 0.07 
7 34158292 rs10236500 0.91 9.98E-01 < 0.01 3.89 
6.04E-
02 0.07 
7 34159138 rs1345347 1.19 4.85E-01 0.19 1.29 
5.78E-
01 0.27 
7 34164659 rs1014580 1.22 4.43E-01 0.19 1.34 
5.23E-
01 0.29 
7 34164677 rs1014581 1.08 7.12E-01 0.39 0.81 
6.05E-
01 0.45 
7 34167361 rs10486631 0.89 6.81E-01 0.19 0.26 
1.45E-
01 0.10 
7 34168028 rs6462533 1.05 8.28E-01 0.40 0.82 
6.50E-
01 0.43 
7 34169964 rs1861362 1.22 4.30E-01 0.19 0.47 
2.32E-
01 0.21 
7 34173852 rs10951406 1.15 5.94E-01 0.20 1.04 
9.24E-
01 0.46 
7 34174173 rs6961966 0.95 8.45E-01 0.20 0.43 
2.35E-
01 0.16 
7 34178283 rs12673452 0.03 3.96E-01 0.01 1.03 
9.63E-
01 0.12 
7 34178645 rs10486632 1.16 5.70E-01 0.20 0.62 
2.96E-
01 0.32 
 203 
 
 
7 34191345 rs1014578 1.03 8.79E-01 0.40 0.77 
5.15E-
01 0.42 
7 34192011 rs918037 1.13 5.75E-01 0.40 0.60 
2.23E-
01 0.41 
7 34192762 rs6968741 1.34 3.87E-01 0.06 1.22 
6.24E-
01 0.17 
7 34193589 rs11972404 1.85 3.02E-01 0.03 0.90 
8.23E-
01 0.23 
7 34193952 rs17169667 1.09 7.93E-01 0.11 1.64 
2.63E-
01 0.49 
7 34194102 rs2058681 1.24 3.30E-01 0.32 0.77 
7.94E-
01 0.06 
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Supplementary Figures for Chapter 4 
 
Figure 10: NC CATHGEN Participants.  The distribution of CATHGEN 
participants overlaid with the primary and secondary roadway network (red lines) for 
North Carolina.  To protect patient health information counties with 10 or fewer 
participants are suppressed and represented by hatch marks.  All other counties have 
the CATHGEN participants locations (blue dots) randomized within a small area to 
preserve the overall structure and still protect patient health information. 
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Figure 11: Plot of the linkage disequilibrium in BMP8A for the EA cohort 
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Figure 12: Plot of the linkage disequilibrium in BMP8A for the AA cohort 
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Appendix D – Chapter 5 Supplemental Materials 
 
 
Figure 13:  LD in intergenic region on chromosome 18 in AA cohort 
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